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general hypothesis of this dissertation was that magnetic resonance imaging (MRI) can be used to
characterize the properties of injectable materials once delivered to the myocardium and evaluate the
temporal effects of injectable materials on myocardial tissue properties post-MI. To test this hypothesis,
injectable hyaluronic acid (HA) hydrogels were developed with a range of gelation, degradation and
mechanical properties by altering the initiator concentration, macromer modification, and macromer
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demonstrated that hydrogel therapy led to improved global LV structure and function, increased wall
thickness, preserved borderzone contractility, and increased infarct stiffness, respectively. This work
demonstrates that MRI can be used to simultaneously study hydrogel properties after injection into the
myocardium and evaluate the ability of injectable hydrogels to alter myocardial tissue properties to ultimately
improve cardiac outcomes and enable future optimization of biomaterial therapies to attenuate adverse
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ABSTRACT 
 
MRI EVALUATION OF INJECTABLE HYALURONIC ACID HYDROGEL THERAPY TO 
ATTENUATE MYOCARDIAL INFARCT REMODELING 
  
Shauna M. Dorsey 
Jason A. Burdick, Ph.D. 
 
Left ventricular (LV) remodeling following myocardial infarction (MI) leads to maladaptive 
processes that often progress to heart failure. Injectable biomaterials can alter the mechanical 
signaling post-MI to limit this progression. To design optimal therapies, noninvasive techniques 
are needed to elucidate the reciprocal interaction between the injected material and the 
surrounding myocardial tissue. Towards this goal, the general hypothesis of this dissertation was 
that magnetic resonance imaging (MRI) can be used to characterize the properties of injectable 
materials once delivered to the myocardium and evaluate the temporal effects of injectable 
materials on myocardial tissue properties post-MI.  
To test this hypothesis, injectable hyaluronic acid (HA) hydrogels were developed with a 
range of gelation, degradation and mechanical properties by altering the initiator concentration, 
macromer modification, and macromer concentration, respectively. Non-contrast MRI was then 
used to characterize the properties (e.g., distribution, chemical composition) of injectable HA 
hydrogels in myocardial explants. Altering hydrogel gelation led to differences in distribution in 
myocardial tissue, as quantified by T2-weighted MRI. As an alternative to conventional (i.e.T2-
weighted) MRI where contrast depends on differences in MR properties and thus, is non-specific 
for the material, chemical exchange saturation transfer (CEST) MRI was used to specifically 
image hydrogels based on their functional (i.e. exchangeable proton) groups. CEST contrast 
vi 
 
correlated with changes in material properties, specifically macromer concentration. Furthermore, 
CEST MRI was shown to simultaneously visualize and discriminate between different injectable 
materials based on their unique chemistry. Finally, the effect of injectable HA hydrogels on 
myocardial tissue properties was temporally evaluated in a porcine infarct model up to 12 weeks 
post-MI. Outcome assessment using MRI (e.g. cine, late-gadolinium enhancement, and spatial 
modulation of magnetization MRI) and finite element (FE) modeling demonstrated that hydrogel 
therapy led to improved global LV structure and function, increased wall thickness, preserved 
borderzone contractility, and increased infarct stiffness, respectively.  
This work demonstrates that MRI can be used to simultaneously study hydrogel 
properties after injection into the myocardium and evaluate the ability of injectable hydrogels to 
alter myocardial tissue properties to ultimately improve cardiac outcomes and enable future 
optimization of biomaterial therapies to attenuate adverse remodeling post-MI. 
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CHAPTER 1 
 
Introduction 
 
1.1. Significance  
Cardiovascular disease (CVD) remains to be the leading cause of death in the United 
States. Although there has been a dramatic reduction in the death rate due to CVD over the past 
four decades, CVD still accounts for nearly 1 of every 3 deaths in the U.S.
1
 Of these deaths, 
about half are due to coronary heart disease (CHD), which causes myocardial infarction (MI). 
Each year, approximately 600,000 Americans suffer their first MI and another 300,000 have a 
recurrent attack, with an additional 150,000 silent MIs estimated.
1
 Advances in the treatment of 
acute MI have reduced hospital mortality to about 6%.
1
 However, in spite of this success, or 
perhaps because of it, MI has become a major cause of heart failure with approximately 20% of 
patients developing heart failure within 5 years of their first MI.
1
 MI initiates a dynamic process of 
left ventricular (LV) remodeling, which includes both maladaptive biological and mechanical 
changes that may lead to altered contractile properties and ultimately, heart failure. Despite 
current standard of treatment, LV remodeling caused by a MI is responsible for 70% of the 5.1 
million cases of heart failure present in the U.S.
2
  
1.2. LV Remodeling Post-MI  
MI occurs following coronary artery occlusion, resulting in depletion of nutrients and 
oxygen to the myocardium and subsequent cardiomyocyte death. This cardiomyocyte necrosis 
leads to an influx of inflammatory cells (i.e., macrophages, monocytes, and neutrophils) into the 
infarcted area to remove the necrotic debris.
3
 Fibroblasts also infiltrating the infarct region secrete 
bioactive molecules, such matrix metalloproteinases (MMPs).
4,5
 Although initially essential to 
provide the necessary substructure for subsequent scar formation, MMP upregulation is not met 
2 
 
by a concomitant upregulation of their endogenous inhibitors (TIMPs), leading to a substantial 
increase in the breakdown of cardiomyocyte extracellular matrix (ECM) and collagen.
6
 To 
counteract the ECM breakdown, fibroblasts and myofibroblasts secrete collagen which leads to 
the formation of a fibrotic scar that is non-contractile and maladaptive.
3,5,7,8
 Furthermore, since 
cardiomyocytes are tethered together with collagen, this leads to continuous stretch and slippage 
of cardiomyocytes from one another, which weakens the myocardial wall and makes it 
susceptible to global geometric changes, including thinning and dilatation.
9,10  
 
 
Figure 1.1. Schematic of LV remodeling following MI, highlighting the infarct expansion and 
global geometric changes that occur over time. Figure adapted from [11].  
The mechanical phenomenon that both initiates and sustains the entire adverse LV 
remodeling process is the initial infarct expansion (Figure 1.1).
12-15
  From a structural perspective, 
early infarct expansion results from thinning of the ventricular wall and increased compliance. 
However, it is a progressive pathologic process that eventually causes abnormal stress 
distributions in the borderzone (BZ) regions surrounding the infarct. As part of this self-
perpetuating process, increased regional BZ stresses lead to maladaptive cellular and enzymatic 
processes, such as additional cardiomyocyte apoptosis and MMP activation.
13-15
 Once initiated, 
3 
 
these biological processes are difficult to reverse by medical or surgical means and ultimately 
lead to altered contractile properties and heart failure.
4
  
1.3. Strategies for the Treatment of MI  
Clinical approaches to MI focus on the acute setting, yet few therapies have been 
developed to prevent the progression from MI to eventual heart failure, at which point heart 
transplantation remains the only definitive treatment. Current treatments focus on two main 
approaches: 1) restoring blood flow to the occluded vessel to reperfuse the ischemic tissue 
through the use of bypass surgery, balloon angioplasty, or coronary stents or 2) replacing the 
damaged heart tissue using ventricular assist devices, artificial hearts, or ideally, heart 
transplants. Pharmacological therapies, such as angiotensin-converting enzyme (ACE) inhibitors 
and beta-blockers, help by either reducing the blood volume to decrease demands on the heart or 
minimizing arrhythmias to limit recurrent MI attacks, respectively.
11,16
 Whereas reperfusion and 
pharmacologics have been shown to delay the onset of heart failure post infarction, they do little 
to address the changes in the myocardial tissue properties that occur during remodeling.  
As suggested above, limiting initial infarct expansion has been identified as a potential 
therapy to alter myocardial properties post-MI and reduce the morbidity associated with LV 
remodeling that leads to heart failure.
17
 Previous strategies to limit infarct expansion include 
surgical reconstruction of the dilated LV and physical restraint of the ventricle or infarct region 
using polymeric meshed materials to prevent dilation.
18-21
 Injectable biomaterials have been 
explored to circumvent the surgical placement of LV restraining devices or cardiac patches. 
Injectable biomaterials offer the potential for minimally invasive delivery, which decreases 
damage to the target and surrounding tissues and enables more rapid clinical translation. 
Recently, injectable hydrogels have been used to mechanically stabilize the myocardial wall and 
modulate maladaptive biological processes post-MI through delivery of therapies, such as cells 
and growth factors (Figure 1.2),
22,23
 as will be discussed more in depth in Chapter 3. Hydrogels 
are water-swollen networks of polymer chains with a high degree of flexibility, similar to natural 
4 
 
tissue
24
 and can be formed through numerous mechanisms, including in situ formation.
25
 Due to 
their high tissue-like water content, structural similarity to native macromolecular components, 
and mechanical properties resembling those of soft tissues, they have been used for numerous 
applications in tissue engineering and drug delivery.
26
  
 
Figure 1.2. Delivery of injectable hydrogels as bulking therapy to stabilize the LV wall and alter 
the local myocardial wall stresses post-MI. Figure adapted from [27].  
1.4. Principles of MRI  
In addition to developing therapies to attenuate LV remodeling, noninvasive techniques 
are also needed to assess the effects of these therapies once delivered to the myocardium. 
Imaging can noninvasively provide mechanistic information over time regarding the presence and 
distribution of hydrogels throughout the tissue and simultaneously investigate the impact of 
injectable materials on myocardial properties post-MI, which may lead to better design principles 
for future material optimization. Magnetic resonance imaging (MRI) offers advantages over other 
imaging modalities, such as optical
28-31
 or x-ray imaging,
32-35
  due to its high spatial and temporal 
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resolution at any tissue depth without the use of ionizing radiation,
36,37
  and thus, has been widely 
used in the clinic and applied to evaluate cardiac outcomes following MI.
38-40
 To understand the 
ability of MRI to assess injectable hydrogel properties, as will be discussed in Chapters 5 and 6, 
and evaluate the alterations in myocardial tissue properties with hydrogel therapy, as will be 
discussed in Chapter 7, an exploration of the basic principles of MRI is needed. 
A MRI signal is generated from manipulating the water protons in materials or tissues 
using oscillating magnetic fields. Any nucleus with an odd number of protons or neutrons can be 
exploited for MRI but the protons in water are primarily targeted since biological tissues have a 
high water content. Due to their charge and intrinsic spin property, water protons have a magnetic 
dipole moment causing them to act like a bar magnet.
41
 In the absence of a magnetic field, water 
protons are randomly oriented and precessing (i.e., spinning) at their natural frequency. To image 
a material or tissue, the dipole moment property of water protons is manipulated using magnetic 
fields.
36
 When placed in an external, static magnetic field of strength B (referred to as B0), the 
protons align themselves with and begin precessing around the magnetic field. Approximately half 
of the protons point in the direction of the field and half point in the opposite direction. Over time, 
slightly more protons align with the B0 field (about one in a million), creating a macroscopic 
magnetic moment referred to as the net magnetization (M) vector.
41
 As a reference, the 
conventional MRI coordinate system specifies that both the B0 field and the magnetization vector 
M are aligned along the z-axis at equilibrium. The maximum signal is obtained when the net 
magnetization is perpendicular to the B0 field (i.e., in the x-y plane).  
Therefore, to acquire a signal and subsequently generate an image, the protons must be 
further manipulated. To do so, the MR scanner contains a radiofrequency (RF) coil situated within 
the larger main (B0) magnet. The RF coil is selectively tuned to the resonance frequency of water 
protons and creates a secondary magnetic field (B1) which rotates the net magnetization of the 
protons away from their alignment with B0. The degree of rotation (e.g. 90
o
, 180
o
) is specified in 
the pulse sequence, which describes the series of RF pulses.
37,41
  For instance, application of a 
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90
o
 RF pulse causes the protons to become perpendicular to the B0 field. Whereas the B0 field is 
always present, the B1 field can be turned on and off. When the B1 magnetic field is removed, the 
protons relax back to their equilibrium state and realign so that their net magnetization M is again 
parallel with B0. During this relaxation process, protons emit energy in the form of an free-
induction decay (FID) that can then be detected by the RF coil and processed (by Fourier 
transformation) to generate an image.
36,41
 Gradient coils also embedded within the main magnet 
are applied during the RF pulse train to produce gradients in the B0 magnetic field and encode 
slice, phase and frequency information.
41
  This encoding process enables extraction of three-
dimensional information and, once reconstructed, results in images with high spatial resolution.  
Image contrast between tissues or materials is generated based on differences in 
composition, specifically proton density and relaxation properties. The relaxation properties 
describe the manner by which protons respond to RF pulse manipulation. During a RF pulse, 
interactions between protons cause them to precess at slightly different rates, leading them to 
dephase (or spread out) from one another, which results in signal decay. Transverse (T2) 
relaxation describes this rate of proton dephasing and magnetization decay in the transverse 
plane.
37
  When the RF pulse is turned off, the protons first rephrase rapidly and then recover back 
to equilibrium along the longitudinal axis (i.e., z-axis) by the process of longitudinal (T1) 
relaxation.
41
  In terms of the magnetization, the Mxy component of the magnetization vector 
decays rapidly and the Mz component slowly recovers along the z-axis; these are independent 
but simultaneous processes.
36,37,41
 These MR properties (i.e., T1/T2 relaxation times, proton 
density) are intrinsic to the material or tissue of interest but can be manipulated to enhance 
differences in endogenous image contrast, as will be discussed further in Chapters 5 and 6 in 
references to visualizing injectable hydrogels in the myocardium.   
1.5. Cardiac MRI  
Noninvasive imaging techniques are needed not only to visualize the injected material 
once delivered to the myocardium but also to assess cardiac outcomes to determine the impact 
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of injectable hydrogel therapies on the heart. The evaluation of cardiac disease and therapeutic 
interventions with noninvasive imaging techniques has assumed increasing importance over the 
past few decades, with the goal of defining anatomic abnormalities in the heart and coronary 
arteries to provide insight to the pathophysiology of cardiac diseases. Advances in rapid MRI 
acquisition techniques and its application to cardiac imaging have shown its tremendous potential 
for evaluation of cardiac diseases and the efficacy therapeutic interventions.
42-49
 When compared 
with other well-established cardiac imaging modalities, such as echocardiography, single-photon 
emission computed tomography (SPECT), or positron-emission tomography (PET), cardiac MRI 
offers an excellent depiction of myocardial wall motion, high image contrast, and high spatial 
resolution without using ionizing radiation. Its efficacy, together with its excellent safety profile and 
increasing availability, makes cardiac MRI an important and sophisticated tool for noninvasive 3D 
evaluation of cardiovascular structure, function and viability. 
The most accurate method for evaluating the morphology and function of the heart has 
become cine MRI. Cine MRI enables noninvasive assessment of global morphology and altered 
regional wall motion in all segments of the LV, with high spatial and temporal resolution.
50,51
 
Direct imaging of non-viable myocardial regions can be performed using myocardial late-
gadolinium enhancement (LGE) MRI. LGE is exclusively related to irreversible injury, irrespective 
of contractile function or age of injury and hence, can be used to detect regions of infarction.
52
 
Using gadolinium-based contrast agents, this technique visualizes MI as regions of bright signal 
compared to normal myocardium. Finally, myocardial tagging with MRI can be used to directly 
visualize the contractility of the ventricles. Using pre-saturation pulses, a grid of dark lines or 
“tags” is produced immediately following the R-wave trigger and then, as the tissue moves and 
deforms through the cardiac cycle, the tagging pattern moves correspondingly.
50,53-55
 By acquiring 
images perpendicular to the tagging planes, the tags can be used to track the motion of the heart. 
The power of myocardial tagging lies in the ability to perform quantitative myocardial strain 
analysis with great accuracy and precision.
36,43
 Using MRI tagging data, theoretical finite element 
(FE) models can compute myocardial stress and strain distributions in the LV post-MI.
56-59
 
8 
 
Recently, FE models have been developed to investigate the effects of injectable biomaterials on 
attenuating adverse LV remodeling post-MI.
56,60-62
 In one study, simulations indicated that 
injection of a noncontractile material to an infarcted LV has the potential to reduce elevated 
myofiber stresses.
60,61
 However, the use of in vivo-derived MRI data as an input to a FE model 
has yet to be explored prior to this dissertation (as will be addressed in Chapter 7).   
1.6. Summary  
Motivated by the clinical burden of heart failure, injectable biomaterials are a promising 
therapy to target the tissue remodeling process that is known to cause progression from MI to 
heart failure. Despite experimental successes in animal models, only one injectable material has 
progressed to clinical trials.
63,64
 Therefore, to more efficiently develop injectable systems with 
optimal materials properties to attenuate cardiac remodeling post-MI, noninvasive tools are 
needed to simultaneously investigate materials properties and cardiac outcomes. To address this 
need, this dissertation will focus on the use of MRI to both examine material properties once 
delivered to the myocardium as well as assess the impact of injectable materials on myocardial 
remodeling post-MI. The imaging techniques explored can be applied to a wide range of 
injectable materials to better understand the material-myocardial interactions and facilitate 
selection of injectable systems with higher translational potential for MI repair.  
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CHAPTER 2 
 
Research Overview 
 
2.1. Objectives 
Cardiovascular disease is the leading cause of death in the U.S. Each year, over one 
million of U.S. residents have myocardial infarctions (MI) and roughly one-third of them progress 
to heart failure and death. MI leads to abnormal stress distributions in the myocardium, which 
results in maladaptive biologic processes that may lead to altered contractile properties and heart 
failure. Although numerous surgical and pharmacological have been shown to delay the onset of 
heart failure post-MI, they do little to address the myocardial tissue remodeling that occurs 
following infarction. Hence, there is a need for new therapeutic interventions that target the post-
MI left ventricular (LV) remodeling process to further limit progression to heart failure. 
Injectable biomaterials, specifically hydrogels, have become an attractive therapy to 
provide mechanical stabilization to attenuate adverse remodeling after MI. Despite the wide range 
of injectable hydrogels investigated for MI-induced remodeling, there is a lack of techniques to 
evaluate the properties of injected hydrogels and their impact on myocardial tissue in vivo. 
Imaging modalities, such as magnetic resonance imaging (MRI), can noninvasively characterize 
biomaterial and myocardial properties, which may lead to better design principles for future 
biomaterial optimization. Therefore, the purpose of this dissertation is to use injectable hyaluronic 
acid (HA) hydrogels and MRI as a platform to investigate the presence and composition of 
hydrogels once injected into the myocardium and the effect of injectable hydrogels on myocardial 
tissue properties for the attenuation of LV remodeling post-MI. 
Towards this goal, an HA hydrogel system will be developed and examined for the range 
of properties that are attainable. After understanding how hydrogel properties can be tuned for an 
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intended application, non-contrast MRI techniques will be used to visualize and quantify 
differences in hydrogel distribution based on gelation in myocardial explants and differences with 
macromer concentration and chemistry using chemical exchange saturation transfer (CEST). 
Finally, a single degradable hydrogel formulation will be applied to an in vivo infarct model and 
MRI will be used to evaluate differences in myocardial tissue properties after hydrogel delivery 
throughout the remodeling process. 
2.2. Specific Aims and Hypotheses 
The global hypothesis of this dissertation is that MRI can be used to evaluate the 
properties of injectable materials once delivered to the myocardium and systematically investigate 
the therapeutic effects of injectable materials on tissue properties of the remodeling myocardium 
post-MI. This advance would provide technology and insight into design criteria for targeted 
biomaterial therapies for MI repair. This hypothesis will be systematically investigated using the 
following three Specific Aims. 
Specific Hypothesis 1: Hydrogel degradation, mechanics, and rate of gelation can be controlled 
by altering macromer chemistry, macromer concentration, and initiation conditions.  
Specific Aim 1: Synthesize and characterize degradable HA hydrogels with a range of properties, 
particularly gelation, degradation, and mechanics.  
HA will be modified with a hydrolytically degradable functional group, hydroxyethyl  
methacrylate (HeMA), to generate the gel precursor, HeMA-HA. HeMA-HA can be crosslinked 
through a radical polymerization reaction to form HA hydrogels and will be further optimized to 
obtain formulations with a range of gelation times, degradation profiles, and mechanical 
properties. These properties will be assessed in vitro using rheological characterization, an uronic 
acid assay to measure HA release, and compressive mechanical testing, respectively. 
Characterization will be performed for both pure HeMA-HA homopolymer hydrogels and 
copolymer hydrogels with a hydrolytically stable macromer, methacrylated HA (MeHA). Hydrogels 
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will be formed with a range of initiator concentrations, macromer modifications, and macromer 
concentrations to explore the parameter space of tunable properties. The ability to tune hydrogel 
properties will then be utilized in subsequent imaging (Aim 2) and in vivo (Aim 3) studies. 
Specific Hypothesis 2: Non-contrast MRI can be used to visualize and quantify differences in 
hydrogel distribution volume and macromer chemistry within myocardial tissue. 
Specific Aim 2: Visualize HA hydrogels using MRI as a means to examine hydrogel dispersion 
and detect differences in hydrogel chemical composition ex vivo. 
The gelation of HA hydrogels will be altered to form hydrogels with varied distribution in 
myocardial tissue, through changes in initiator concentration and macromer modification. Three-
dimensional hydrogel dispersion volumes will be visualized and quantified using conventional (T2-
weighted) MRI. As an alternative to the radically polymerized MeHA and HeMA-HA hydrogels, 
guest-host chemistry will also be introduced into HA hydrogels to form materials through 
supramolecular self-assembly. Thus, the effect of both the timing of gelation and the mechanism 
of hydrogel formation on hydrogel distribution in myocardial tissue will be assessed. 
To expand upon traditional MRI approaches, a new MRI acquisition technique will be 
explored that is based on chemical exchange saturation transfer (CEST), where the signal relies 
on the exchange of protons in specific molecules (either endogenous to or engineered into the 
material) with bulk water protons. CEST MRI will be used to identify the exchangeable proton 
groups in HA hydrogels and manipulate those protons to visualize HeMA-HA hydrogels either 
alone or after injection into tissue. Changes in the CEST contrast with changes in hydrogel bulk 
properties (i.e. macromer concentration) will be investigated. To detect differences in hydrogel 
chemistry using CEST MRI, an arginine-based peptide will be coupled to HeMA-HA hydrogels to 
introduce an additional exchangeable proton group known to generate a CEST effect. 
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Specific Hypothesis 3: The delivery of HA hydrogels to the myocardium post-MI alters LV 
volumes, cardiac function, and myocardial wall thicknesses, strains and stiffnesses to attenuate 
remodeling. 
Specific Aim 3: Assess the temporal effects of degradable HA hydrogel therapy on long-term 
myocardial tissue remodeling post-MI using cardiac MRI and finite element (FE) modeling in an in 
vivo porcine infarct model. 
A previously characterized HeMA-HA hydrogel formulation (selected based on Aim 1) will 
be applied to an in vivo porcine infarct model and cardiac MRI will be used to evaluate myocardial 
tissue properties over time, up to 12 weeks post-MI. More specifically, cine MRI will assess global 
LV structure and function, late-gadolinium enhancement (LGE) MRI will visualize changes (i.e. 
thinning, expansion) in the infarct region, and spatial modulation of magnetization (SPAMM) 
tagging will measure myocardial strains as an assessment of wall motion and contractility. Finite 
element (FE) modeling with MRI-derived strain inputs will be used to simulate the impact of 
injectable hydrogels on regional myocardial stiffness over time. 
2.3. Chapter Outline 
Chapter 1 presented the translational motivation for designing injectable hydrogels as 
bulking agents to attenuate LV remodeling and the use of imaging, specifically MRI, as a tool to 
noninvasively assess the effects of these therapies. An extensive review of natural and synthetic 
injectable hydrogels as acellular, cellular, and therapeutic delivery vehicle therapies for MI 
treatment will be presented in Chapter 3. Chapter 4 will then focus on the in vitro characterization 
of hydrolytically degradation HA hydrogels. The effect of altering material parameters (e.g. 
initiator concentration, macromer modification, and macromer concentration) on the resulting 
hydrogel properties (e.g. gelation, degradation, and mechanics) will be investigated in both pure 
HeMA-HA and HeMA-HA/MeHA copolymer hydrogels. 
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Based on an understanding of the tunability of injectable HA hydrogels, the next portion 
of the dissertation (Chapters 5 and 6) will focus on the noninvasive characterization of hydrogel 
properties in myocardial explants using non-contrast agent based-MRI techniques. Chapter 5 will 
explore the use of conventional MRI to qualitatively and quantitatively assess three-dimensional 
HA hydrogel dispersion. Differences in hydrogel volume distribution in tissue will be induced by 
alterations in gelation conditions. Chapter 6 will utilize MRI with endogenous CEST contrast to 
detect differences in material properties (i.e. macromer concentration) and visualize HA hydrogels 
in tissues by manipulating the exchangeable protons. In contrast to traditional MRI, CEST MRI 
will be applied to discriminate between injectable materials based on their distinctive chemistries. 
After exploring the ability to examine differences in hydrogel properties after injection into 
the myocardium, the following portion of the dissertation (Chapter 7) will focus on understanding 
the impact of hydrogels on the surrounding myocardial tissue properties in an in vivo porcine 
infarct model. Cardiac MRI will be used to temporally evaluate the effect of injectable HA 
hydrogels on remodeling post-MI by measuring global LV volumes and functional outputs as well 
as regional thicknesses, wall strains, and myocardial stiffnesses with the use of FE modeling. 
Finally, Chapter 8 will summarize the main conclusions and discuss the limitations and future 
directions of each Specific Aim. 
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CHAPTER 3 
 
A Review of Hydrogels in Cardiac Tissue Engineering 
 
(Adapted from: Dorsey SM, Burdick JA. In: Khademhosseini A, Demirci U, editors. Applications of 
Hydrogels in Regenerative Medicine, in press.) 
3.1. Introduction  
Heart failure is a major public health issue that affects almost 23 million individuals 
worldwide and 5 million individuals in the US alone.
1
 As discussed in Chapter 1, survival after the 
diagnosis of heart failure has improved but the death rates remain high, with half of patients dying 
within 5 years.
2
 In fact, one in every nine U.S. death certificates in 2010 mentioned heart failure 
as a contributing factor.
2
 Moreover, the majority of heart failure cases have been attributed to the 
process of left ventricular (LV) remodeling following myocardial infarction (MI).
2,3
 As described in 
Chapter 1, injectable hydrogels are a promising therapy to attenuate this adverse remodeling by 
limiting infarct expansion to prevent progression to heart failure. In contrast to LV restraints and 
surgical reconstruction of the LV as means to alter geometry post-MI, injectable hydrogels offers 
the potential of minimally-invasively, percutaneous delivery to facilitate clinical translation.  
Both natural and synthetic materials have been explored as acellular bulking agents to 
mechanically stabilize the myocardium and as delivery vehicles for cells and/or therapeutic 
molecules to modulate the maladaptive biological processes after infarction (Figure 3.1). Various 
materials, cells, and therapeutic molecules have shown positive outcomes in animal models and, 
in doing so, provide insight for future material development and optimization. However, many 
questions remain before injectable hydrogel systems can be safely translated to patients. Future 
work should focus on elucidating the mechanism behind the positive outcomes of hydrogel 
delivery in vivo and the application of these systems to clinically relevant scenarios, including 
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minimally-invasive, percutaneous delivery. Further development of injectable hydrogel systems 
for cardiac repair will have considerable clinical impact with respect to broadening our 
understanding of the mechanisms of remodeling post-MI and improving therapies to prevent 
progression to heart failure. Towards this goal, this chapter will focus the in vivo applications of 
biomaterials for 1) tissue bulking, 2) cell delivery, 3) small molecule delivery, and 4) combined cell 
and molecule delivery (Figure 3.1) approaches, with an emphasis on injectable hydrogels.   
 
Figure 3.1. Schematic of injectable hydrogel strategies for MI repair. Hydrogels can be used as 
acellular bulking agents (A) or as a delivery vehicle for cells (B), therapeutic molecules (C), or a 
combination of cells and molecules (D).  
3.2. Acellular Approaches 
3.2.1. LV Restraints 
Over the past decade, it has become evident that the regional mechanical changes in the 
myocardial tissue properties following MI must be considered when designing biomaterial-based 
approaches for cardiac repair.
4,5
 After MI, the myocardial wall thins in the infarct region and the 
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LV dilates as the heart shifts to a more spherical shape; this leads to an increase in stress in the 
borderzone (BZ) regions surrounding the infarct. As described by the Law of Laplace (Equation 
3.1), stress (T) is directly proportional to pressure (P) and the radius of curvature (R) and 
inversely proportional to the myocardial thickness (h). Therefore, an increase in the ventricular 
radius (R) and decrease in wall thickness (h) leads to an increase in myocardial stress.  
    
   
 
           (3.1) 
Previous strategies to attenuate LV expansion include the use of polymeric meshes wrapped 
around the heart or sutured to the infarct surface, referred to as LV restraints. The theory behind 
the use of ventricular restraints is that by forcing the heart to maintain its elliptical shape and 
preventing an increase in the ventricular radius (R) of the LV, this will, in turn, lead to decreased 
myocardial wall stress (T) to ultimately attenuate LV remodeling.
6-9
  
Several studies examined the use of biomaterial supports to restrain the LV to prevent 
dilatation and adverse remodeling.
10
 Kelley et al. demonstrated preserved LV geometry and 
cardiac function in a sheep MI model with suturing of a poly(propylene) (Marlex) mesh to the 
infarct.
7
 Subsequently, Bowen et al. demonstrated that the poly(propylene) restraint has biological 
significance, leading to increased collagen and decreased protease (MMP-1, MMP-2) activity in 
the BZ myocardium.
11
 Since these initial studies, the use of heart-wrapping techniques has 
shown that infarct expansion limitation has a pronounced effect in ameliorating post-MI 
remodeling
6-9,12
, motivating translation to clinical trials. Acorn Cardiovascular, Inc. (St. Paul, 
Minnesota) developed the first commercially available restraint, consisting of a knitted polyester 
mesh to be fitted around both ventricles. In both canine
13,14
 and ovine
12,15
 infarct models, the 
Acorn CorCap restraint decreased LV volumes and improved function. This led to a clinical trial 
encompassing 300 patients where the use of CorCap decreased LV volumes, improved quality of 
life, and decreased the likelihood of additional cardiac procedures.
16
 More recently, Paracor 
Medical (Sunnyvale, California) developed a HeartNet LV support system made from a nitinol 
25 
 
mesh that is placed around the ventricles. Similarly, both canine
17
 and ovine
18
 MI models showed 
decreased LV end diastolic volume (EDV) and end systolic volume (ESV). An initial safety and 
feasibility clinical study suggested a functional and clinical benefit from the Paracore HeartNet 
device,
19
 leading to a phase II clinical trial (PEERLESS-HF).
20
 However, the clinical trial was 
stopped prematurely due to limited effects on certain functional end points.
21
 Ultimately, despite 
promising results in both large animal models and clinical trials, a major limitation of polymeric LV 
restraints is the highly invasive surgical procedure necessary for implantation. Thus, minimally 
invasive approaches are needed to limit infarct expansion and preserve LV geometry post-MI.  
3.2.2. Injectable Hydrogels as Bulking Agents 
Similar to infarct restraints, acellular injectable biomaterials can also limit infarct 
expansion by bulking the damaged myocardial wall to provide mechanical stabilization.
23
 Infarcts 
naturally stiffen over time as wound healing progresses and collagen is deposited. Therefore, the 
goal of injectable hydrogels is to modify the material properties of the infarct region before the 
body compensates for the remodeling process; in doing so, infarct expansion and remodeling 
post-MI can be limited.
23
 Referring back to the Law of Laplace (Equation 3.1), the theory behind 
the use of injectable hydrogels as bulking agents is that they increase the wall thickness (h) to 
decrease LV dilatation (R) and in turn, decrease wall stress (T). Theoretical finite element (FE) 
models have been used to evaluate the ability of injectable biomaterials to attenuate remodeling 
(Figure 3.2).
22,24,25
 Simulated injections of a non-contractile material into an infarcted LV were 
shown to decrease LV dilatation and reduce elevated myofiber stresses.
24
 In a subsequent study, 
injection of a tissue filler into the infarct reduced stress in the LV and improved ejection fraction 
(EF) in an ovine infarct model.
25
 For the first time, the use of injectable biomaterials presents the 
real possibility of limiting adverse LV remodeling using minimally invasive delivery. 
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Figure 3.2. Finite element (FE) model of simulated polymer injections, demonstrating injected 
materials and the importance of injection pattern (A) and volume of material dispersion (B) in 
decreasing myocardial stress. Figure adapted from [22]. 
3.2.2.1. Natural Acellular Hydrogels 
Hydrogels can be grouped into either natural or synthetic materials. Natural materials 
offer several advantages due to their inherent biological properties, including presentation of 
receptor-binding ligands and susceptibility to cell-triggered proteolytic degradation
26,27
 For cardiac 
applications where the goal is to replace or repair the damaged ECM, natural biomaterials more 
closely mimic features of the native ECM, enabling them to increase cell adhesion, activate cell 
proliferation, and maintain cell differentiation.
28
 Commonly used natural, injectable materials for 
cardiac repair include fibrin, alginate, collagen, Matrigel, chitosan, hyaluronic acid, keratin, and 
decellularized matrices (Table 3.1). 
Fibrin:  Fibrin, a fibrillar protein consisting of fibrinogen and thrombin, is natively a blood 
component critical to the clotting cascade. A two component system is required to form fibrin 
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hydrogels: 1) fibrinogen and aprotinin, a fibrinolysis inhibitor, and 2) thrombin, factor XIIIa, and 
calcium chloride (CaCl2). When combined, fibrinogen converts to fibrin and self-assembles to 
form a mesh crosslinked by factor XIIIa. Fibrin naturally has binding domains for soluble growth 
factors and cellular integrin receptors, making it an ideal candidate for wound healing 
applications.
29
 Fibrin hydrogels have been used for MI therapy
30-33
 due to favorable properties 
such as biodegradability, mechanical strength, and angiogenic activity.
34
  
Christman et al. first injected fibrin and showed positive outcomes on cardiac function.
30-
32
 Specifically, MI was induced in rats (temporary coronary occlusion) followed by injection of 
fibrin glue ten days later.  Assessment five weeks after delivery revealed preserved infarct wall 
thickness and fractional shortening (FS) as compared to bovine serum albumin (BSA) controls.
30
 
In a subsequent study, Christman et al. showed that injectable fibrin alone significantly decreased 
infarct area and increased arteriole density in the infarct region as compared to control BSA 
injections.
31
 The ability of injectable fibrin to induce neovascularization in the infarct region was 
later confirmed by Huang et al.
33
 
Alginate: Alginate is a naturally occurring, linear polysaccharide derived from seaweed. 
Its tailorability and non-thrombogenicity make it attractive for cardiac repair.
35-37
 It consists of 
linked ß-D-mannuronate and α-L-guluronate residues that crosslink into hydrogels in the 
presence of calcium.
38
 Alginate’s unique gelation enables delivery using minimally invasive, 
catheter-based intracoronary infusion, which relies on the infarct myocardium’s leaky vasculature. 
Due to inadequate levels of calcium in the vasculature, alginate does not crosslink until it reaches 
the infarct, where high levels of calcium induce gelation.
36
  
Landa et al. delivered alginate to rats at seven and 60 days post-MI (permanent coronary 
occlusion) for acute and chronic remodeling, respectively.
37
 Eight weeks after injection, delivery 
into recent or old infarcts increased scar thickness and attenuated LV systolic and diastolic 
dilatation and dysfunction. However, FS was not improved in either group.
37
 These results 
provide insight into the timing for hydrogel delivery post-MI. In contrast, Leor et al. delivered 
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alginate hydrogels to a clinically relevant, porcine MI model using a coronary catheter.
36
 To 
investigate the effects of delivering different hydrogel volumes, alginate solutions at incremental 
volumes (1, 2, or 4 mL) were delivered four days post-MI (temporary occlusion). At 60 days after 
delivery, intracoronary injection of alginate (2 and 4 mL) prevented and even reversed LV systolic 
and diastolic dilatation. In addition, the 2 mL alginate injection led to myofibroblast infiltration and 
increased scar thickness as compared to saline controls.
36
 Similar to the study by Landa et al., 
there were no significant FS improvements.  
Due to the positive results of alginate in both small
37
 and large
36
 animal models, it has 
become the first injectable acellular biomaterial used in clinical trials. An injectable system of 
sodium alginate and calcium gluconate was first developed and tested by BioLineRx, Ltd. as BL-
1040. In a phase I/II pilot clinical trial, the safety and feasibility of BL-1040 was demonstrated in 
27 patients, including improved survival, preserved LV EDV and ESV, prevention of FS 
deterioration, improved mitral regurgitation, and limitation of systolic wall thinning 
(NCT00557531).
39
 Since then, BioLine, Ltd. out-licensed BL-1040 to Ikaria Holdings, Inc., which 
is currently performing a placebo-controlled, double-blind phase II clinical trial with 300 patients 
(NCT01226563).
40
 More recently, LoneStar Heart, Inc. developed an injectable alginate hydrogel 
(Algisyl-LVR) that demonstrated improved LV function and decreased myofiber stress
41
 in a 
safety and feasibility phase II clinical trial of 11 patients with dilated cardiomyopathy undergoing 
open-heart surgery (NCT00847964).
42,43
 Subsequently, in an ongoing randomized, controlled 
phase II/III clinical trial,  Algisyl-LVR was delivered to 35 heart failure patients and compared to 
38 patients who received standard medical care. Primary 6-month results showed significantly 
improved clinical outcomes in terms of peak maximum oxygen uptake VO2 and a 6-minute walk 
test with hydrogel therapy (NCT01311791),
44
 leading to an open-label rollover trial for those 
enrolled in the control portion of the study (NCT02226679).
45
  
Several studies have studied the effect of modifying normally non-adhesive alginate with 
adhesive peptides such as Arg-Gly-Asp (RGD) or Tyr-Ile-Gly-Ser-Arg (YIGSR).
46,47
 Yu et al. 
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delivered modified and unmodified alginate to rats five weeks post-MI (temporary occlusion).
46
 
Five weeks after injection, delivery of either RGD modified or unmodified alginate led to 
decreased EDV and ESV, improved FS, significantly increased myocardial wall thickness, and 
significantly increased arteriogenesis as compared to BSA controls. Although both groups led to 
increased arterioles in the infarct, the RGD modified alginate group had the highest number of 
arterioles,
46
 demonstrating that surface modification can influence the infarct microenvironment.  
Further, Tsur-Gang et al. delivered unmodified alginate, alginate modified with adhesion peptides 
RGD and YIGSR, and alginate modified with a non-specific peptide, RGE, to rats  seven days 
post-MI (permanent occlusion).
47
 In this case, unmodified alginate led to the best improvements 
in infarct thickness, LV geometry, and FS 60 days after injection. However, no significant 
differences were seen in relative infarct thickness, cell infiltration, or blood vessel density between 
the groups.
47
 Differences in material viscosity may explain some of these findings. 
Due to the positive benefits of fibrin and alginate alone, Mukherjee et al. delivered a 
fibrin-alginate composite to pigs one week post-MI (permanent occlusion).
48
 Injections were 
performed using a double-barrel syringe; one component was composed of fibrinogen, 
fibronectin, factor XIII, plasminogen, and gelatin-grafted alginate dissolved in an aprotinin solution 
while the other consisted of thrombin and CaCl2. Assessment performed at one, two, and three 
weeks after delivery demonstrated significantly increased wall thickness at one week and limited 
LV expansion at two and three weeks post-injection. However, no functional improvements were 
observed. In addition, the composite led to significantly reduced soluble collagen vulnerable to 
protease degradation and decreased protease levels (e.g., MMP-2) in the infarct as compared to 
saline controls, providing a potential mechanism for attenuated infarct expansion.
48
  
Collagen: Collagen is the most abundant protein in the human body and the predominant 
ECM protein. Due to extensive ECM damage post-MI, delivery of injectable collagen is well-suited 
for cardiac repair.
49
 Collagen can be prepared in an injectable form which self-assembles at 
physiological pH and temperature into a fibrous hydrogel.
50
 In addition, collagen has been shown 
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to promote angiogenesis and myoblast infiltration in the ischemic myocardium.
33
  Dai et al. 
delivered commercially available Zyderm (INAMED Corp., Santa Barbara, California), a bovine 
dermal collagen (95% collagen type I, 5% collagen type III) to rats one week post-MI (permanent 
occlusion).
51
 Six weeks after delivery, collagen treated animals had higher stroke volume (SV), 
increased EF, increased wall thickness, and absence of paradoxical LV systolic bulging as 
compared to controls.
51
 Unlike other natural hydrogels for cardiac repair, this study did not show 
increased angiogenesis or cell infiltration, potentially due to differences in collagen types or 
concentration injected, limiting cell migration into the infarct.   
Matrigel: As an alternative to pure collagen, Matrigel (BD Biosciences) is a commercially 
available, purified matrix isolated from a mouse sarcoma line that encompasses collagen as well 
as basement membrane proteins, including laminin and entactin, and growth factors.
52,53
 Similar 
to collagen, it undergoes a phase transition at physiological temperature to generate hydrogels.  
Ou et al. delivered Matrigel to rats immediately post-MI (permanent occlusion) and demonstrated 
significantly increased vessel density, enhanced recruitment of cardiac progenitor cells (CPCs), 
improved LV peak rate of pressure rise, increased wall thickness, and enhanced EF four weeks 
post-MI.
54
 In contrast, Kofidis et al. delivered growth-factor free Matrigel to mice immediately post-
MI (permanent occlusion) but did not demonstrate significantly increased FS at two weeks post-
MI as compared to controls but did show trends towards increased scar thickening and improved 
function.
55
 In another study, Kofidis et al. delivered Matrigel to a rat MI model and saw trends 
towards increased wall thickness and decreased end diastolic diameter (EDD) compared to 
controls two weeks post-MI.
56
  
Chitosan: Chitosan is a non-mammalian, linear polysaccharide derived by deacetylating 
chitin, the main component of crustacean exoskeletons. Chitosan undergoes a temperature-
induced phase transition to form hydrogels at physiological temperature when mixed with glycerol 
phosphate and a glyoxal salt solution.
57,58
 Gelation temperature can be altered by changing the 
glyoxal concentration and degradation kinetics can be controlled by the degree of 
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deacetylation.
59-61
 Lu et al. delivered a previously developed chitosan hydrogel
59
 to rats one week 
post-MI (permanent occlusion).  Four weeks after injection, the myocardial wall thickness was 
significantly increased, LV EDD and end systolic diameter (ESD) significantly decreased, EF and 
FS enhanced, infarct size decreased, and microvessels within the infarct increased for animals 
treated with chitosan as compared to saline controls.
57
 These results were further confirmed by 
Wang et al.
62
 and Liu et al.
58
 where chitosan alone resulted in significant improvements in EF, FS, 
infarct size, wall thickness, and vessel density.  
Hyaluronic acid: Hyaluronic acid (HA) is a linear polysaccharide abundant in the body 
that serves a role in processes such as scar reduction, cell migration, and angiogenesis.
63
 Even 
though HA is naturally derived, it is often chemically modified to tune its material properties and 
enable hydrogel formation.
64-66
 Yoon et al. developed HA hydrogels consisting of acrylated HA 
with thiol-terminated PEG crosslinkers (PEG-SH4). Injection into rats two weeks post-MI 
(permanent occlusion) led to increased vessel formation, decreased apoptosis, reduced infarct 
area, and significantly enhanced EF and SV as compared to infarct controls at four weeks after 
delivery. Interestingly, results showed increased wall thickness while histology revealed complete 
hydrogel degradation at four weeks.
64
  
 
Figure 3.3. Natural, injectable hydrogel for acellular cardiac repair. Chemical structure of 
methacrylated HA (A) and representative H&E stain of the hydrogel at 8 weeks post-MI (B). G = 
Gel, Scale bar = 50 mm. Figure adapted from [65]. 
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Ifkovits et al. developed methacrylated HA (MeHA) hydrogels crosslinked with redox 
radical initiators, ammonium persulfate (APS) and N,N,N′,N′-tetramethylethylenediamine 
(TEMED).
65
 Two formulations with different initial mechanics but similar degradation were injected 
into sheep thirty minutes post-MI (permanent occlusion). Both hydrogels significantly increased 
wall thickness relative to infarct controls eight weeks post-MI (Figure 3.3). However, only the 
higher modulus gels significantly reduced infarct expansion with trends toward decreased EDV 
and ESV and increased EF.
65
 In a subsequent study, Tous et al. compared stable MeHA 
hydrogels with hydrolytically degradable HA hydrogels and demonstrated that stable hydrogels 
improved wall thickness and LV volumes more efficiently than degradable hydrogels.
66
 These 
studies highlight the importance of material properties (e.g., mechanics, degradation) in MI repair.   
 Keratin: Keratin is another injectable, natural hydrogel being explored for cardiac 
applications. It can be extracted from human hair or animal wool and processed into an injectable 
material that self-assembles into a fibrous hydrogel.
67
 Shen et al. delivered keratin-based 
hydrogels to rats immediately post-MI (permanent occlusion) and revealed increased 
angiogenesis, increased wall thickness, decreased infarct size, and enhanced EF and FS as 
compared to saline controls at four and eight weeks post-MI.
68
 Based on these results, keratin-
based hydrogels are a promising acellular therapy for cardiac repair.   
Decellularized ECM: Decellularization of tissues is appealing for tissue engineering 
because tissue-specific materials can be generated from the same tissue being treated.
69
 
Decellularized ECM more closely mimics the unique ECM composition of each tissue, which 
includes specific fibrous proteins (collagen, fibrin, elastin, etc.), proteoglycans and 
glycosaminoglycans. In addition, its natural thermoresponsive behavior enables it to be a liquid 
hydrogel precursor at 25°C and then self-assemble to form nanofibrous hydrogels at 37°C.
70-73
  
Singelyn et al. utilized a decellularized porcine ECM that self-assembles to form a 
myocardial matrix at physiological temperature.
70-72
 When injected into the LV of healthy rats, it 
induced significant increases in arteriole formation 11 days after injection.
70
 Injection into infarcted 
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rats two weeks post-MI (temporary occlusion) led to preserved cardiac function and structure at 
one and four weeks after delivery, as evidenced by maintained EF, EDV, and ESV. Histology 
revealed increased proliferating cells and recruitment of endogenous CPCs to the infarct. A 
feasibility study was then performed to assess the efficacy of catheter delivery in a porcine model; 
histology confirmed hydrogel retention and distribution. This was the first study to successfully 
demonstrate transendocardial injections of an in situ gelling material in a clinically relevant, large 
animal model.
71
 In a subsequent study, Seif-Naraghi et al. delivered this porcine ECM hydrogel to 
pigs two weeks post-MI (permanent occlusion) using a NOGA-guided MyoStar catheter (Biologics 
Delivery Systems, Irwindale, California). Three months after delivery, echocardiography revealed 
increased cardiac function, decreased LV volumes, and improved global wall motion scores.
72
  
Okada et al. developed injectable hydrogels from decellularized small intestinal 
submucosa (SIS) and injected them into mice immediately post-MI (permanent occlusion).
73
 Two 
hydrogel forms, SIS-B and SIS-C, were evaluated for their therapeutic potential post-MI. SIS-B 
was characterized to have increased mechanical properties and significantly more basic fibroblast 
growth factor (bFGF) as compared to SIS-C. Assessment at two and six weeks post-MI revealed 
SIS-B delivery led to reduced infarct size, increased capillary density, preserved LV end systolic 
geometry, and improved cardiac contractility whereas SIS-C had minimal to no benefits as 
compared to saline controls.
73
 Since no further information was provided on the two SDS forms, it 
can be hypothesized that the outcomes were due to differences in bFGF concentration.  
3.2.2.2. Synthetic Acellular Hydrogels 
Despite several advantageous properties, natural materials are generally limited in the 
ability to tailor their properties. In contrast, synthetic materials have defined material properties, 
including molecular weight, gelation, hydrophilic/hydrophobic properties, degradation, and 
mechanics, without batch-to-batch variations.
27
 Despite their inherent lack of bioactivity, synthetic 
materials can be modified with cell binding sites or adhesive ligands to encourage cell 
interaction.
74
 For cardiac applications, synthetic materials can be designed to trigger cellular 
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events, minimize the immune response, and degrade at a controlled rate, thus enabling cell 
integration and potentially, improvements in cardiac function long-term.
26
 Various synthetic 
materials have been explored for cardiac repair therapy, including poly(N-isopropylacrylamide) 
(PNIPAAm) and poly(ethylene glycol) (PEG) based hydrogels (Table 3.1). 
Poly(N-isopropylacrylamide) (PNIPAAm): Several studies have focused on the use of 
PNIPAAm-based hydrogels due to their thermoresponsive properties.
75-78
 Fujimoto et al. 
developed a hydrogel from the copolymerization of NIPAAm, acrylic acid (AAc) and hydroxylethyl 
methacrylate-poly(trimethylene carbonate) (HEMAPTMC) to generate poly(NIPAAm-co-AAc-co-
HEMAPTMC), which gels at 37°C and degrades over five months.
75
 Injection into rats two weeks 
post-MI (permanent occlusion) led to significantly increased wall thickness, maintained LV end 
diastolic area, and preserved percent LV fractional area change compared to saline controls at 
four and eight weeks post-MI. There was also enhanced capillary density and positive staining for 
α-smooth muscle actin in the infarct, providing insight to the mechanism of functional repair.
75
  
Similarly, Wang et al. developed a thermosensitive hydrogel consisting of biodegradable 
dextran grafted to hydrophobic poly(ϵ-caprolactone)-2-hydroxylethyl methacrylate (PCL-HEMA) 
and copolymerized with thermoresponsive PNIPAAm to form Dex-PCL-HEMA/PNIPAAm.
76
 
Injection into rabbits four days post-MI (permanent occlusion) led to significantly increased EF, 
reduced EDD and ESD, increased end systolic pressure (ESP), decreased end diastolic pressure 
(EDP), increased cardiac contractility, and reduced infarct size as compared to saline controls at 
one month after delivery. Hydrogel treatment led to significantly increased infarct thickness 
despite no histological evidence of the material remaining at 30 days.
76
  
Wall et al. developed semi-interpenetrating polymer network (sIPN) hydrogels with RGD 
adhesion sites and MMP degradable crosslinkers.
77
 Thermoresponsive poly(N-
isopropylacrylamide-co-acrylic acid) [p(NIPAAm-co-AAc)] was gelled using free radical 
polymerization induced by APS and TEMED. Injection into mice immediately post-MI (permanent 
ligation) led to significantly increased wall thickness and increased FS as compared to saline 
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controls with a trend towards improved EF at six weeks post-MI. In addition, there were no 
statistical differences in FS or EF between animals treated with sIPN injection as compared to 
sham-operated, noninfarcted mice by six weeks.
77
 
 Polyethylene glycol (PEG): PEG and its derivatives have been widely studied as 
injectable hydrogels for MI repair.
79-84
 Jiang et al. developed a novel hydrogel consisting of α-
cyclodextrin (α-CD) and linear triblock copolymer, poly(ethylene glycol)-b-polycaprolactone-
(dodecanedioic acid)-polycaprolactone-poly(ethylene glycol)  (MPEG-PCL-MPEG), where 
degradation is controlled by the triblock copolymer.
79
 Injection into rabbits one week post-MI 
(permanent occlusion) resulted in significantly improved LV EF, decreased EDD and ESD, 
reduced scar thickness, and decreased infarct size at four weeks after delivery. In a subsequent 
study, Wang et al. applied the same α-CD/MPEG-PCL-MPEG hydrogel to rats five minutes post-
MI (permanent occlusion) and demonstrated significantly improved FS, decreased LV EDD and 
ESD, increased ESP, and decreased infarct size as compared to saline controls one month after 
delivery.
82
 In both studies, no significant improvements were seen in infarct neovascularization.  
Wu et al. developed a thermoresponsive PEG-based hydrogel consisting of an aliphatic, 
triblock copolymer, poly (δ-valerolactone)-block-poly (ethylene glycol)-block-poly (δ-
valerolactone) (PVL-b-PEG-b-PVL).
83
 This polymer dissolves in water at room temperature, but 
gels at 37°C. Injection into rats one week post-MI (permanent occlusion) led to significantly 
increased EF, improved end systolic elastance, improved preload recruitable strong work, 
reduced ESV and EDV, decreased infarct area, increased wall thickness, and increased blood 
vessel density five weeks after injection.
83
 Similarly, Kraehenbuehl et al. delivered a MMP-
responsive, PEG-vinylsulfone (PEG-VS) hydrogel to rats one hour post-MI (permanent occlusion) 
and showed significantly increased EF and decreased ESV with trends toward decreased EDV 
and reduced infarct size as compared to saline controls at six weeks post-MI.
84
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Table 3.1. Summary of acellular hydrogel systems and their assessment in animal MI models. 
 
Material 
Animal/  
MI Model 
Injection 
Time  
(post-MI) 
Injection 
Volume 
Evaluation 
Time (post-
delivery) 
Ref. 
Alginate 
 
Rat; Proximal 
LCA ligation 
1 week and 
2 months 
100-150 μL 2 months 
37 
Swine; Transient 
LAD occlusion 
4 days 
1, 2, and 4 
mL 
2 months 
36 
Rat; Proximal 
LCA ligation 
1 week 130 μL 2 months 
47 
Collagen 
Rat; Proximal 
LCA ligation 
1 week 100 μL 6 weeks 
51 
Matrigel 
Rat; LAD 
ligation 
Immediate 
50 μL x 5 
sites 
4 weeks 
54 
Hyaluronic acid 
Rat; LCX 
ligation 
2 weeks 50 μL 4 weeks 
64 
Sheep; LAD and 
D2 ligation 
30 minutes 
200 μL x 20 
sites 
2 and 8 
weeks 
65 
Sheep; LAD and 
D2 ligation 
30 minutes 
200 μL x 20 
sites 
2 and 8 
weeks 
66 
Keratin 
Rat; LAD 
ligation 
Immediate 100 μL 
4 and 8 
weeks 
68 
Decellularized 
ventricular 
ECM 
Rat; LAD 
ligation/ 
reperfusion 
2 weeks 75 μL 
1 and 4 
weeks 
71 
Swine; LAD 
embolization 
2 weeks 
250 μL x 14-
15 sites 
3 months 
72 
Decellularized 
SIS ECM 
Mouse; LAD 
ligation 
Immediate 20 μL 
2 and 6 
weeks 
73 
Poly(NIPAAm-
co-AAc-co-
HEMAPTMC) 
Rat; LAD 
ligation 
2 weeks 
100 μL x 5 
sites 
4 and 8 
weeks 
75 
Dex-PCL-
HEMA/ 
PNIPAAm 
Rabbit; Proximal 
LCA ligation 
4 days 
50 µL x 4 
sites 
1 month 
76 
αCD/MPEG-
PCL-MPEG 
Rabbit; LAD 
ligation 
1 week 
50 μL x 4 
sites 
4 weeks 
79 
PEG-VS 
Rat; LAD 
ligation 
2 minutes 
100 μL (via 
2-3 sites) 
4 and 13 
weeks 
80 
Rat; LCA 
ligation 
9 days 100 μL 
7 and 50 
days 
81 
*SIS = small intestinal submucosa, LAD = left anterior descending coronary artery; LCX = left 
circumflex coronary artery, LCA = left coronary artery, OM1 = obtuse marginal I branch, OM2 = 
obtuse marginal II branch, D2 = second diagonal branch  
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In contrast to degradable PEG hydrogels, Dobner et al. delivered a non-degradable PEG-
VS hydrogel polymerized with dithiothreitol (DTT) to rats two minutes post-MI (permanent 
occlusion).
80
 At four weeks post-MI, the PEG-VS hydrogel significantly increased wall thickness 
and decreased LV EDD. However, at 13 weeks, the pathological progression of the treatment 
animals was similar to that of saline controls. FS was not improved in hydrogel animals at either 
time point.
80
 Rane et al. applied the same bioinert, non-degradable PEG-VS hydrogel to rats nine 
days post-MI (permanent occlusion) and demonstrated significant increases in wall thickness as 
compared to saline controls at 50 days post-MI.
81
 Despite this, there was a steady decline in 
cardiac function and expansion of LV volumes in both the hydrogel and control animals. In 
addition, there were no significant differences in neovascularization or cell infiltration between 
hydrogel and control groups.
81
 Similar to Dobner et al., Rane et al. found that increased wall 
thickness alone was insufficient to cause positive structural and functional outcomes. These 
studies suggest that the bioactivity and ability for cells to infiltrate degradable biomaterials are 
important to preserving cardiac function post-MI. In addition, prolonged material presence alone 
may be insufficient to attenuate adverse LV remodeling. 
3.3. Cellular Approaches 
3.3.1. Cell Delivery 
MI results in the loss of over one billion cardiomyocytes in the infarct region.
85
 It was 
previously believed that after such massive cardiomyocyte loss, the adult myocardium lacked an 
intrinsic regenerative capacity for repair.
86
 Recently, studies have confirmed the activation of 
resident cardiac stem/progenitor cells and/or recruitment of endogenous stem cells post-MI.
87
 
However, this innate regenerative capacity is not sufficient to compensate for the large-scale 
tissue loss post-MI.
88
 Thus, the delivery of exogenous cells has emerged as a therapy for MI 
repair.
89
 A variety of cell types have been shown to be effective for cardiac repair, including fetal 
or neonatal cardiomyocytes, embryonic stem cells (ESCs), skeletal myoblasts, bone marrow-
derived stem cells (BSCs), adipose-derived stem cells, and cardiac stem cells (CSCs).
90,91
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ESCs offer the advantage of differentiating into both cardiomyocyte and vascular 
lineages but are limited due to their immunogenicity, risk of tumor development, and ethical 
concerns.
92
 Skeletal myoblasts have fewer ethical concerns and offer the advantages of being 
autologous, easy to obtain and expand, and resistant to ischemia.
93
 However, they cannot 
differentiate into cardiomyocytes
94
 and, even though they are naturally contractile, they have a 
limited ability to contract synchronously with host cardiomyocytes.
95
 BSCs are another autologous 
option that can be readily isolated, rapidly expanded in culture, and can maintain or modify their 
phenotype to complement the host tissue.
96
 The bone marrow is a common source of adult 
stem/progenitor cells, including mesenchymal stem cells (MSCs), endothelial progenitor cells 
(EPCs), and hematopoietic stem cells (HSCs).
97
 However, it remains unclear if BSCs can truly 
differentiate into cardiomyocytes in vivo.
94
 In contrast, resident CSCs are multipotent and can 
differentiate into cardiomyocytes in vivo,
87
 but there are concerns with scalability and autologous 
isolation from patients with recent MI.
98
 Thus, each cell type offers a unique set of advantages 
and limitations, making it challenging to select an ideal cell source for cardiac repair.  
Cell delivery, or cellular cardiomyoplasty, involves directly delivering cells to the infarcted 
myocardium using intramyocardial injection, intracoronary infusion, or interstitial retrograde 
coronary venous delivery. The feasibility of delivering cells alone to the heart has been confirmed 
for nearly two decades.
99
 While both animal models
91
 and clinical studies
90
 demonstrate 
significant improvements in cardiac function, this improvement is often not clinically relevant and, 
for the most part, transient.
100
 This transiency is due to unsatisfactory cell retention, survival, and 
engraftment.
89
 Regardless of the delivery method, there is lack of cell retention at the injection 
site due to the low viscosity of a cell-saline suspension, causing the cells to leak out during 
injection.
101
 Of the small percentage of cells that do engraft, they often lack appropriate 
functionality to have a therapeutic effect.
102
 Hofmann et al. and Hou et al. showed that less than 
10% of BMCs delivered are detected two hours after injection.
103,104
 Of the retained cells, 
approximately 90% die within the first week due to the myriad of stresses encountered upon 
injection into the infarct, including physical stress, ischemia due to microvasculature obstruction, 
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myocardial hypoxia, inflammation, and release of cytokines and reactive oxygen species.
105
 In 
addition, due to ECM breakdown post-MI, the retained cells lack an anchoring matrix which may 
result in anoikis, a form of programmed cell death due to loss of normal cell-matrix interactions.
106
 
Ultimately, in spite of enthusiasm for cell delivery, regeneration of functional, integrated 
myocardium in the infarct has yet to be demonstrated in large animal models or patients. 
Due to these challenges, biomaterials have been explored to enhance cell retention and 
engraftment for cardiac repair by improving cell attachment, migration, and survival upon 
delivery.
33
 In addition, biomaterials can enhance tissue angiogenesis,
31,33
 activate cells to 
produce cytokines,
33
 enhance cell retention,
31
 and influence cell differentiation.
107
 Polymers can 
be designed to influence integrin binding sites with a range of matrix pore sizes, substrate 
topography, and substrate rigidity.
108
 Biomaterial approaches for cell delivery include in vitro 
engineered cardiac muscle patches and injectable biomaterials. 
3.3.2. Cardiac Patches 
Cardiac patches may provide structural support to limit LV dilation post-MI, similar to LV 
restraints, but with the added benefit of cell delivery. They are constructed by seeding cells onto a 
biomaterial scaffold in vitro for subsequent in vivo implantation onto the infarcted 
myocardium.
109,110
 Theoretically, cardiac function improves through the combination of cell-
mediated remodeling
111
 and material-based mechanical stabilization which attenuates myocardial 
dilatation.
112
 Because the cells are anchored to the scaffold, cardiac patches lead to better 
engraftment when compared to cell delivery alone.
112
  
Li et al. demonstrated the use of a cardiac patch to deliver cells for cardiac repair.
113
 
Fetal cardiomyocytes were seeded on a gelatin mesh in vitro and subsequently implanted onto 
the infarct of a rat MI model, leading to prolonged cell survival over five weeks and a trend 
towards improved LV function.
113
 Since this early study, a variety of natural and synthetic cardiac 
patches have led to positive functional outcomes in vivo as compared to injection of cells 
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alone.
109,110
  Hamdi et al. compared delivery of skeletal myoblasts through intramyocardial 
injection, formation as a cell sheet, or using a collagen-based cardiac patch at four weeks post-
MI.
114
 Animals that received the cell sheet or cell seeded scaffold had significantly improved EF 
and increased vessel density one month after delivery as compared to culture medium 
controls.
114
 The promising results in animal models have led to clinical trials involving cardiac 
patches for MI repair. In the MAGNUM phase I clinical trial, BMCs were seeded on type I collagen 
cardiac patches and delivered to ten patients with coronary artery bypass grafts and intrainfarct 
implantation of autologous bone marrow cells. The combined cell injection and cardiac patch 
approach led to improved LV EDV and increased scar thickness as compared to cell injection 
alone.
115
 Additional studies using 3D fibrin cardiac patches have shown similar results.
116-118
  
Despite success with cardiac patches, major drawbacks still remain. Although the 
purpose is to improve cell engraftment, the reality is there is low engraftment within patches when 
implanted in vivo due to inadequate angiogenesis.
112,116,117
 Low vascularization limits graft 
thickness due to an inability to support the high oxygen and nutrient demands of cells at depths 
greater than ~100 μm.
119
 In addition, the patches must be sutured to the infarct,
35
 a technique 
which may be useful to prevent LV dilatation but is unlikely to directly contribute to myocardial 
contractility and function. The location of the patch on the epicardial surface of the heart also 
limits the region of therapeutic benefit. Most importantly, the invasive surgical procedure 
necessary for implantation limits clinical translation. 
3.3.3. Injectable Hydrogels for Cell Delivery 
Injectable hydrogels for cell delivery offer the advantage of enhancing cell retention, 
survival, and engraftment with the potential for minimally-invasive, percutaneous catheter-based 
delivery,
36,71,72
 which may enhance clinical translation.
37,53,57,120
 As compared to rigid cardiac 
patches with limited radial engraftment, injectable hydrogels can form in situ, integrate into the 
host tissue, and adapt to the surrounding contracting myocardium.
121
 One of their major benefits 
is that hydrogel crosslinking typically occurs after the addition of cells, enabling complete cell 
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encapsulation into a viscous but flowable delivery matrix that solidifies upon injection into the 
myocardium. Hydrogel shape, stiffness, and thickness can be controlled to ensure formation into 
the geometry of the injection site.
122
 Hydrogels not only provide three-dimensional support to 
enhance cell retention, but also permit control over the biophysical and biochemical 
microenvironment of the transplanted cells to prolong survival and engraftment.
123
 In turn, 
encapsulated cells are allowed to produce their own ECM and remodel the construct into a more 
suitable environment.  
Delivery of cells using injectable biomaterials may provide additional benefit over 
acellular materials. However, many studies show similar functional benefits with delivery of 
hydrogels alone. As previously discussed in Section 3.2.2, injection of hydrogels into the infarct 
region results in improved passive myocardial properties, mechanical stabilization due to LV 
geometry alterations, and ultimately, reduced myocardial wall stress.
24
 However, to improve 
cardiac function long-term, the therapy should also contribute to active myocardial regeneration, 
including the introduction of viable, contractile tissue.
124
 This can potentially be achieved by 
combining cell approaches with injectable hydrogels. Ultimately, hydrogels provide a platform for 
cell delivery, a structural matrix to direct tissue formation, and an improved microenvironment for 
myocardial repair.
30,74
 Similar to acellular approaches both natural and synthetic hydrogels have 
been utilized to deliver cells for myocardial repair (Table 3.2). 
3.3.3.1. Natural Hydrogels for Cell Delivery 
Natural materials are popular choice for cell delivery due to their inherent ability to be 
recognized by cell-surface receptors and potential for cell-mediated remodeling, thus facilitating 
cell-biomaterial interactions. Similar to acellular approaches, commonly used naturally derived 
hydrogels for cell delivery include fibrin, alginate, collagen, Matrigel, chitosan, and self-
assembling peptides.  
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Table 3.2. Summary of cellular hydrogel systems and their assessment in animal MI models. 
 
Material 
Animal/  
MI Model 
Cells Delivered 
Injection 
Time  
(post-MI) 
Injection 
Volume 
Evaluation 
Time (post-
delivery) 
Ref. 
Fibrin 
 
Rat; LAD 
ligation/ 
reperfusion 
Skeletal 
myoblasts 
(5×10
6
) 
10 days
43
 
or 1 
week
44
 
50 μL 5 weeks 30,31 
Rat; 
cryoinjury 
BMNCs (2×10
7
) 3 weeks 
100 μL x 
2 sites 
8 weeks 
127 
Sheep; LCX 
constriction  
Endothelial cells 4 weeks 
800  μL x 
3 sites 
2 months 
129 
Rat; LAD 
ligation 
MSCs (5×10
5
) Immediate 
150  μL x 
2 sites 
90 minutes 
128 
Collagen 
Rat; LAD 
ligation 
MSCs (2×10
6
) 1 week 70 μL 4 weeks 
133 
Matrigel 
Mouse; 
LAD ligation 
ESCs (1×10
6
) Immediate 50 μL 2 weeks 
55 
Rat; LAD 
ligation/ 
heterotopic 
transplant 
ESCs (2×10
6
) Immediate 125 μL 2 weeks 134 
Chitosan 
Rat; LAD 
ligation 
ESCs (1×10
7
) 1 week 100 μL 4 weeks 
57 
Rat; LAD 
ligation 
Adipose-derived 
MSCs (4×10
6
) 
1 week 
100 μL 
(via 3 
sites) 
4 weeks 
58 
Self-
assembling 
peptides 
Minipigs; 
Mid-LAD 
ligation 
BMNCs (1×10
8
) Immediate 
50 μL x 
40 sites 
4 weeks 
135 
Dex-PCL-
HEMA/ 
PNIPAAm 
Rabbit; 
Proximal 
LCA ligation 
BMNCs (1×10
7
) 1 week 
50 µL x 4 
sites 
1 month 
78 
αCD/MPEG
-PCL-
MPEG 
Rat; LCA 
ligation 
BMNCs (2×10
7
) 1 week 
50 μL x 4 
sites 
4 weeks 
136 
Oligo(PEG 
fumarate) 
Rat; LAD 
ligation 
ESCs (1×10
6
) 1 week 
100 μL 
(via  3 
sites) 
4 weeks 
137 
PEGylated-
fibrinogen 
Rat; 
Proximal 
LAD ligation 
Neonatal cardio-
myocytes 
(3×10
6
) 
1 week 300 μL 30 days 
138 
 
* BMNCs = bone marrow-derived mononuclear cells, MSCs = mesenchymal stem cells, ESCs = 
embryonic stem cells, CPCs = cardiac progenitor cells, ELC = endothelial-like cells, SMLC = 
smooth muscle-like cells (see Table 3.1 for additional abbreviations)  
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Fibrin: Injectable fibrin has been used to deliver a variety of cell types, including skeletal 
myoblasts,
30,31
 BSCs,
125
 bone marrow mononuclear cells (BMNCs),
126,127
 bone marrow-derived 
CSCs,
118
 MSCs,
128
 endothelial cells,
129
 and adipose-derived stem cells.
130,131
 Regardless of the 
cell source, delivery of cells encapsulated in fibrin leads to enhanced neovascularization, 
improved LV function, and attenuated LV remodeling.
132
  Christman et al. demonstrated the 
benefits of injectable hydrogels for cell delivery over traditional cellular cardiomyoplasty.
31
 
Injection of skeletal myoblasts encapsulated in fibrin glue in rats one week post-MI (temporary 
occlusion) led to a significantly greater cell area relative to myoblasts injected in BSA five weeks 
after delivery, indicating that fibrin increases cell survival by potentially serving as a temporary 
ECM for the injected cells.
31
 Similar to previous studies,
30
 fibrin glue, with or without cells, induced 
neovascularization in the ischemic myocardium and reduced infarct expansion.  
Ryu et al. delivered BMNCs with and without fibrin encapsulation to rats three weeks 
following MI (cryoinjury).
127
 Eight weeks after delivery, histological evaluation revealed increased 
neovascularization when cells were delivered using fibrin hydrogels, including significantly 
increased microvessel density and larger internal vessel diameters, as compared to delivery of 
cells alone or culture medium controls.
127
 However, it is unclear if the improvements were due to 
fibrin alone or BMMC delivery due to lack of a fibrin control. Chekanov et al. reported similar 
results when delivering endothelial cells with and without a fibrin matrix to an ovine chronic 
ischemia cardiomyopathy model.
129
 Finally, Martens et al. delivered labeled MSCs encapsulated 
in fibrin to rats immediately post-MI (permanent occlusion) using a minimally invasive, 
percutaneous catheter.
128
 Ninety minutes after delivery, cells delivered using fibrin had 
significantly increased retention in the heart and reduction of redistribution to the liver and kidney 
as compared to cells delivered alone.
128
  
Alginate: Alginate hydrogels have also been utilized for cell delivery for cardiac repair. Yu 
et al. used injectable, RGD modified, alginate hydrogel microspheres to deliver encapsulated 
MSCs (temporary occlusion).
139
 Alginate encapsulation improved cell attachment and growth and 
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increased angiogenic growth factor expression in vitro.  Injection of alginate, with or without cells, 
into rats one week post-MI (temporary occlusion) led to preserved wall thickness and significantly 
improved FS at ten weeks after delivery as compared to baseline. Histology demonstrated that 
each treatment group (alginate alone, cells alone, and alginate with cells) reduced infarct area 
and increased arteriole density indicative of angiogenesis, with no significant differences between 
the groups. Despite comparable functional outcomes between the groups, the use of alginate 
significantly increased cell survival over cells alone or saline controls.
139
  
Collagen: Collagen has also been used to deliver cells for MI repair. Dai et al. delivered 
nanoparticle labeled MSCs encapsulated in a commercially available collagen matrix to rats one 
week post-MI (permanent occlusion).
133
 Four weeks following injection, collagen encapsulation 
significantly reduced MSC relocation to regions of non-infarcted myocardium and remote organs 
relative to delivery of cells alone. However, cell delivery using collagen hydrogels did not 
significantly improve LV EF as compared to saline controls. EF was significantly increased in 
animals that received collagen alone, consistent with a previous study,
51
 as well as cells alone as 
compared to saline.
133
 To assess the translational potential of collagen-cell systems, Thompson 
et al. injected autologous BMCs encapsulated in a collagen hydrogel into the myocardium of pigs 
using a composite catheter system (TransAccess).
140
 Histology revealed hydrogel retention in the 
myocardium immediately after injection and at 14 and 28 days following injection, indicating the 
efficacy of intramyocardial catheter delivery.  However, since this procedure was only performed 
on non-infarcted hearts, it is difficult to assess the effects of this therapy on LV remodeling.
140
  
Matrigel: Several cell types have been delivered using Matrigel hydrogels, including 
ESCs
55,134
 and ESC-derived cardiomyocytes.
53
 Laflamme et al. delivered human ESC-derived 
cardiomyocytes encapsulated in Matrigel to rats four days post-MI (temporary occlusion) and saw 
preserved cell retention in the infarct as compared to cell delivery in serum free medium at one 
week after injection.
53
 Kofidis et al. delivered labeled mouse ESCs encapsulated in Matrigel to a 
rat heterotopic heart transplant model immediately post-MI (permanent occlusion).
134
 Two weeks 
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later, delivery of Matrigel encapsulated ESCs led to significantly increased FS, increased 
thickness in the posterior and septal walls, and reduced EDD as compared with controls 
(infarcted, Matrigel alone,  ESCs alone).
134
 These functional and structural results were confirmed 
in a subsequent study using a mouse MI model. In this study, the Matrigel encapsulated ESCs 
showed expression of gap junction protein connexin 43 at intercellular sites, indicating possible 
connections with the host myocardium.
55
  
Composites of collagen and Matrigel have also been used for MI repair.  The Zimmerman 
group developed a novel cardiac muscle construct known as engineered heart tissue (EHT), 
which consists of neonatal cardiomyocytes with an artificial ECM made from collagen type I, 
Matrigel and cell growth medium.
141
 Due to the properties of collagen and Matrigel, EHT remains 
a liquid at room temperature but solidifies at 37°C. Zhang et al. delivered liquid EHT as an 
injectable hydrogel to rats three weeks post-MI (permanent occlusion). One month after delivery, 
collagen-Matrigel encapsulated cardiomyocytes led to increased wall thickness, decreased LV 
ESD, and enhanced FS as compared to matrix alone, cells alone, or medium controls.
142
  
Chitosan: Chitosan hydrogels have also been used for cell delivery post-MI. Lu et al. 
delivered chitosan encapsulated ESCs to rats one week post-MI (permanent occlusion) and saw 
significantly improved 24-hour cell retention and four-week graft size as compared to delivery of 
ESCs alone.
57
 In addition, delivery of ESCs encapsulated in chitosan led to significantly increased 
microvasculature density in the infarct, increased wall thickness, reduced infarct area, decreased 
EDD and ESD, and improved FS and EF at four weeks after injection as compared to chitosan 
alone, ESCs alone, or saline controls.
57
 These results were later confirmed by delivering a 
chitosan hydrogel with encapsulated adipose-derived MSCs to a rat MI model. Even though 
injection of chitosan or cells alone improved cardiac structure and function as compared to saline 
controls, the combination of cells with chitosan further improved outcomes.
58
  
Self-assembling peptides: Self-assembling peptides consist of alternating hydrophilic and 
hydrophobic amino acids that can form stable β-sheets. At physiological osmolarity and pH, these 
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peptides self-assemble to form nanofibrous hydrogels. Due to the ability of their structure to 
promote cell organization, these biologically inspired materials have been used for cell delivery in 
both small
143,144
 and large
135
 animal models. Various cells have been delivered, including 
cardiomyocytes,
143,145
 CPCs,
146
 skeletal myoblasts,
144
 and BMNCs.
135
 Dubois et al. injected 
skeletal myoblasts with self-assembling peptides into rats two weeks post-MI (permanent 
ligation).
144
 One month after injection, peptide nanofibers alone significantly increased 
angiogenesis, but did not improve encapsulated skeletal myoblast survival. Consistent with the 
decreased cell survival, no functional improvements were seen in any of the therapy groups 
relative to culture medium controls.
144
 In contrast, Lin et al. used self-assembling peptides to 
deliver cells to a large animal MI model.
135
 Injection of BMNCs and self-assembling peptides to 
minipigs immediately post-MI (permanent occlusion) significantly increased EF as compared to all 
other groups (cells alone, peptides alone, saline controls) and increased interventricular septum 
(IVS) systolic and diastolic thickness relative to saline controls at four weeks after delivery. In 
addition, peptide nanofibers alone significantly enhanced diastolic function as evidenced by 
increased IVS diastolic thickness relative to BMNCs or saline controls, whereas BMNCs alone 
significantly improved EF and increased IVS systolic thickness relative to saline controls. Overall, 
the delivery of cells and nanofibers led to the greatest improvements in cardiac function.
135
  
3.3.3.2. Synthetic Hydrogels for Cell Delivery 
Synthetic hydrogels can also be used as cell carriers post-MI. Due to their tunability, 
small peptides can be added to promote cell interactions or degradation. Similar to acellular gels, 
the primary synthetic materials used for cell delivery are PNIPAAm- and PEG-based hydrogels. 
Poly(N-isopropylacrylamide) (PIPAAm): Thermoresponsive PIPAAm hydrogels have 
successfully encapsulated and delivered cells post-MI in several studies.
77,78
 Li et al. delivered 
BMNCs encapsulated in a thermoresponsive Dex-PCL-HEMA/PNIPAAm hydrogel to rabbits one 
week post-MI (permanent occlusion), as previously discussed in Section 3.2.2.2.
78
 Histology 
performed 48 hours after injection showed significantly increased cell retention in the infarct with 
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the presence of the hydrogel as compared to BMNCs alone. Thirty days post injection, delivery of 
BMNCs in hydrogels significantly decreased infarct size, increased neovascularization, reduced 
LV EDD and ESD, and increased EF as compared to cells alone, hydrogel alone, or culture 
medium controls. Even though material alone led to improved structural and functional cardiac 
outcomes relative to the medium control, there were no improvements in neovascularization, 
providing motivation for cell encapsulation strategies to repair the damaged myocardium.
78
 
Similarly, Wall et al. injected bone marrow-derived MSCs encapsulated in p(NIPAAm-co-AAc) 
hydrogels into mice immediately post-MI (permanent occlusion) and saw trends towards 
increased FS and EF and decreased EDV at 2 weeks as compared to saline controls.
77
  
 
Figure 3.4. Synthetic hydrogel for cell delivery post-MI. Schematic of PEG-fibrinogen hydrogel 
assembly (A). Infarct thickness (B) and Masson’s Trichrome staining (C) of infarcted hearts 
injected with saline, PEG hydrogel alone, rat cardiomyocytes alone, or combined cell-hydrogel 
therapy at 30 days post-MI. Scale bar = 3 mm. *p<0.05 vs. saline controls, †<0.005 vs. all other 
groups. Figure adapted from [138].  
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Poly(ethylene glycol) (PEG): PEG hydrogels have delivered several cell types, including 
ESC-derived vascular cells,
84
 BMNCs,
117,136
 and ESCs.
137
 Wang et al. delivered BMNCs 
encapsulated in an α-CD/MPEG-PCL-MPEG hydrogel to rabbits seven days post-MI (permanent 
occlusion), as previously discussed in Section 3.2.2.2.
136
 Four weeks after delivery, hydrogel 
encapsulated BMNCs led to significantly increased cell retention and neovascularization in the 
infarct, decreased LV EDD, reduced infarct size, and increased EF as compared to cells alone or 
saline controls.
136
 Similarly, Wang et al. delivered ESCs encapsulated in a biodegradable 
oligo(poly[ethylene glycol] fumarate) (OPF) hydrogel to rats one week post-MI (permanent 
occlusion) and showed significantly improved 24-hour cell retention and four-week graft size 
relative to ESCs delivery alone.
137
 Four weeks after injection, delivery of OPF encapsulated ESCs 
significantly decreased infarct area, reduced collagen deposition in the infarct (fibrosis), increased 
infarct neovascularization, decreased LV EDV and ESV, and increased FS as compared to ESCs 
alone, OPF alone, or saline controls. Even though outcomes were most pronounced with the cell-
hydrogel system, delivery of OPF alone or ESCs alone led to significantly reduced infarct area, 
decreased fibrosis, reduced LV volumes and enhanced FS as compared to saline controls. In 
addition, each treatment group showed significantly decreased protease expression (i.e., MMP-2, 
MMP-9) relative to saline controls, with the cell-hydrogel system leading to the greatest decrease, 
which could favor infarct stiffening at later time points.
137
  
Building on the benefits of synthetic and natural systems, Habib et al. used a 
photopolymerizable, biodegradable PEGylated-fibrinogen hydrogel  to deliver neonatal rat 
cardiomyocytes to rats one week post-MI (permanent occlusion).
138
 Thirty days following 
injection, delivery of hydrogel encapsulated neonatal cardiomyocytes encapsulated led to 
significantly increased FS as compared to all other groups (cells alone, hydrogel alone, saline 
controls),  decreased wall motion score index (measure of regional systolic function) relative to 
saline controls, and preserved LV EDD as compared to hydrogel alone or saline. Histology 
revealed that co-injection of the cells and hydrogel significantly increased the cell-graft area and 
wall thickness as compared to all other groups (Figure 3.4).
138
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Table 3.3. Summary of hydrogels for molecule delivery and their evaluation in animal MI models. 
 
Material 
Animal/  
MI Model 
Molecules 
Delivered 
Injection 
Time  
(post-MI) 
Injection 
Volume 
Evaluation 
Time (post-
delivery) 
Ref. 
Alginate 
 
Rat; LAD 
ligation 
IGF-1  
(250 ng), HGF  
(250 ng) 
6 days 120 μL 4 weeks 147 
Rat; LAD 
ligation 
VEGF  
(3 μg), PDGF 
(3 μg) 
1 week 100 μL 4 weeks 
148 
Chitosan 
Rat; LAD 
ligation 
FGF (2 μg) 1 week 
100 μL 
(via 3 
sites) 
4 weeks 
62 
Hyaluronic 
acid 
Mouse; 
cryoinjury 
SDF-1α  
(0.25 μg) 
Immediate 25 μL 1 week 149 
Gelatin 
Rat; LAD 
ligation 
FGF 
 (120 μg) 
Immediate 
57 μL x 6 
sites 
2 and 4 
weeks 
150 
Dog; LAD 
ligation 
FGF  
(100 μg) 
Immediate 
1 mL x 5 
sites 
10 and 17 
days 
151 
Self-
assembling 
peptides 
Rat; LCA 
ligation 
FGF  
(40 ng), PDGF  
(160 ng) 
Immediate 
50 μL (via 
3 sites) 
4 and 8 
weeks 
152 
Rat; LCA 
ligation 
SDF-1α  
(30 nmol/L) 
Immediate 
80 μL (via 
3 sites) 
4 weeks 
153 
αCD/MPEG
-PCL-
MPEG 
Rat; LCA 
ligation 
EPO  
(600 U) 
5 minutes 
100 μL x 
3 sites 
1 month 
82 
PVL-b-
PEG-b-PVL 
Rat; LAD 
ligation 
VEGF   
(40 ng) 
1 week 
25 μL x 4 
sites 
1, 2, 3, and 
5 weeks 
83 
 
* IGF-1 = insulin-like growth factor 1, HGF = hepatocyte growth factor, VEGF = vascular 
endothelial growth factor, PDGF = platelet derived growth factor, FGF = fibroblast growth factor, 
SDF-1α = stromal cell derived factor-1 alpha, EPO = erythropoietin (see Tables 1 and 2 for 
additional abbreviations) 
3.4. Injectable Hydrogels for Molecule Delivery 
In addition to providing mechanical stabilization to the injured myocardium and serving as 
an exogenous cell delivery vehicle, injectable hydrogels can encapsulate and deliver therapeutic 
molecules to the myocardium post-MI. Tissue repair is a complex process controlled in part by 
growth factors and cytokines that regulate the pathways of wound healing and tissue generation. 
Therefore, delivery of exogenous molecules, such as growth factors, cytokines, and stem-cell 
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mobilizing factors, can modulate endogenous biological responses post-MI.
154
 Delivery of 
therapeutic molecules alone, either by direct myocardial injection or systemic intravenous 
circulation, has helped restore cardiac function in some animal models.
155
 However, clinical trials 
have been less conclusive and there are limitations with molecule delivery alone, such as the 
need for high concentrations or repeated doses due to high diffusion rates and short half-lives.
156
 
In addition, systemic delivery introduces numerous safety concerns and off-target effects, such as 
increased incidence of restenosis, elevated blood pressure and viscosity, and thrombolytic events 
in congestive heart failure patients.
157
 Due to limitations in molecule delivery alone, injectable 
hydrogels have been used as vehicles to localize molecules and tailor release kinetics through 
changes in polymer-molecule interactions, polymer hydrophobicity, and hydrogel degradation 
(Figure 3.5).
158,159
 Hydrogels can both sustain local molecule release and prolong molecule 
bioactivity.
160
 For cardiac applications, injectable hydrogels deliver anti-apoptotic molecules, 
angiogenic factors, or chemoattractants to attenuate remodeling post-MI (Table 3.3).  
3.4.1. Anti-Apoptotic Factors 
Hydrogels have been used to deliver anti-apoptotic factors post-MI to attenuate further 
cardiomyocyte loss. Ruvinov et al. delivered insulin-like growth factor 1 (IGF-1) and hepatocyte 
growth factor (HGF) via alginate microparticles to rats six days post-MI (permanent occlusion).
147
 
This growth factor combination was selected due to the cytoprotective properties of IGF-1 and 
pro-angiogenic and anti-fibrotic effects of HGF. To increase growth factor affinity to the hydrogel, 
alginate was chemically modified with sulfate groups; due to differences in sulfate affinity between 
IGF-1 and HGF, there was sequential release of IGF-1 then HGF. Four weeks post injection, the 
dual IGF-1/HGF affinity-bound alginate hydrogel significantly decreased fibrosis, reduced 
apoptosis, increased vessel density and area, and increased cardiomyocyte proliferation relative 
to IGF/HGF alone and hydrogel alone. Compared to saline controls, the hydrogel system 
significantly increased scar thickness, limited infarct expansion and reduced fibrosis. There was 
also evidence of cardiogenesis (GATA-4-positive cells) indicative of endogenous regeneration.
147
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Davis et al. used self-assembling peptide nanofibers to deliver IGF-1 to rats immediately 
post-MI (permanent occlusion).
143
 To sustain IGF-1 release, biotinylated IGF-1 was tethered to 
biotinylated self-assembling peptides using a streptavidin linker complexed to the IGF-1. This 
strategy enables IGF-1 binding but does not prevent peptide self-assembly into hydrogels. A 
preliminary study in healthy rats demonstrated that tethering of IGF-1 to peptide nanofibers led to 
significant retention in the myocardium for 28 days and preserved bioactivity for 14 days as 
compared to untethered IGF-1 or IGF alone. However, when delivered to the rat MI model, no 
differences in cardiac function were observed between treatment groups at 1 or 21 days post-
MI.
143
 In contrast, Kraehenbuehl et al. demonstrated improvements in cardiac function with 
hydrogel-based growth factor delivery. Thymosin ß-4 (Tβ4), a pro-angiogenic and pro-survival 
factor, was encapsulated in an MMP degradable PEG-VS hydrogel and injected into rats one 
hour post-MI (permanent occlusion).
84
 Six weeks later, PEG hydrogels with or without Tβ4 led to 
significantly decreased LV ESV and increased EF as compared to saline controls, with a trend 
towards decreased infarct size and reduced LV EDV. However, outcomes were more pronounced 
with Tβ4. Interestingly, delivery of Tβ4 using PEG hydrogels led to a significantly smaller LV ESV 
as compared to hydrogels alone, demonstrating the beneficial effects of growth factor delivery.
84
 
3.4.2. Angiogenic Factors 
Hydrogels can also deliver pro-angiogenic factors to increase vascularization to the 
ischemic myocardium and generate an environment more conducive to cell infiltration for repair. 
Basic fibroblast growth factor (bFGF) is a powerful angiogenic molecule that has been delivered 
using hydrogels to sustain its release and prolong its activity.
60,62,150-152,161-164
 For instance, bFGF 
encapsulation in gelatin hydrogel microspheres increases its in vivo half-life from days to 
weeks.
161-163
 Hence, gelatin has been used to deliver FGF in both small
150
 and large
151
 animal 
models. Shao et al. delivered gelatin encapsulated bFGF to rats immediately post-MI (permanent 
occlusion) and saw significantly increased capillary and arteriolar density in the BZ, reduced 
cardiomyocyte apoptosis, increased infarct thickness, and reduced infarct expansion as 
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compared to saline controls at four weeks after delivery.
150
 Similarly, Liu et al. delivered gelatin 
encapsulated bFGF microspheres to dogs immediately post-MI (permanent occlusion) and found 
significantly increased microvessel density and improved EF as compared to controls of gelatin 
microspheres in saline at 10 and 17 days post-MI.
151
 Similar improvements in vascularization and 
cardiac function have been shown for bFGF delivery from chitosan hydrogels post-MI.
62,164
  
 
Figure 3.5. Molecule release from injectable, natural hydrogels. Growth factor release of VEGF 
and PDGF (A) tracks with alginate hydrogel degradation (B) in vitro. Figure adapted from [148]. 
Despite increased neovascularization with pro-angiogenic factor delivery, there is 
concern that the newly formed vessels lack stability and connectivity.
165
 To enhance vessel 
stability, multiple pro-angiogenic factors can be simultaneously or sequentially released from 
hydrogels.
148,152,166
 Kim et al. delivered both bFGF and platelet derived growth factor (PDGF) 
using self-assembling peptides to rats immediately post-MI (permanent occlusion).
152
 The goal is 
to first stimulate vessel formation using bFGF, then recruit smooth muscle cells to form stable 
vasculature using PDGF. In addition, self-assembling peptide nanofibers alone recruit endothelial 
cells and vascular smooth muscle cells,
145
 where both cell types are needed for stable vessel  
formation. Dual bFGF/PDGF delivery from peptide nanofibers significantly reduced infarct size, 
53 
 
increased wall thickness, decreased cardiomyocyte apoptosis, and increased capillary and 
arteriole density at four and eight weeks after delivery and significantly improved cardiac function 
and contractility (LV EDP, +dP/dt, -dP/dt) after four weeks relative to sucrose controls. Similarly, 
Hao et al. sequentially delivered vascular endothelial growth factor (VEGF) then PDGF from 
alginate hydrogels (Figure 3.5) to rats one week post-MI (permanent occlusion).
148
 Four weeks 
later, sequential release of VEGF then PDGF significantly increased α-actin positive vessels 
density, indicating smooth muscle cell vessel stabilization, and increased the systolic velocity-
time integral, a marker of myocardial function, as compared to VEGF or PDGF alone.
148
  
To further control angiogenic factor delivery, Wu et al. conjugated VEGF to a PVL-b-
PEG-b-PVL hydrogel (as discussed Section 3.2.2.2) and injected the system into rats one week 
post-MI (permanent occlusion).
83
 Five weeks after delivery, animals that received VEGF tethered 
to the hydrogel had improved EF and FE, increased contractility (+dP/dt, -dP/dt), preserved EDV 
and ESV, increased wall thickness, and increased vessel density as compared to VEGF mixed 
with the hydrogel, hydrogel alone, or saline controls.
83
 Similar to previous studies,
143,147
 
conjugating biomolecules to injectable hydrogels prolongs their release and biological effects. 
3.4.3. Chemoattractants 
In addition to promoting cell survival and angiogenesis, therapeutic molecule delivery 
from injectable hydrogels can also focus on recruiting endogenous cells to repair the damaged 
myocardium. Stromal cell derived factor-1 alpha (SDF-1α) is a chemokine shown to selectively 
recruit stem and progenitor cells.
149,153
 Segers et al. locally delivered SDF-1α to rats immediately 
post-MI (permanent occlusion) using self-assembling peptide nanofibers.
153
 SDF-1α release was 
tailored by tethering it to the hydrogel using a peptide sequence susceptible to endogenous 
protease cleavage. Four weeks following injection, delivery of SDF-1α tethered to peptide 
nanofibers significantly increased recruitment of cells expressing the SDF-1α receptor 
(CXCR4+/c-Kit+ cells), increased capillary and arteriole density in the infarct, and improved EF 
relative to infarct controls.
153
 Similar to self-assembling peptides being well-suited for molecule 
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delivery due to their ability to tether proteins,
154
 HA has been shown to cooperate with SDF-1α 
mediated BMC homing
167
 and thus, may be well-suited for SDF-1α delivery. In addition to their 
native binding affinity, both SDF-1α and HA stimulate BMC chemotaxis in vitro through their 
CXCR4 and CD44 receptors, respectively.
149
 Purcell et al. delivered SDF-1α encapsulated in a 
degradable HA hydrogel to mice immediately post-MI (cryoinjury) to assess their synergistic 
effects on cell homing.
149
 Seven days after delivery, HA hydrogel encapsulation of SDF-1α led to 
significantly increased endogenous BMC homing and engraftment in the infarct as compared to 
SDF-1α alone or hydrogel alone.
149
 In a subsequent study, MacArthur et al. demonstrated that 
sustained release of an engineered SDF-1α analog (ESA) from degradable HA hydrogels causes 
both endogenous EPC recruitment to the myocardium and preserved LV function.
168
 
3.5. Combined Hydrogel Delivery of Cells and Molecules 
Building from the benefits of delivery of hydrogels alone and hydrogels with encapsulated 
cells or molecules, optimal therapies may rely on a combination of all three. Growth and 
differentiating factors can further improve encapsulated cell survival and differentiation and 
impact the nearby environment to facilitate graft integration. Relative to other material delivery 
systems, hydrogels are advantageous due to their ability to simultaneously mechanically support 
the myocardium and serve as a controlled delivery platform. By improving long-term cell survival 
and engraftment, myocardial reconstruction and/or stem-cell mediated regeneration can occur.  
Both natural and synthetic hydrogels have been used to simultaneously deliver cells and 
anti-apoptotic or angiogenic therapeutic molecules to the infarct post-MI (Table 3.4). Laflamme et 
al. delivered Matrigel encapsulated human ESC-derived cardiomyocytes with pro-survival growth 
factors, including IGF-1, cyclosporine A, anti-apoptotic peptide Bcl-XL BH4, caspase inhibitor 
ZVAD-fmk and vasodilator pinacidil, to rats four days post-MI (temporary occlusion).
53
 Delivery of 
Matrigel with both cells and growth factors led to significantly increased cell engraftment in the 
infarct as compared to delivery of cells with Matrigel alone one week following injection. Four 
weeks after delivery, the hydrogel-cell-growth factor system significantly increased FS and 
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preserved LV EDD as compared to non-cardiac cells with growth factors, growth factors alone, or 
culture media controls.
53
 In a subsequent study, Fernandes et al. delivered the same system to 
rats one month post-MI (temporary occlusion) and saw successful cell engraftment into the infarct 
three months after injection. Despite improved cell engraftment, there were no significant 
differences in LV EDD, EDV and ESV, SV, or FS between any of the groups at any time point.
120
  
Davis et al. delivered neonatal cardiomyocytes and IGF-1 tethered to self-assembling 
peptide nanofibers to rats immediately post-MI (permanent occlusion).
143
 A preliminary study in 
healthy rats demonstrated that peptide tethered IGF-1 delivery significantly decreased activation 
of caspase-3, an apoptosis marker, in the encapsulated cardiomyocytes and increased 
transplanted cell area, as compared to untethered IGF-1 or no IGF-1 controls two weeks after 
delivery. Three weeks after delivery to the rat MI model, the tethered IGF-1 cell therapy 
significantly decreased apoptosis of the encapsulated cardiomyocytes compared with peptides 
alone or untethered IGF-1 and overall, significantly decreased LV dilatation and increased FS as 
compared with all other groups.
143
 In another study by the same group, Padin-Iruegas et al. 
delivered rat CPCs with IGF-1-modified self-assembling peptide nanofibers to rats immediately 
post-MI (permanent occlusion).
146
 One month following delivery, CPCs encapsulated in IGF-1 
tethered peptides significantly enhanced myocardial regeneration (as indicated by increased 
cardiomyocyte mass, volume, and number), decreased infarct size, decreased wall stress, 
enhanced contractility (+dP/dt, -dP/dt), and increased EF as compared to CPCs or IGF-1 tethered 
peptides alone.
146
 In contrast to previous studies,
169
 Dubois et al. delivered skeletal myoblasts 
encapsulated in PDGF loaded self-assembling peptide nanofibers to rats two weeks post-MI 
(permanent occlusion) and saw no improvements in LV EF or encapsulated cell survival despite 
increases in angiogenesis as compared to medium controls at one month after injection.
144
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Table 3.4. Summary of hydrogels for cell and molecule delivery and their in vivo assessment. 
 
Material 
Animal/  
MI Model 
Cells and 
Molecules 
Delivered 
Injection 
Time  
(post-MI) 
Injection 
Volume 
Evaluation 
Time (post-
delivery) 
Ref. 
Fibrin with 
PLGA 
nano-
spheres 
Rat; LCA 
ligation 
BMNCs (2×10
7
),  
TGF-β1 (2 ng) 
1 week 100 μL 4 weeks 126 
Matrigel 
Rat: LAD 
ligation/ 
reperfusion 
ESC-derived 
cardio-myocytes 
(1×10
7
), IGF-1 (7 
ng), pinacidil  
(50 μM), 
cyclosporine A 
(0.2 μM), Bcl-
XL BH4 (50 nM), 
ZVAD  
(100 μM) 
4 days
61
  
or  
1 
month
128
 
70 μL 
1and 4 
weeks
61
  
or 1, 2, and 
3 months
128
 
7, 11, 
50 
Self-
assembling 
peptides 
Rat; LCA 
ligation 
Skeletal 
myoblasts 
(5×10
6
),  
PDGF  
(100 ng) 
2 weeks 
200 μL 
(via 3-4 
sites) 
1 month 
144 
Rat; LCA 
ligation 
Neonatal 
cardiomyocyte 
(5×10
5
),  
IGF-1 (25 ng) 
Immediate 80 μL 
1, 14, 21, 
and 28 
days 
143 
Rat; LCA 
ligation 
CPCs (1×10
5
), 
IGF-1 (1 ng) 
Immediate 
5 μL/ 
injection 
(multiple 
sites) 
1 month 
146 
PEG-VS 
Rat; LAD 
ligation 
ESC-derived 
ELCs (6.6 ×10
5
) 
and SMLCs (3.3 
×10
5
) , 
 Tβ4 (2.5 μg) 
1 hour 60 μL 
3 days and 
6 weeks 
84 
PEGylated-
fibrinogen 
Mouse; 
LAD ligation 
BMNCs (5×10
5
),  
HGF (100 ng) 
Immediate 50 μL 
2 and 4 
weeks 
117 
 
* PLGA = poly(lactic-co-glycolic acid), CPCs = cardiac progenitor cells, ELC = endothelial-like 
cells, SMLC = smooth muscle-like cells, TGF-β1 = transforming growth factor-beta 1, Bcl-XL BH4 
= cell-permeable TAT peptide, ZVAD = benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethyl 
ketone, FGF = fibroblast growth factor, Tβ4 = thymosin beta-4 (see Tables 1, 2, and 3 for 
additional abbreviations). 
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Synthetic hydrogels have also been used to simultaneously deliver cells and 
biomolecules for MI repair. Kraehenbuehl et al. delivered human ESC-derived endothelial- and 
smooth muscle like cells (ELCs, SMLCs) encapsulated in an MMP degradable, PEG-VS hydrogel 
loaded with Tβ4 to rats one hour post-MI (permanent ligation).
84
 Six weeks post-MI, delivery of 
ELCs/SMLCs encapsulated in a Tβ4-loaded hydrogel significantly increased neovascularization 
in the infarct, decreased infarct size, reduced LV EDV ESV, and increased EF relative to saline 
controls. Also, the combined cell-Tβ4 delivery from PEG hydrogels significantly increased EF 
compared to PEG hydrogels with Tβ4 or PEG hydrogels alone.
84
 Zhang et al. delivered murine 
BMNCs and HGF covalently bound to PEGylated-fibrinogen hydrogels to mice immediately post-
MI (permanent occlusion) and saw significantly decreased apoptosis in the BZ and infarct, 
increased angiogenesis, decreased fibrosis, decreased LV EDV and ESV, and increased EF as 
compared to saline controls at four weeks post-MI.
117
 Delivery of BMNCs alone led to significantly 
decreased apoptosis in BZ regions, increased angiogenesis, and decreased fibrosis whereas 
delivery of HGF-bound hydrogel led to significantly decreased apoptosis and increased 
angiogenesis in the infarct relative to saline controls. In addition, BMNCs delivery using a HGF-
loaded hydrogel significantly increased cell engraftment in the infarct 15-fold relative to delivery of 
BMNCs alone. All treatment groups (BMSCs, hydrogel+HGF, hydrogel+HGF+BMNCs) improved 
LV volumes and FS relative to controls, with no statistical difference in FS between groups.
117
  
3.6. Future Directions and Conclusions  
As discussed throughout this chapter, a range of injectable hydrogels, cell types, and 
molecules have been delivered with the intent of attenuating remodeling post-MI. Although many 
hydrogels have shown positive outcomes in animal models, only one material has progressed to 
advanced clinical trials (NCT01226563, NCT01311791).
39,40,42,44,45
 Therefore, several areas must 
be explored prior to clinical translation. For example, the exact mechanism by which injectable 
biomaterials lead to positive functional outcomes is not fully understand and is likely quite 
complex, involving both mechanical (e.g., stress reduction) and biological (e.g., exogenous cell 
58 
 
delivery, endogenous cell recruitment, angiogenesis, inflammatory response) interactions. It is 
evident that increased myocardial wall thickness,
32,37,48,80,81
 decreased infarct size,
32
 and/or 
increased angiogenesis
51,79,136
 do not directly correlate with improved cardiac function; thus, 
finding specific correlations may improve future therapy design. Theoretical FE models provide 
some insight into the mechanisms by which injectable materials impact LV remodeling
22,24,25
 and 
further development of such models may improve our understanding of material injection post-MI.  
 
Figure 3.6. Percutaneous catheter delivery of decellularized ventricular ECM to healthy rats. 
NOGA maps representing injection sites (A) and representative H&E stain indicating presence of 
hydrogel within the myocardium (B). Scale bar = 1 mm. Figure adapted from [71]. 
From a translational perspective, it is important to elucidate the effects of hydrogel 
properties (e.g., mechanics, degradation), injection parameters (e.g., volume, number of 
injection), mode of delivery (e.g., direction injection vs. catheter delivery) (Figure 3.6), and timing 
of delivery (e.g., acute vs. chronic MI) on LV remodeling. Much of this can be explored through 
both experimental and modeling approaches and by selecting the most appropriate mimic of 
clinical scenarios to enhance our understanding of outcomes. Future studies should further 
investigate the mechanisms by which hydrogels act on the heart, including both biological and 
mechanical effects, and focus on clinically relevant parameters, such as the mode of delivery. 
This information has considerable clinical impact with respect to improved therapies to attenuate 
LV remodeling and ultimately, to aid patients by preventing progression to heart failure.  
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CHAPTER 4 
 
In Vitro Characterization of Hydrolytically Degradable Hyaluronic Acid Hydrogels 
 
4.1. Introduction  
Injectable biomaterials have become an attractive therapy to attenuate LV remodeling. 
Particularly, acellular hydrogels have been explored to limit infarct expansion by bulking the 
myocardial wall to modulate myocardial remodeling.
1
 Hydrogels are water-swollen networks of 
polymer chains with a high degree of flexibility, similar to natural tissue
2
 and, as a result, have 
been explored for a variety of tissue engineering and drug delivery applications.
3-6
 For cardiac 
repair post-MI, hydrogels can be used to mechanically stabilize the myocardial wall as well as 
modulate maladaptive biological processes through delivery of therapies, such as cells and 
growth factors,
7-11
 as thoroughly discussed in Chapter 3. Moreover, recent work from our group 
was the first to demonstrate the importance of injectable biomaterial properties, specifically 
mechanical stiffness and degradation, on attenuating LV remodeling in an ovine infarct model.
12,13
 
However, despite the wide range of materials investigated for MI repair, there is still a need for 
tunable hydrogel systems to further investigate the correlation between specific hydrogel 
properties and the resulting in vivo outcomes.  
One such tunable biomaterial is hyaluronic acid (HA). HA is a linear, negatively charged, 
non-sulfated glycosaminoglycans (GAG) ubiquitously found in the extracellular matrix (ECM) of 
tissues.
14
 More specifically, HA is an ideal candidate for cardiac repair because it is found in the 
native cardiac ECM and plays a role in cardiac embryogenesis, angiogenesis, cell migration and 
scar reduction. It helps maintain myocardial homeostasis both structurally through its mechanical 
properties and functionally through cell and growth factor interactions.
15-17
 Furthermore, HA can 
be readily modified with numerous reactive groups  (e.g., aldehydes,
18,19
 malemides,
20
 hydrazides 
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and dihydrazides,
19,21,22
 thiols,
23,24
 norbornenes,
24
 adamantanes,
25
 cyclodextrins,
25
 and 
methacrylates and acrylates
12-14,26-28
) at the carboxyl and hydroxyl groups on each repeat unit to 
enable tunability of material properties towards specific applications,
14,29,30
 including MI repair.
12,13
 
In addition to the type and degree of HA modification, the macromer molecular weight and 
concentration can also be varied to tailor material properties.
13,14,27,28
  
The addition of reactive groups not only enables tunability of material properties but also 
crosslinking into hydrogels, where the mechanism of gelation depends on the specific functional 
group.
31
 Hydrogels form by various gelation mechanisms, including self-assembly, ionic 
crosslinking, covalent crosslinking through chemical reactions, and inherent phase transition 
behavior.
32
 Due to their unique gelation properties, hydrogels offer the advantage of initially being 
in a viscous form during delivery and then solidifying into a stable gel once delivered to the 
intended target tissue. One crosslinking approach is to radically polymerize the methacrylate 
groups on HA using an initiator or stimulus, such as light, temperature, or oxidation-reduction 
(redox) species; the radicals propagate through the methacrylate vinyl groups to form kinetic 
chains to crosslink the macromer.
12-14,26-28,31
 The properties of the resulting hydrogel thus depend 
on the concentration of the initiator as well as the macromer modification and concentration. 
Previous studies have demonstrated that the mechanical properties of methacrylated HA (MeHA, 
Figure 4.1B) hydrogels can be tuned through both the macromer modification and initiator 
concentration: as the amount of reactive methacrylates or free radicals increases, the crosslinking 
density and thus, mechanics increase.
12,13
 In addition, crosslinking via redox chemical 
initiators
12,13,33
 circumvents the depth penetration limitations of photopolymerization
14,28,31
 and 
increases the potential for clinical translation because the pre-polymer solution can be 
administered (ideally via catheter) directly to the target organ.  
To further tune hydrogel properties (i.e., degradation), HA can also be modified to include 
a hydrolytically degradable functional group, hydroxyethyl methacrylate (HeMA), to produce the 
gel precursor HeMA-HA (Figure 4.1A). Similar to MeHA, HeMA-HA contains a reactive 
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methacrylate for free-radical initiated crosslinking: when the macromer is mixed with chemical 
initiators, stable hydrogels form within minutes.
12
 In contrast to MeHA, HeMA-HA contains ester 
bonds that are hydrolytically unstable. While HA is enzymatically degraded in the body by 
hyaluronidases,
16,34
 this process occurs over the time frame of months to years and is dependent 
on the physiological concentration of hyaluronidase in vivo. The addition of HeMA enables finely-
tuned, multimodal hydrogel degradation: enzymatic degradation through the HA backbone and 
hydrolysis through the ester groups of HeMA. In this tunable system, the rate of crosslinking, and 
therefore gelation onset, can be controlled through the initiator concentration whereas the rate of 
degradation and maintenance of mechanical properties can be controlled through the HeMA 
modification on HA and the HA concentration.  
 
Figure 4.1. Chemical structures of HeMA-HA (A) and MeHA (B) macromers.  
In this chapter, the tunability of HA hydrogels was examined in two systems: 1) pure 
HeMA-HA hydrogels and 2) copolymer hydrogels consisting of HeMA-HA and MeHA. A two 
component redox initiator system of ammonium persulfate (APS) and N,N,N,N’,N’-
tetramethylenediamine (TEMED) was used to induce polymerization of both macromers into 
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hydrogels. In addition to offering the potential for noninvasive, catheter-based delivery, the use of 
redox initiators for crosslinking provides enhanced control over gelation timing.
12,13
 Kinetic chains 
were formed through crosslinking the reactive methacrylate groups on all macromers to generate 
hydrogel networks where the bulk properties depended on three parameters: initiator 
concentration, macromer modification, and macromer concentration. The effect of altering each of 
these material parameters on the resulting hydrogel properties (i.e., gelation, degradation, and 
mechanics) was investigated to provide insight into the design and material properties of HA 
hydrogels towards the identification of optimal material properties for targeted MI therapies. 
4.2. Materials and Methods  
4.2.1. Synthesis of Hydroxyethyl Methacrylated HA (HeMA-HA) Macromer  
HA was modified with hydroxyethyl methacrylate (HeMA) by coupling HA-
tetrabutylammonium salt (HA-TBA) to 2-hydroxyethyl-methacryl-succinate (HeMA-COOH), as 
previously described.
12
 HA-TBA was synthesized by converting HA-sodium salt (HA-Na, 75 kDa, 
Lifecore) to a TBA salt using an acidic ion exchange (25°C, 8hrs) with Dowex resin (50W×8-200, 
Sigma), followed by neutralization with TBA hydroxide (TBA-OH, Sigma) to pH 7.02-7.05 and 
subsequent lyophilization.
30
 The conversion of Na to TBA enabled HA-TBA to be soluble in 
dimethyl sulfoxide (DMSO). 
1
H-NMR (Bruker, 360 MHz) was used to determine the amount of 
TBA coupled to HA. HeMA-COOH was synthesized by reacting 2-hydroxyethyl-methacrylate 
(Acros) with succinic anhydride (Sigma) in dichloroethane (DCE) via a ring opening 
polymerization (65°C, 16hrs) catalyzed by N-methylimidazole (Sigma). HeMA-COOH was purified 
by washing with hydrochloric acid then deionized (DI) water. Excess DCE was removed by rotary 
evaporator. 
1
H-NMR (Bruker, 360 MHz) was performed to confirm HeMA-COOH formation and 
purity. Finally, HA-TBA was coupled to HeMA-COOH in anhydrous DMSO (Acros) through an 
esterification reaction (45°C, 20hrs) using 4-dimethylaminopyridine (DMAP, Sigma) and the 
coupling agent di-tert-butyl dicarbonate (BOC2O, Sigma) (Figure 4.2A). The macromer was 
purified by dialyzing against DI water, acetone precipitating, and dialyzing again. The macromer 
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was then lyophilized and the HeMA modification on HA was assessed with 
1
H-NMR (Bruker, 360 
MHz) (Figure 4.2B). Modification was altered by varying the ratio of BOC2O to HeMA-COOH.  
 
Figure 4.2. HeMA-HA macromer synthesis. HeMA-HA was synthesized by coupling HeMA-
COOH to HA-TBA using DMAP and the coupling agent BOC2O in DMSO (A). Methacrylation 
were assessed with 
1
H-NMR by normalizing to the integral of peak 4 (B).  
4.2.2. Synthesis of Methacrylated HA (MeHA) Macromer  
As previously described, methacrylated HA (MeHA) was synthesized by reacting a 1 wt% 
solution of Na-HA (75 kDa, Lifecore) with a 20-fold excess of methacrylic anhydride (MA; Sigma) 
in DI H2O on ice.
14
 The solution was titrated with concentrated sodium hydroxide (Sigma) to 
maintain a constant pH of 8.0 (4°C, 24hrs) (Figure 4.3A). The macromer was purified by 
dialyzing against DI H2O and subsequently lyophilized. 
1
H-NMR (Bruker, 360 MHz) was used to 
assess purity and the extent of methacrylation on the HA backbone (Figure 4.3B). Modification 
was altered by varying the amount of MA relative to HA. 
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Figure 4.3. MeHA macromer synthesis. MeHA was synthesized by reacting Na-HA with a excess 
of methacrylic anhydride (MA) at 4°C in DI water. The pH was maintained at 8.0 using NaOH (A). 
Methacrylation was assessed with 
1
H-NMR by normalizing to the integral of peak D (B).  
4.2.3. HA Hydrogel Formation  
HA macromers were crosslinked into hydrogels and characterized in vitro for gelation, 
degradation, and initial and temporal mechanics. Hydrogel formation was induced by crosslinking 
the methacrylate groups on HA using a redox radial initiator system of APS (Sigma) and TEMED 
(Sigma) (Figure 4.4A).
33
 APS and TEMED were mixed with HA macromers dissolved in PBS to 
initiate gelation. For initial characterization studies of 10% and 35% modified HeMA-HA, 10 mM 
APS and 10 mM TEMED was used to induce crosslinking. For all subsequent studies, an initiator 
concentration of 5 mM APS and 5 mM TEMED was used (Tables 4.1, 4.2). Gel onset and 
completion were quantified using an AR2000ex Rheometer (TA Instruments) by monitoring the 
storage (G’) and loss (G”) moduli over time at 37°C under 1% strain and a frequency of 1 Hz in a 
cone-plate geometry (1°, 20 mm diameter) (Figure 4.4B).
12
 Gel onset was defined as the time 
where G’ and G” intersect and the viscosity (|n*|) was greater than one. Gel completion was 
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defined as the time where the percent change in both G’ and |n*| were less than 1% for ten 
consecutive time steps. 
 
Figure 4.4. Mechanism of hydrogel formation. Hydrogel formation was induced using a two 
component radical initiator system of APS and TEMED (A). Representative rheological time 
sweep after mixing HeMA-HA macromer initiators, where the intersection of the storage (G’) and 
loss (G”) moduli is defined as gel onset (B). 
4.2.4. In Vitro Hydrogel Characterization  
For in vitro characterization of degradation and compressive mechanics, hydrogels (~50 
μL) were formed in between two glass slides within a Teflon mold sealed with vacuum grease by 
mixing macromer solutions with APS and TEMED and incubating at 37°C for 30 minutes. Unless 
otherwise specified, degradation was monitored in PBS at 37°C. In all cases, HA mass loss was 
quantified using an uronic acid assay.
35,36
 Hyaluronidase (Sigma) was added to PBS solutions 
surrounding the hydrogels at 0.3 mg/mL to completely enzymatically degrade the hydrogels after 
20 weeks, if necessary. Compressive mechanical testing was performed using a Dynamic 
Mechanical Analyzer (DMA, Q800 TA Instruments) at a strain rate of 10%/min and compressive 
moduli were calculated from 10 to 20% strain.
37 
Degradation and mechanics were assessed 
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immediately after gelation (day 0) and at desired time points throughout the degradation process 
(i.e., 1, 7, 14, 28, 56, 84 days, etc. after gelation).  
Table 4.1. In vitro characterization studies of pure HeMA-HA hydrogels.  
 
 Macromer Chemical Initiators 
Study Mod. (%) Conc. (wt%) APS Conc. (mM) TEMED Conc. (mM) 
1 
10 4, 7, 10 5, 7.5, 10 5, 7.5, 10 
35 4, 7, 10 5, 7.5, 10 5, 7.5, 10 
 
2 
10 4, 7, 10 10 10 
35 4, 7, 10 10 10 
3 25 7 5, 7.5, 10 5, 7.5, 10 
 
4 
10 2, 4, 6, 8, 10, 12 5 5 
25 2, 4, 6, 8, 10, 12 5 5 
40 2, 4, 6, 8, 10, 12 5 5 
5 
10 8, 10, 12 5 5 
40 4, 5, 6 5 5 
 
Characterization studies were performed on two hydrogel systems 1) pure HeMA-HA 
hydrogels (Table 4.1) and 2) HeMA-HA/MeHA copolymer hydrogels (Table 4.2). Initial HeMA-HA 
hydrogel characterization studies examined the effect of altering macromer concentration and 
modification on hydrogel properties using 10% and 35% modified HeMA-HA at 4, 7, and 10 wt% 
gelled using 10 mM APS/TEMED. To select a single initiator concentration for gelation, the 
compressive modulus at one day after hydrogel formation was measured for hydrogels formed at 
three initiator concentrations (5 mM, 7.5 mM, 10 mM APS/TEMED) for the two modifications at 
the three macromer concentrations. A subsequent study examined differences in crosslinking 
density due to initiator concentration using three initiator concentrations (5 mM, 7.5 mM, 10 mM 
APS/TEMED) at a single macromer modification (25% modified) and macromer concentration (7 
wt%). After varying the initiators, a concentration of 5 mM APS and 5 mM TEMED was selected 
for use in all subsequent studies (Table 4.1). To further examine the tunability of HeMA-HA 
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hydrogels, a more extensive study was performed with varying both the macromer modification 
(10%, 25%, 40% modified HeMA-HA) and concentration (2, 4, 6, 8, 10, 12 wt%). Based on this 
study, six hydrogel formulations at various macromer modifications and concentrations (10% 
modified at 8, 10, 12 wt%; 40% modified at 4, 5, 6 wt%) were selected for temporal assessment. 
Table 4.2. In vitro characterization studies of HeMA-HA and MeHA copolymer hydrogels. 
 
 Macromer Copolymer Ratio (v/v) Chemical Initiators 
Study Mod. (%) Conc. (wt%) HeMA-HA MeHA 
APS Conc. 
(mM) 
TEMED Conc. 
(mM) 
1 
25% HeMA-HA,  
30% MeHA 
 
4, 6, 8, 10 
100 0 5 5 
75 25 5 5 
50 50 5 5 
25 75 5 5 
0 100 5 5 
2 
25% HeMA-HA,  
30% MeHA 
5, 6, 7 
75 25 5 5 
25 75 5 5 
 
To further evaluate the tunability of hydrogel degradation in this HA system, copolymers 
of HeMA-HA and MeHA were formulated into hydrogels by mixing different volumetric ratios of 
the macromers dissolved at the same concentrations in PBS. The amount of MeHA introduced 
into HeMA-HA hydrogels (100:0, 75:25, 50:50, 25:75, 0:100 HeMA-HA:MeHA) was varied at 
various macromer concentrations (4, 6, 8, 10 wt%). Based on this initial study, six copolymer 
hydrogel formulations at three macromer concentrations (5, 6, 7 wt%) and two copolymer ratios 
(75: 25, 25:75 HeMA-HA:MeHA) were selected for assessment of temporal mechanics. 
Macromer modification (25% modified HeMA-HA; 30% modified MeHA) and initiator 
concentration (5 mM APS/TEMED) were maintained throughout these copolymer hydrogel 
characterization studies (Table 4.2).  
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4.2.5. Statistical Analysis 
Data is presented as mean ± standard deviation (SD) or mean ± standard error of the 
mean (SEM), as indicated in each figure legend. Statistical differences between groups were 
assessed using a one-way ANOVA with Tukey’s post hoc evaluation (JMP Statistical Software; 
SAS Institute; Cary, NC). A p<0.05 was considered statistically significant. 
4.3. Results  
4.3.1. HA Macromer Synthesis and Characterization  
Two HA macromers were synthesized for evaluation in in vitro characterization studies 
(Figure 4.1). First, HA was chemically modified to include a hydrolytically degradable group, 
HeMA, to enable both free-radical initiated crosslinking through the methacrylate and tunable 
degradation through the ester bond hydrolysis (Figure 4.2). Secondly, a non-hydrolytically 
degradable methacrylate group was added to the HA backbone to facilitate free radial initiated 
crosslinking in a stable hydrogel system as a comparison to the hydrolytically degradable 
macromer described above, HeMA-HA (Figure 4.3). As described above, 
1
H NMR was used to 
evaluate the degree of modification on all macromers (Figures 4.2B, 4.3B). Each macromer was 
synthesized at a range of modifications for subsequent in vitro characterization (Tables 4.1, 4.2).  
4.3.2. In Vitro Characterization of HeMA-HA Hydrogels  
For the initial HeMA-HA in vitro characterization study, initiator concentration, macromer 
modification, and macromer concentration were simultaneously varied to assess their impact on 
initial compressive mechanics. Two macromer modifications (10%, 35%) were investigated at 
three macromer concentrations (4, 7, 10 wt%) and three initiator concentrations (5 mM, 7.5 mM, 
10 mM APS/TEMED) (Table 4.1). An increase in any of the three parameters led to an increase 
in compressive moduli (Figure 4.5). At each initiator concentration, increased modification 
resulted in significantly increased (p<0.05) mechanics for all groups. Similarly, increased moduli 
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due to increased macromer concentration were statistically significant except when comparing 4 
wt% and 7 wt% gels formed using 5 mM and 10 mM APS/TEMED with 10% modified HeMA-HA. 
At each modification, differences in moduli based on initiator concentration were not statistically 
significant (p>0.05) whereas differences due to macromer concentration were statistically 
significant except for comparison between 4 wt% and 7 wt% gels formed from 10% modified 
HeMA-HA. Finally, at each macromer concentration, changes in initiator concentration did not 
result in statistically significant changes in mechanics whereas changes in macromer modification 
did. The largest differences in mechanics with changes in initiator concentration were seen with 
35% modified gels at 10 wt% (Figure 4.5). However, due to minimal changes in mechanics with 
changes in initiator concentration, subsequent experiments investigated simultaneously altering 
the macromer modification and concentration at a constant initiator concentration.  
 
Figure 4.5. Tunability of mechanical properties of HeMA-HA hydrogels. Compressive moduli at 
day 1 after hydrogel formation, n=3-4/group, as a function of initiator concentration, macromer 
modification, and macromer concentration. Data presented as mean ± SD. See Appendix 4.1 for 
statistics information.   
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Figure 4.6. Initial in vitro characterization studies of pure HeMA-HA hydrogels at various 
macromer modifications and concentrations. Gel onset and completion, n=3-4/group, as a 
function of macromer modification and concentration gelled using 10 mM APS/TEMED (A). 
Degradation time and initial (day 0) compressive moduli, n=3-4/group (B). Temporal degradation 
(C) and mechanics (D), n=3-4/group. Data presented as mean ± SD. *p<0.05 vs. 10% modified 
HeMA-HA at 4 wt% in panel A. All groups were significant (p<0.05) in panel B. In panel C, 
*p<0.05 for 4 vs. 7 wt%, 
+
p<0.05 for 7 vs. 10 wt%, and 
#
p<0.05 for 4 vs. 7 wt% for 10% modified 
gels and 
δ
p<0.05 for 7 vs. 10 wt% for 25% modified gels. See Appendix 4.1 for more statistics.  
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Hydrogel properties (i.e., gelation, degradation, and mechanics) were then examined for 
the two macromer modifications and three macromer concentrations but a single initiator 
concentration of 10 mM APS/TEMED (Table 4.1). Assessment of gelation demonstrated that as 
macromer modification or macromer concentration increased, the time to gel onset or completion 
decreased (Figure 4.6A). Within a single modification (i.e., 10% modified HeMA-HA), increased 
macromer concentration led to a statistically significant decrease in gel onset. Similar to gelation, 
as the macromer modification or concentration increased, the time to degradation and the initial 
compressive modulus increased (Figure 4.6B). All final degradation times and initial moduli were 
statistically significant for each time point, both between modifications at a single macromer 
concentration and between macromer concentrations within a single modification.  
 
Figure 4.7. Effect of initiator concentration on HeMA-HA hydrogel gelation and mechanics. Gel 
onset and completion, n=3-4/group, as a function of initiator concentration at a single modification 
(25%) and macromer concentration (7 wt%) (A). Initial (day 0) compressive moduli, n=3-4/group 
(B). Data presented as mean ± SD. All values were statistically significant (p<0.05) aside from 
comparison of gel onset between 7.5 mM and 10 mM APS/TEMED in panel A.  
Degradation assessment revealed that increased modification led to a statistically 
significant decrease in hydrogel mass loss at each time point except for 4 wt% gels one week 
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after gelation (Figure 4.6C). Temporal degradation (Figure 4.6C) and mechanics (Figure 4.6D) 
further showed that increased macromer modification or concentration led to gels that degraded 
more slowly and maintained their mechanics longer. Formulations with a higher modification but 
lower macromer concentration degraded slower than formulations with a lower modification but 
higher macromer concentration (Figure 4.6C,D). Thus, altering the macromer modification along 
with the concentration can tailor hydrogel degradation while maintaining similar initial mechanics.  
Simultaneously, the effect of altering the initiator concentration was examined in 
hydrogels at a single macromer modification (25%) and concentration (7 wt%) (Table 4.1). As 
predicted from the initial study using 10% and 35% modified HeMA-HA, as initiator concentration 
increased, the time to gel onset and completion decreased whereas the mechanics increased 
(Figure 4.7A). All gel onset times, gel completion times, and initial compressive moduli were 
statistically significant (p<0.05) between initiator concentrations aside from comparison of gel 
onset between hydrogels gelled using 7.5 mM and 10 mM APS/TEMED (p>0.05). Based on this 
study, a single initiator concentration of 5 mM APS/TEMED was selected for subsequent studies.  
To further explore the effect of altering the macromer modification and concentration on 
hydrogel gelation, degradation, and mechanics, a more thorough study was performed with gels 
formed from three macromer modifications (10%, 25%, 40%) each at six concentrations (2, 4, 6, 
8, 10, 12 wt%) (Table 4.1).  As anticipated from Figure 4.7, increased macromer modification or 
concentration resulted in decreased time to gel onset or completion (Figure 4.7A). Statistically 
significant differences in gelation were observed for comparisons between modifications relative 
to 10% modified gels at each macromer concentration. Similarly, as predicted from Figure 4.6, 
increased macromer modification or concentration led to increased degradation time and initial 
compressive mechanics (Figure 4.7B). The majority of degradation and mechanics comparisons 
between modifications at a given macromer concentration and between macromer concentrations 
at a single modification were statistically significant (Appendix 4.1).  
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Figure 4.8. Extensive analysis of the effect of macromer modification and concentration on 
HeMA-HA hydrogel properties. Gelation onset and completion, n=3-4/group, for gels formed with 
5 mM APS/TEMED (A). Degradation time and initial compressive moduli, n=3-4/group, (B). Data 
presented as mean ± SD. In panel A, *p<0.05 vs. 2 wt% and 
+
p<0.05 vs. 12 wt% for gel 
completion comparisons at the same modification. See Appendix 4.1 for additional statistics. 
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Figure 4.9. Tuning HeMA-HA hydrogel degradation by altering the macromer modification and 
concentration. Temporal degradation profiles of hydrogels, n=3-4/group, formed from 10% 
modified (A), 25% modified (B), and 40% modified (C) HeMA-HA at various macromer 
concentrations. Data presented as mean ± SD. See Appendix 4.1 for statistical information.   
Hydrogel mass loss over time showed that increased macromer modification or 
concentration prolonged hydrogel degradation (Figure 4.8). Comparisons between modifications 
at each macromer concentration showed that all 10% modified gels had a statistically significant 
increase in mass loss at each time point as compared to both 25% and 40% modified gels. 
Comparisons between 25% and 40% modified hydrogels became progressively more significantly 
different over time: at day one, mass loss of 25% and 40% modified gels was not statistically 
significant (p>0.05) but past day one, mass loss between 25% and 40% modified gels diverged 
and remained significantly different (p<0.05) for the remainder of the study. These differences 
arose at 1 week for 6 wt% gels, 2 weeks for 2 wt% gels, 8 weeks for 4 wt% and 8 wt% gels, 12 
weeks for 10 wt% gels, and 16 weeks for 12 wt% gels. Within each modification, comparisons 
between macromer concentrations were statistically varied but gradually became more 
statistically significant with time in all three groups (Appendix 4.1).  
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Figure 4.10. In vitro characterization of selected HeMA-HA hydrogel formulations with similar 
gelation and initial mechanics but different rates of degradation. Gelation onset and completion, 
n=3-4/group, as a function of HeMA-HA modification and macromer concentration gelled using 5 
mM APS/TEMED (A). Degradation time and initial compressive moduli, n=3-4/group (B). 
Temporal degradation (C) and mechanics (D) profiles, n=3-4/group. Data presented as mean ± 
SD. In panels A and B, *p<0.05. Additional statistical information is present in Appendix 4.1.  
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Figure 4.11. Effect of combining non-degradable MeHA and degradable HeMA-HA into a single 
copolymer hydrogel system at various macromer concentrations. Gel onset and completion, n=3-
4/group, as a function of HeMA-HA:MeHA ratio (v/v) at various macromer concentrations (A). 
Degradation time and initial compressive moduli, n=3-4/group (B). All remaining hydrogels were 
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degraded at 20 weeks after formation. Data presented as mean ± SD. In panel A, *p<0.05 vs. 
100:0 and 
+
p<0.05 vs. 75:25 for gel onset comparisons at each macromer concentration. For gel 
completions comparisons between concentrations, 
δ
p<0.05  for all 4 vs. 10 wt% ratios, 4 vs. 8 
wt% at 25:75 and 50:50, and 6 vs. 10 wt% at 25:75 and 50:50. In panel B, all degradation values 
were statistically significant (p<0.05). For initial moduli comparisons, *p<0.05 vs. 100:0, 
+
p<0.05 
vs. 75:25, and 
#
p<0.05 vs. 0:100 copolymers. See Appendix 4.1 for more statistical information.  
The thorough HeMA-HA characterization study (Figures 4.8, 4.9) was used to select a 
limited number of formulations to investigate temporally for changes in mechanics. By altering a 
combination of the macromer modification and concentration, the goal was to examine 
mechanical changes in hydrogels with similar gelation and initial mechanics but different rates of 
degradation. Therefore, the properties of following pairs of formulations were compared: 1) 10% 
modified HeMA-HA at 8 wt% vs. 40% modified at 4 wt%, 2) 10% modified at 10 wt% vs. 40% 
modified at 5 wt%, and 2) 10% modified at 12 wt% vs. 40% modified at 6 wt% (Table 4.1). 
Comparing between the hydrogels in each pair, in vitro assessment demonstrated similar gelation 
properties that were not statistically significant (p>0.05) for the first hydrogel pair for time to 
gelation onset (Figure 4.10A). In addition, initial compressive mechanics were similar within the 
pairs and not statistically significant for both the second and third pairs (Figure 4.10B). As 
anticipated, despite similarities in gelation and mechanics, the degradation was significantly 
different (p<0.05) between the formulations in all three hydrogel pairs (Figure 4.10B).  
The degradation (Figure 4.10C) and temporal mechanics (Figure 4.10D) were then 
examined for three pairs of hydrogel formulations out to 12 weeks. Degradation for 40% modified 
hydrogels was statistically less than 10% modified gels at each time point (Figure 4.10C). As the 
study progressed, differences in degradation between the gels within each pair became evident. 
In contrast, compressive moduli were not statistically significant within the pairs at the earlier time 
points, but became statistically different (p<0.05) at 2 weeks and beyond (Figure 4.10D). Thus, 
there was a narrow window during which the degradation was varied but mechanics maintained. 
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The mechanics for all 10% modified gels were not statistically significant throughout the study 
regardless of macromer concentration. As predicted from Figure 4.9, all 10% modified gels had 
statistically greater mass loss and significantly lower (p<0.05) mechanics than all 40% modified 
gels at each time point. Despite similarities in initial mechanics within each pair (Figure 4.10B), 
as the hydrogels degraded, the moduli became gradually different over time (Figure 4.10D), 
demonstrating the interdependence between degradation and mechanics in HeMA-HA hydrogels. 
4.3.3. Characterization of HeMA-HA/MeHA Copolymer Hydrogel Properties 
To further explore the tunability of HA hydrogels, the properties of a HeMA-HA and MeHA 
copolymer system of were assessed. Copolymer blends were generated using macromers of 
approximately the same modification (i.e., 25% modified HeMA-HA, 30% modified MeHA) but 
different ratios of HeMA-HA to MeHA (i.e., 75:25, 50:50, 25:75 for HeMA-HA:MeHA). The three 
copolymers were also compared to pure HeMA-HA (i.e., 100:0) and pure MeHA (i.e., 0:100) gels 
(Table 4.2). For the initial study, the properties were examined at four macromer concentrations 
(4, 6, 8, 10 wt%), which were selected based on the previous HeMA-HA studies (Section 4.3.2). 
At each macromer concentration, the gel onset and completion time decreased as the amount of 
MeHA increased (Figure 4.11A). The accelerated gelation with increased MeHA was statistically 
significant relative to pure HeMA-HA hydrogels, particularly for the 4 wt% and 10 wt% gels. Gel 
completion was relatively unaffected by MeHA content, with statistically significant differences 
only seen between macromer concentrations (Appendix 4.1). As anticipated, pure HeMA-HA 
hydrogels degraded at the quickest rate and pure MeHA gels at the slowest, with copolymers 
falling in between; as the ratio of MeHA increased, degradation significantly increased (p<0.05) 
(Figure 4.11B). In contrast, the initial moduli decreased as the amount of MeHA increased, with 
hydrogels made from HeMA-HA alone having the highest mechanics and those made from MeHA 
alone displaying the lowest mechanics (Figure 4.11B). Pure HeMA-HA hydrogels had statistically 
higher mechanics relative to MeHA homopolymer hydrogels at all macromer concentrations aside 
from 6 wt% and relative to certain copolymer hydrogels at 4 wt% and 10 wt%.  
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Figure 4.12. Tuning hydrogel degradation by altering the ratio of HeMA-HA to MeHA at various 
macromer concentrations. Temporal degradation of HeMA-HA:MeHA copolymer hydrogels, n=3-
4/group, formed using different copolymer ratios at macromer concentrations of 4 wt% (A), 6 wt% 
(B), 8 wt% (C), and 10 wt% (D). All remaining hydrogels were degraded at 20 weeks after 
formation. Data presented as mean ± SD. Refer to Appendix 4.1 for statistical assessment.  
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Quantification of hydrogel mass loss as a measure of degradation over time 
demonstrated that HA release from hydrogels containing MeHA was minimal throughout the 20 
week study whereas pure HeMA-HA hydrogels degraded prior to the final time point (Figure 
4.12). The degradation rate of HeMA-HA homopoloymers was statistically higher than MeHA 
homopolymer hydrogels at all time points for 4 wt% gels, past week 2 for 6 wt% gels, past week 4 
for 8 wt% gels, and past week 8 for 12 wt% gels. As the amount of MeHA incorporated into the 
copolymer hydrogels increased, the amount of HA released at each time point decreased, 
particularly at later time points (prior to gel degradation at week 20). For the earlier time points, 
hydrogel mass loss was similar between both the homopolymer and copolymer hydrogels. At 8 
weeks, a burst of HA release was observed in the HeMA-HA hydrogels that was statistically 
significant relative to all copolymer ratios and for all macromer concentrations aside from 10 wt% 
(which reached statistical significance for all copolymer ratios by 12 weeks).  
Similar to the previous HeMA-HA characterization studies (Section 4.3.2), specific 
formulations were selected for temporal mechanical assessment. Two copolymer ratios (75:25, 
25:75, HeMA-HA:MeHA) were examined at three macromer concentrations (5, 6, 7 wt%) (Table 
4.2). These particular ratios and macromer concentrations were selected for temporal 
assessment with the goal of having similar initial mechanics but different rates of degradation: the 
ratios were used to tune the degradation where as the macromer concentrations were used to 
target different mechanical profiles. At each macromer concentration, the gelation onset times 
were significantly greater (p<0.05) for the 75:25 copolymer hydrogels as compared to the 25:75 
hydrogels whereas the gel completion times were not statistically significant (Figure 4.13A). As 
intended, statistically significant (p<0.05) degradation times were generated by altering the 
copolymer ratio (Figure 4.13B). The initial mechanics were similar between the copolymer ratios 
for all macromer concentrations and statistically significantly so for 6 wt% and 7 wt% hydrogels 
(Figure 4.13B). In addition, statistically significant differences in initial moduli were generated by 
altering the macromer concentration at each copolymer ratio.  
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Figure 4.13. In vitro characterization of selected HeMA-HA/MeHA copolymer hydrogels. Gel 
onset and completion, n=3-4/group, as a function of copolymer ratio and macromer concentration 
gelled using 5 mM APS/TEMED (A). Degradation time and initial compressive moduli, n=3-
4/group (B). Temporal degradation (C) and mechanics (D) profiles, n=3-4/group. All remaining 
25:75 hydrogels were degraded at 20 weeks. Data presented as mean ± SD. For panel A, 
+
p<0.05 vs. 5 wt% gels at the same ratio. For panels A and B, *p<0.05 for 75:25 vs. 25:75 
copolymers. See Appendix 4.1 for additional statistical comparisons.  
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As predicted from the previous copolymer study (Figure 4.12), temporal assessment of 
degradation (Figure 4.13C) and mechanics (Figure 4.13D) demonstrated that copolymer ratio 
had a larger impact on the rate of hydrogel degradation and decline in mechanics over time than 
macromer concentration. When comparing between the two copolymer ratios, the 5 wt% 
copolymer hydrogels had statistically significant (p<0.05) amounts of hydrogel mass loss at each 
time point whereas the 6 wt% and 7 wt% copolymer hydrogels developed statistically significant  
differences after 8 and 12 weeks, respectively (Figure 4.13C). These differences in degradation 
were maintained for the rest of the study. In addition, the initial (day 0) compressive moduli were 
not statistically significant (p>0.05) for comparison between the two copolymer ratios at each 
macromer concentration and this was maintained until 12 weeks, at which time the moduli for the 
ratios diverged and became statistically significant (Figure 4.13D). More importantly, statistically 
significant differences in compressive moduli based on changes in macromer concentration 
persisted until week 8 for both copolymer ratios, where higher macromer concentration led to 
prolonged retention of mechanics. Thus, degradation was successfully tuned based on the 
copolymer ratio whereas mechanics were tuned using differences in macromer concentration.   
4.4. Discussion  
In this chapter, characterization studies were performed to better understand techniques 
to tune hydrogel properties and to select formulations for subsequent imaging (Chapters 5, 6) and 
in vivo (Chapter 7) studies. The initial characterization experiment simultaneously investigated the 
effect of altering the initiator concentration, macromer modification, and macromer concentration 
to tune HeMA-HA hydrogel mechanics. As the concentration of APS and TEMED increased, 
more free radicals were generated in the pre-polymer solution, leading to accelerated kinetic 
chain formation between methacrylate groups on the HA backbone (Figure 4.5). Initiator 
concentration had a larger impact on hydrogels formed at higher macromer modifications and 
concentrations (i.e., 35% modified HeMA-HA at 10 wt%). As more potential crosslinking options 
became available (due to an increase in modification or concentration), the initiator concentration 
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became the rate limiting step in hydrogel formation. This suggests that a portion of the 
methacrylates remained unreacted in the lower initiator concentration groups for the 10 wt%, 35% 
modified hydrogels, leading to lower mechanics. Particularly at lower modifications or macromer 
concentrations, initiator concentration within the range investigated played a minor role in altering 
hydrogel mechanics, implying that all possible methacrylates were crosslinked using the lowest 
initiator concentration of 5 mM APS/TEMED. Therefore, subsequent characterization studies 
focused on altering the macromer modification and concentration at a single initiator 
concentration. Based on previous in vivo work from our group,
12,13
 an initiator concentration of 5 
mM APS/TEMED was selected so the resulting hydrogels would form instantaneously upon 
delivery to the target site (i.e., myocardium) but allow sufficient time for injection prior to gelation.  
In pure HeMA-HA hydrogels, as either the modification or macromer concentration 
increased, the number of reactive methacrylates available for crosslinking increased. For a single 
initiator concentration, this led a decrease in the gelation time since crosslinks formed more 
rapidly (Figures 4.6A, 4.8A). Similarly, an increase in the modification or macromer concentration 
increased the total number of efficient crosslinks per unit volume (i.e., crosslinking density), which 
resulted in stiffer gels that required a greater force to deform during bulk compression (Figures 
4.6B, 4.8B).
38
 Past work by our group confirmed that changes in HA modification correlate with 
changes in bulk hydrogel mechanics.
12,13
 Furthermore, in HeMA-HA hydrogels, crosslinks are 
formed through the HeMA groups, which are also the sites susceptible to hydrolysis at the ester 
bonds. Thus, degradation and mechanics are intertwined. As anticipated, the increase in 
crosslinking density with increased modification or macromer concentration led to more bonds 
needing to hydrolyze and less free volume to accommodate water and hence, slower degradation 
(Figures 4.6C, 4.9). For hydrogels with approximately the same initial mechanics, formulations 
with a higher modification but lower macromer concentration maintained their mechanics for 
longer and degraded slower than formulations with a lower modification but higher macromer 
concentration (Figure 4.10). Thus, by altering the modification along with the macromer 
concentration, the degradation and mechanics of HeMA-HA hydrogels were tailored.   
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As another approach to tuning HA hydrogel properties, MeHA was introduced at different 
ratios to examine the effect of introducing a non-hydrolytically degradable macromer into a 
hydrolytically degradable HeMA-HA hydrogel system. Previous work by our group with MeHA and 
α-hydroxy ester block copolymers demonstrated that hydrogel properties (i.e., mechanics, 
degradation) can be tailored by adjusting the ratio of the MeHA block to the hydrolytically 
degradable block.
12,39
 Assessment of gelation demonstrated that increased MeHA incorporation 
relative to HeMA-HA resulted in accelerated gelation times, potentially due to the smaller size of 
the methacrylate (Me) functional group leading lower viscosity of the macromer solution and more 
rapid crosslink formation (Figure 4.11A). However, the initial compressive moduli prior to swelling 
decreased as the amount of MeHA present increased, indicating less overall crosslink formation 
with MeHA hydrogels for the same modification of HeMA and Me on HA (Figure 4.11B). Due to 
the difference in length between the two functional groups, this suggests that crosslinking was 
preferenced to the HeMA groups since they extend further outward from the HA chains.  
Degradation was tuned based the degree of MeHA incorporation, where more MeHA, 
and thus, less hydrolytically susceptible ester bonds, led to prolonged degradation (Figure 4.12). 
In all macromer concentrations, hydrogel mass loss was similar between the copolymer and 
homopolymer hydrogels until about 8 weeks (Figure 4.12). After this point, a burst release of HA 
was observed from the HeMA-HA hydrogels due to the bulk degradation exhibited by 
hydrolytically degradable gels: as the hydrogels swell and crosslinks are moved farther apart, a 
threshold in the number of crosslinks broken is reached, resulting in an exponential increase in 
mass loss. Due to the extensive amount of time required for MeHA degradation, degradation was 
evaluated out to 20 weeks, at which point the hydrogels were degraded via exogenous 
hyaluronidase. Temporal changes in mechanics with degradation were then evaluated for two 
copolymer formulations (Figure 4.13). The ratios of 75:25 and 25:75 for HeMA-HA:MeHA were 
selected to generate differences in degradation (with similar initial mechanics within a given 
macromer concentration, Figure 4.13B) whereas the different macromer concentrations were 
selected to target different mechanical profiles that would be relevant to post-MI remodeling.
40
 As 
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anticipated, as more ester (HeMA) groups were present, the hydrogels became more susceptible 
to hydrolysis and therefore, degraded and lost their mechanics at a faster rate (Figure 4.13C,D). 
4.5. Conclusions  
In summary, this chapter highlights the versatility of HeMA-HA-based systems to 
generate hydrogels with a range of gelation, degradation and mechanical profiles to fit a specific, 
desired application. Pure HeMA-HA hydrogels served as a platform to investigate changes in 
macromer modification and concentration within a homopolymer system, where increases in 
either macromer modification or concentration led to accelerated gelation, prolonged degradation, 
and high mechanics. The incorporation of MeHA to form a copolymer hydrogel system provided 
the opportunity to tune degradation based on the functional group manipulated for hydrogel 
crosslinking. While both HeMA-HA and MeHA are enzymatically degradable through the HA 
backbone, HeMA-HA hydrogels are also susceptible to hydrolysis of the HeMA side groups, 
leading to more rapid degradation. Whereas the use of copolymers was effective in tuning 
hydrogel properties, the remainder of this dissertation will focus primarily on the use of MeHA and 
HeMA-HA homopolymers for simplicity in experimental design. The next two chapters will focus 
on the ability to image injectable HA hydrogels in myocardial explants using MRI.  
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4.7. Appendix 4.1. Statistical comparisons for selected in vitro characterization figures.   
Figure 4.5. Tunability of mechanical properties of HeMA-HA hydrogels.  
Within each initiator concentration, all comparisons between modifications were 
statistically significant (p<0.05) except for 4 wt% hydrogels at 10 mM APS/TEMED. All 
comparisons between macromer concentrations for a given initiator concentration were 
statistically significant (p<0.05)  aside from 4 vs. 7 wt% for 10% modified hydrogels formed using 
5 mM and 10 mM APS/TEMED. Statistical comparison between initiator concentrations were 
statistically significant (p<0.05) for all comparisons to 5 mM except for 35% modified HeMA-HA at 
4 wt%. Between initiator concentrations, all comparisons to 5 mM were statistically significant 
(p<0.05) except for 35% modified hydrogels at 4 wt% and 10% modified hydrogels at 10 wt%. 
Comparisons in moduli for 7.5 vs. 10 mM were statistically significant (p<0.05) for 10 wt% gels at 
both modifications and for 10% modified gels at 10 wt%. 
Figure 4.6. Initial in vitro characterization studies of pure HeMA-HA hydrogels at various 
modifications and macromer concentrations. 
*p<0.05 vs. 10% modified HeMA-HA at 4 wt% in panel A. Between modifications, gel 
onset at 4 wt% and gel completion at 7 wt% were statically significant (p<0.05). All groups were 
statistically significant (p<0.05) in panel B. In panel C, comparisons between modifications are all 
statistically significant (p<0.05) except for 4 wt% hydrogels at 1 week. For comparisons between 
macromer concentrations, *p<0.05 for 4 vs. 7 wt%, 
+
p<0.05 for 7 vs. 10 wt%, and 
#
p<0.05 for 4 
vs. 7 wt% for 10% modified hydrogels and 
δ
p<0.05  for 7 vs. 10 wt% for 25% modified hydrogels. 
In panel D, all compressive moduli prior to normalization were statistically significant (p<0.05) 
except for 10% vs. 35% mod for 4 wt% hydrogels at days 0, 14 and 28, 4 vs. 7 wt% for 10% 
modified gels at days 7, 14, and 28, and 7 vs. 10 wt% for 10% modified gels at days 14 and 56.  
Figure 4.8. Extensive analysis on the effect of macromer modification and concentration on 
HeMA-HA hydrogel properties. 
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In panel A, gelation comparisons between modifications were statistically significant 
(p<0.05) for all macromer concentrations relative to 10% modification except for 10% vs. 25% 
modified gels at 4 wt% for gel onset and 2 wt% for gel completion. For 25% vs. 40% modified 
gels, values were significant (p<0.05) at 4 wt% for gel onset and at 8 wt% and 10 wt% for gel 
completion. Gel onset comparisons between macromer concentrations were statistically 
significant (p<0.05) for all 10% modified hydrogels except 6 vs. 8 wt%, 6 vs. 10 wt%, 8 vs. 10 
wt%, 8 vs. 12 wt%, and 10 vs. 12 wt%. For the other two modifications, gel onset was statistically 
significant (p<0.05) for all other macromer concentrations relative to 2 wt% except for 2 vs. 4 wt% 
for 25% modified hydrogels. For gel completion comparisons, *p<0.05 vs. 2 wt% and 
+
p<0.05 vs. 
12 wt% at the same modification. In panel B, all degradation comparisons were statistically 
significant (p<0.05) except for 10% modified hydrogels at 2 vs. 4 wt% and 10 vs. 12 wt%. 
Comparison of initial mechanics was statistically significant (p<0.05) between modifications aside 
from 25% vs. 40% modified gels at 4 wt%. Between macromer concentrations, all moduli were 
statistically significant (p<0.05) aside from 2 vs. 4 wt% gels at all modifications, 4 vs. 6 wt% gels 
at 10% and 25% modifications, and 2 vs. 6 wt% hydrogels at 40% modification.   
Figure 4.9. Tuning HeMA-HA hydrogel degradation by altering the macromer modification and 
concentration. 
Between modifications, all mass loss values were statically significant (p<0.05) aside 
certain 25% vs. 40% comparisons: at day 1 - 2, 4, 6, 8, 10, and 12 wt%; at week 1 -  2, 4, 8, 10, 
and 12 wt%; at week 2 - 4, 8, 10, and 12 wt%; at week 4 - 4, 8, 10, and 12 wt%; at week 8 - 8 and 
12 wt%; at week 12 - 12 wt%; and at week 16 - 12 wt%.  Comparisons between macromer 
concentrations at each modification were statistically significant (p<0.05) except for the following 
cases. For 10% modified hydrogels: day – 4 vs. 6 wt%, 6 vs. 10 wt%, 8 vs. 10 wt%, 8 vs. 12 wt%, 
10 vs. 12 wt%; week 1 – 6 vs. 8 wt%, 6 vs. 10 wt%, 6 vs. 12 wt%, 8 vs. 10 wt%, 8 vs. 12 wt%, 10 
vs. 12 wt%; week 2 – 6 vs. 8 wt%, 6 vs. 10 wt%, 8 vs. 10 wt%, 10 vs. 12 wt%; and week 4 – 8 vs. 
10 wt%, 10 vs. 12 wt%. For 25% modified hydrogels: day 1 – 2 vs. 4 wt%, 2 vs. 6 wt%, 2 vs. 8 
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wt%, 4 vs. 6 wt%, 6 vs. 8 wt%, 6 vs. 10 wt%, 8 vs. 12 wt%, 10 vs. 12 wt%; week 1 – 2 vs. 4 wt%, 
4 vs. 6 wt%, 8 vs. 10 wt%, 10 vs. 12 wt%; week 2 – 4 vs. 6 wt%, 8 vs. 10 wt%, 10 vs. 12 wt%; 
week 4 – 4 vs. 6 wt%, 10 vs. 12 wt%; and week 8 – 10 vs. 12 wt%.  For 40% modified hydrogels: 
day 1 and week 1 – 2 vs. 4 wt%, 6 vs. 8 wt%, 6 vs. 10 wt%, 6 vs. 12 wt%, 8 vs. 10 wt%, 8 vs. 12 
wt%, 10 vs. 12 wt%; week 1 – 6 vs. 8 wt%, 6 vs. 10 wt%, 6 vs. 12 wt%, 8 vs. 10 wt%, 8 vs. 12 
wt%, 10 vs. 12 wt%; weeks 2 and 4 - 6 vs. 8 wt%, 8 vs. 10 wt%, 8 vs. 12 wt%, 10 vs. 12 wt%; 
weeks 8, 12, and 16 – 8 vs. 10 wt%, 10 vs. 12 wt%; and week 20 – 10 vs. 12 wt%. 
Figure 4.10. In vitro characterization of selected HeMA-HA hydrogel formulations with similar 
gelation and initial mechanics but different rates of degradation. 
In panels A and B, *p<0.05.  In panel C, comparisons between similar formulations (i.e., 
10% mod at 8 wt% vs. 40% mod at 4 wt%) at each time point were statistically significant 
(p<0.05). At each time point, differences in degradation between 10% and 40% modified 
hydrogels were statistically significant (p<0.05). In panel D, comparisons between similar 
formulations were statistically significant (p<0.05) at 2, 4, 8, and 12 weeks. Differences in moduli 
between the two modifications were significant (p<0.05) at 1, 2, 4, 8, and 12 weeks. 
Figure 4.11. Effect of combining non-degradable MeHA and degradable HeMA-HA into a single 
copolymer hydrogel system at various macromer concentrations. 
In panel A, gel onset comparisons between macromer concentrations at each ratio were 
statistically significant (p<0.05) except for 6 vs. 8 wt% at all ratios, 8 vs. 10 wt% in 0:100 and 
75:25 copolymers, and all pure HeMA-HA (100:0) hydrogels. For gel onset comparisons between 
ratios at each macromer concentration, *p<0.05 vs. 100:0 and 
+
p<0.05  vs. 75:25. For gel 
completions comparisons between modifications, 
δ
p<0.05  for all 4 vs. 10 wt% ratios, 4 vs. 8 wt% 
at 25:75 and 50:50, and 6 vs. 10 wt% at 25:75 and 50:50. No gel completion comparisons 
between ratios were statistical significant (p<0.05). In panel B, all degradation comparisons 
between ratios at a single macromer concentration (aside from at 20 weeks) and all comparisons 
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between macromer concentrations at a given copolymer ratio were statistically significant 
(p<0.05). For initial moduli comparisons, *p<0.05 vs. 100:0, 
+
p<0.05 vs. 75:25, and 
#
p<0.05 vs. 
0:100 copolymers. 
Figure 4.12. Tuning hydrogel degradation by altering the ratio of HeMA-HA to MeHA at various 
macromer concentrations. 
Comparisons between the copolymer ratios at each macromer concentration gradually 
became more statistically significant (p<0.05) with additional time points of assessment. In panel 
A, mass loss differences between ratios for 4 wt% hydrogels were significant (p<0.05) except for 
the following: 75:25 vs. 50:50 and 75:25 vs. 25:75 at day 1; 50:50 vs. 25:75 at day 1 and weeks 
1, 2, 4, 8, and 12; 100:0 vs. 75:25 at weeks 1, 2, and 4; and 25:75 vs. 0:100 at weeks 4, 8, 12, 16 
and 20. In panel B, no comparisons for 6 wt% hydrogels were statistically significant at day 1 or 
week 1.  At weeks 2 and 4, the only significant (p<0.05) comparisons were between 100:0 vs. 
75:25 at both weeks and 100:0 vs. 0:100 at week 4. At weeks 8 and 12, all comparisons were 
statistically significant (p<0.05) except for the following: 75:25 vs. 50:50, 75:25 vs. 25:75, 50:50 
vs. 25:75, and 25:75 vs. 0:100 at week 8; 75:25 vs. 50:50 and 50:50 vs. 25:75 at week 12. At 
weeks 16 and 20, all comparisons were statistically significant (p<0.05). For panels C and D, no 
comparisons for were statistically significant at day 1 or weeks 1, 2, or 4. For 8 wt% hydrogels, all 
comparisons at 8 and 12 weeks were statistically significant (p<0.05) except for the following: 
75:25 vs. 50:50, 75:25 vs. 25:75, 50:50 vs. 0:100, 25:75 vs. 50:50, and 25:75 vs. 0:100 at week 8; 
50:50 vs. 25:75 at week 12. For 10 wt% hydrogels, all comparisons at 8 and 12 weeks were 
statistically significant (p<0.05) except for the following: 100:0 vs. 0:100 and 100:0 vs. 25:75 at 
week 8; 25:75 vs. 0:100 at week 12. For both panels C and D, all comparisons between ratios 
were statistically significant (p<0.05) at weeks 16 and 20. General comparisons between the 
macromer concentrations were statistically significant (p<0.05) for the following: day 1 - 4 vs. 6 
wt%, 4 vs. 10 wt%, 6 vs. 8 wt%; weeks 1, 2, and 4 - 4 vs. 6 wt%, 4 vs. 8 wt%, 4 vs. 10 wt%;  
week 8 – 4 vs. 10 wt%; and week 16 – 4 vs. 10 wt%, 6 vs. 10 wt%, 8 vs. 10 wt%. 
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Figure 4.13. In vitro characterization of selected HeMA-HA/MeHA copolymer hydrogels. 
For panel A, 
+
p<0.05 vs. 5 wt% gels at the same ratio. All comparisons between ratios 
were statistically significant (*p<0.05) for gel onset. There were no statistical differences in gel 
completion. For panel B, degradation was statistically different (p<0.05) between macromer 
concentrations for 75:25 hydrogels and between ratios at the same concentration (*p<0.05). Initial 
moduli were statistically significant (p<0.05) for all comparisons between macromer 
concentrations at each ratio and between ratios for 5 wt% hydrogels (*p<0.05). In panel C, 
comparisons in hydrogel mass loss between ratios statistically significant (p<0.05) for 5 wt% 
copolymers at all time points, 6 wt% gels at weeks 8, 12, and 16, and 7 wt% gels at weeks 12 
and 16. Differences between macromer concentrations statistically significant (p<0.05) for 75:25 
copolymers at 5 vs. 7 wt% at all time points, 5 vs. 6 wt% at day 1, week 1, and week 2, and 6 vs. 
7 wt% at week 4. In panel D, comparisons between ratios were statistically significant (p<0.05) at 
week 12 for all macromer concentrations. At each ratio, all differences between macromer 
concentrations were statistically significant (p<0.05) except for 5 vs. 6 wt% gels at both ratios at 
week 8, 6 vs. 7 wt% gels at 25:75 at week 8, and 6 vs. 7 wt% gels at both ratios at week 12.   
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CHAPTER 5 
 
Using MRI to Visualize and Quantify Hyaluronic Acid Hydrogel Distribution in 
Cardiac Tissue 
 
5.1. Introduction 
Injectable hydrogels have become an attractive therapy for many biomedical applications, 
including the attenuation of left ventricular (LV) remodeling after myocardial infarction (MI) by 
mechanically stabilizing the myocardial wall to reduce stress.
1
 Theoretical finite element (FE) 
models have shown that the ability of injectable hydrogels to decrease myocardial stress post-MI 
depends on their material properties, such as mechanics and volume.
2-5
  A FE model of injections 
into the borderzone region that were 20% greater than the stiffness of the native myocardium and 
4.5% of the LV wall volume led to a 20% reduction in myocardial stress in the fiber direction as 
compared to control simulations with no injections.
2
 Another FE model of simulated polymeric 
inclusions illustrated the importance of both the injection pattern and the volume of material 
dispersion, with larger numbers of injections and larger injections volumes having the greatest 
potential to decrease myocardial fiber stress following infarction.
3
 These theoretical models 
illustrate the correlation between positive mechanical outcomes and material properties, 
particularly the material distribution volume. However, the optimal material volume necessary to 
maximize the mechanical benefit remains unclear. One challenge in identifying optimal material 
distribution is the ability to noninvasively assess material properties in tissues.  
Traditional assessment of hydrogel dispersion centers on the use of histological and 
immunohistochemical techniques that, while effective, are ultimately invasive, destructive, and 
limited to two-dimensional slices which prevent accurate three-dimensional volume assessment. 
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In contrast, imaging offers a noninvasive approach to temporally obtain information regarding the 
presence and distribution of hydrogels throughout tissue. Various imaging techniques have been 
show to be useful for material assessment. Optical imaging can be used for both two- and three-
dimensional in vivo material visualization, either through multiphoton microscopy with the use of 
coupled fluorescent dyes or optical coherence tomography, respectively. However, optical 
imaging of materials is limited to small animals
6-8
 or superficial locations within centimeters of the 
tissue surface
9
 since light intensity decays exponentially with increasing tissue depth, thus 
decreasing image sensitivity and resolution.
10,11
  
Similarly, x-ray imaging can also be used to assess materials in both two- and three-
dimensions using standard radiographic or computed tomography (CT) techniques, respectively, 
where image contrast is generated based on difference in the amount of x-rays exiting adjacent 
objects of interest. Therefore, the ability to detect materials using x-rays is dependent on their 
atomic make-up, or density, which is often similar to that of native soft tissues.
12
 Micro-CT (μCT) 
has thus been used extensively to monitor materials for bone applications
13-15
 but requires 
incorporation of contrast agents with high atomic numbers, such as iodine or gold,
12,16,17
 for soft 
tissue applications. Unlike fluorophores for optical imaging, x-ray contrast agents require 
relatively high concentrations for visualization leading to concerns with toxicity and potential 
alteration of materials properties.
16,18
 Moreover, for in vivo applications, frequent temporal 
material assessment using x-ray imaging is challenging due to the increased risk of biological 
(more specifically, carcinogenic) damage with repeated exposure to ionizing radiation.
19
  
To circumvent the depth limitations of optical imaging and ionizing radiation concerns of 
x-ray imaging, magnetic resonance imaging (MRI) can be used to image injectable materials. MRI 
is particularly well-suited for material assessment due to its ability to provide accurate and 
reproducible images with high spatial and temporal resolution in three dimensions.
20
 As 
discussed in Chapter 1, image contrast in MRI is based on differences in the response of water 
protons in materials or tissues to the presence of magnetic fields. Due to their intrinsic spin 
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property, when protons are placed in a static magnetic field of strength B (referred to as B0), they 
act like a bar magnet and align themselves with the main B0 magnetic field oriented along the z-
axis.
21,22
 To generate a signal from the protons, the protons must be rotated to the x-y plane 
using a  secondary magnetic field (B1) that is applied with a radiofrequency (RF) coil within the 
main magnet.
23
 As the protons relax back to their equilibrium state, they give off the energy they 
obtained from the applied RF pulse in the form of a free-induction decay (FID) echo, which is 
detected by the RF coil as the MR signal.
23
 Differences in signal between adjacent materials or 
tissues are due to differences in the rate at which their protons relax to equilibrium (i.e., relaxation 
properties). Transverse (T2) and longitudinal (T1) relaxation are processes that describe the rate 
of proton dephasing in the transverse (i.e., x-y) plane and return to alignment with the B0 field 
along the longitudinal (i.e., z-) axis.
21,22
 Differences in T1/T2 relaxation can be exposed based on 
the degree of rotation of the protons caused by the B1 field, which is specified in the pulse 
sequence, or series of RF pulses. Therefore, tuning the RF pulse sequence can be used to 
enhance differences in relaxation properties, and thus, endogenous MR image contrast. 
Pulse sequences commonly used for conventional MRI include spin echo, gradient echo, 
and inversion recovery sequences. In a spin echo sequence, a 90
o
 RF pulse is applied to rotate 
the protons into the x-y plane, at which point they begin dephasing from one another by T2 
relaxation. An 180
o
 pulse is then applied to rapidly rephase the protons and result in signal (i.e., 
FID echo) generation.
21
 The time between when the 90
o
 pulse is applied and the echo acquired is 
referred to as the echo time (TE). Multiple 90
o
-180
o
 RF pulse trains are needed to generate an 
image and to improve the image signal-to-noise ratio (SNR); the time between pulse train 
repetitions is called the repetition time (TR).
22
 In contrast to a spin-echo sequence, an inversion 
recovery sequence involves first rotating the protons 180
o
. As the protons relax along the z-axis 
by T1 processes, a 90
o
 RF pulse is applied to rotate the protons into the x-y plane where the 
signal can be detected.
21
 Finally, in a gradient echo sequence, the RF pulse produces an angle of 
proton rotation between 0
o
 and 90
o
; since the protons are only partially flipped into the x-y plane, 
some of the longitudinal magnetization is maintained, leading to rapid signal generation.
21
 Each 
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pulse sequence has its benefits. Whereas gradient echo imaging enables rapid acquisition, spin 
echo imaging introduces a T2 dependence and gradient echo imaging highlights differences 
based on T1. Thus, tailoring the pulse sequence, both through the type and selection of the TE 
and TR times, can result in differences in image contrast based on intrinsic MR properties.  
Conventional MRI has been used to image injectable biomaterials based on their intrinsic 
MR properties (e.g., T1/T2 relaxation times, proton density) in both animals and humans.
24
 
However, much of the work has been limited to synthetic injectable materials, such as poly(lactic 
acid),
25
 poly(L-lactide),
26
 or poly(ethylene glycol),
24
 since their intrinsic MR properties often differ 
from those of the surrounding tissue. An alternative approach is to incorporate an exogenous 
contrast agents into the biomaterial, such as iron oxide (FeO)
27
 or gadolinium (Gd
+3
),
28
 to 
generate or enhance the differences in relaxation properties and thus, increase image contrast-
to-noise (CNR). However, similar to the x-ray contrast agent concerns discussed above, high 
concentrations of MR contrast agents are required to generate an effect due to inherent 
sensitivity limitations with MRI. These high concentrations not only have the potential to alter the 
injected biomaterials’ properties and disturb the physiologic environment surrounding the injection 
site but also will produce local toxicity if not properly coated or chelated for the duration of their 
time in vivo.
29
 Thus, there remains a need to develop MRI techniques to image natural, injectable 
materials without the use of contrast agents.  
Towards this goal, this chapter used non-contrast based MRI to image injectable 
hyaluronic acid (HA) hydrogels and assess their material properties following injection into 
myocardial tissue. As discussed in Section 4.1, HA is a linear polysaccharide found in native 
cardiac extracellular matrix and can be modified with numerous reactive groups. The addition and 
amount of these reactive groups enables both hydrogel formation and tuning of hydrogel 
properties (e.g., distribution volume). This chapter builds off the previous characterization chapter 
to investigate the ability to tailor hydrogel three-dimensional volume distribution in tissue by 
altering material properties. Ultimately, the use of MR imaging as a tool to noninvasively 
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investigate material properties could provide insight on material design criteria for injectable 
biomaterials to attenuate LV modeling. 
5.2. Materials and Methods  
5.2.1. Synthesis and Gelation of MeHA Macromers 
Methacrylated HA (MeHA) was synthesized as previously discussed in Section 4.2.2 
through the reaction of HA (75 kDa, Lifecore) and methacrylic anhydride (MA, Sigma) in 
deionized (DI) water at pH 8.0 (4°C, 24hrs), followed by dialysis against DI water for purification. 
The macromer was then frozen and lyophilized.
30
 HA methacrylation was altered by varying the 
amount of MA to HA and assessed with 
1
H-NMR (Bruker, 360 MHz), as shown in Section 4.2.2. 
Two MeHA functionalizations were examined in subsequent ex vivo MR imaging applications: 
~30% (i.e., low MeHA) and ~60% (i.e., high MeHA) modification of the HA repeat units.  
For gelation, the methacrylate groups on MeHA were crosslinked using a two-component 
redox radial initiator system of ammonium persulfate (APS, Sigma) and N,N,N,N’,N’-
tetramethylenediamine (TEMED, Sigma).
31
 APS and TEMED were mixed with MeHA dissolved in 
PBS (4 wt%) to induce hydrogel formation. Macromers were crosslinked using two concentrations 
of the initiators (low A/T: 5 mM APS and 5 mM TEMED or high A/T: 12.5 mM APS, 6.25 mM 
TEMED) to form the following four hydrogel formulations: 1) low MeHA, low A/T, 2) high MeHA, 
low A/T, 3) low MeHA, high A/T, and 4) high MeHA, high A/T. Gelation was evaluated by 
monitoring the storage (G’) and loss (G”) moduli over time at 37°C using an AR2000ex 
Rheometer (TA Instruments) under 1% strain and a frequency of 1 Hz in a cone-plate geometry 
(1°, 20 mm diameter),
32
  as in Section 4.2.3. Gelation onset was defined as the time point when 
the G’ and G” intersected and the viscosity (|n*|) was greater than one. Gel onset times were 
subsequently used to dictate the timing for hydrogel injection into myocardial explants.  
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5.2.2. Synthesis and Gelation of Guest-Host HA Macromers  
In collaboration with another graduate student in our group (Christopher Rodell), guest-
host macromers were synthesized by functionalizing HA (90 kDa, Lifecore) with either 
adamantine (guest) or β-cyclodextrin (host), as previously described.
33
 Briefly, adamantine 
modified HA (Ad-HA) was formed by coupling 1-adamantane acetic acid to HA-tetrabutyl-
ammonium salt (HA-TBA) through an esterifiction reaction in dimethyl sulfoxide (DMSO) 
mediated by 4-dimethylaminopyridine (DMAP, Sigma) and the coupling agent di-tert-butyl 
dicarbonate (BOC2O, Sigma) (45°C, 24hrs).
33
 Purification was carried out by dialyzing against DI 
water, acetone precipitating, and dialyzing again. Cyclodextrin modified HA (CD-HA) was 
synthesized by coupling 6-(6-aminohexyl)amino-6-deoxy- β-cyclodextrin (β-CD-HAD) to HA-TBA 
through an amidation reaction with (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate (BOP, Sigma) as the coupling agent in DMSO (25°C, 2hrs).
33
 The 
macromer was then purified by extensive dialysis against DI water and filtration to remove 
insoluble byproducts from the reaction. Both guest-host macromers were frozen, lyophilized, and 
assessed using 
1
H-NMR (Bruker, 360 MHz) to determine the functionalization. For subsequent 
imaging work in this chapter, adamantine and cyclodextrin modifications of ~50% and ~20% of 
the HA repeat units were selected, respectively.  
Hydrogel formation occurred by supramolecular self-assembly of the guest-host 
components on HA upon mixing solutions of the two macromers dissolved in PBS. Manual stirring 
was used to ensure homogenous interaction and assembly (Figure 5.1). Entrapped air bubbles 
were removed by brief centrifugation. Hydrogels were formed such that the net polymer 
concentration was 5 wt% and the adamantine and cyclodextrin components were 
stoichiometrically balanced. Rheology properties were assessed at 37ºC using the cone and plate 
geometry (1°, 20 mm diameter) discussed in Section 5.2.1 above to obtain oscillatory time 
sweeps under 1% strain and a frequency of 1 Hz.
33
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Figure 5.1. Formation of self-assembling, guest-host HA hydrogels with shear-thinning 
properties. Reversible interaction of adamantane (Ad, guest) and β-cyclodextrin (CD, host) 
functionalized HA to form a guest-host complex (A). Schematic of guest-host hydrogel formation 
by supramolecular self-assembly and disassembly in the presence of shear forces (B). Figure 
adapted from [33]. 
5.2.3. Synthesis and Gelation of HeMA-HA Macromers  
As described previously in Section 4.2.1, HA was modified with hydrolytically degradable 
hydroxyethyl methacrylate (HeMA) to form the gel precursor HeMA-HA by coupling HA-TBA (75 
kDa HA) to 2-hydroxyethyl-methacryl-succinate (HeMA-COOH).
32
 Similar to the synthesis of Ad-
HA above, the reaction was performed in DMSO using DMAP (Sigma) and BOC2O (Sigma) 
(45°C, 20hrs). The macromer was purified by dialyzing against DI water at 4°C, acetone 
precipitating, and dialyzing again. The solution was then frozen and lyophilized to obtain the final 
product. The HeMA modification on HA was evaluated using 
1
H-NMR (Bruker, 360 MHz) and 
found to be ~25% of the HA repeat units, as shown in Section 4.2.1.  
Similar to MeHA gelation, HeMA-HA hydrogel formation was induced by crosslinking the 
macromer dissolved in PBS (8 wt%) with the chemical initiators APS (5 mM, Sigma) and TEMED 
(5 mM, Sigma).
31
 As in Section 4.2.3, rheology was used to assess gelation, where the gel onset 
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and completion times were defined on the time sweeps as when G’ and G” intersected and when 
there was less than a 1% change in both G’ and viscosity (|n*|) for ten time steps, respectively.  
5.2.4. MRI of MeHA in Myocardial Explants 
MeHA hydrogel distribution volume within the myocardium was assessed in healthy lamb 
LV tissue obtained from a local butcher shop. Ex vivo samples were prepared by simulating the in 
vivo injection protocol that will be described in Section 5.2.6. In general, the MeHA macromer 
(low: 30%, high: 60% modified) was dissolved in PBS (4 wt%) and mixed with the specified 
chemical initiators (low: 5/5 mM APS/TEMED, high: 12.5/6.25 mM APS/TEMED). Three minutes 
after adding the initiators (based on rheology, as discussed in Section 5.2.1), 0.3 mL of the 
prepolymer solution was injected into the myocardial LV explant at a depth of approximately 1 cm 
from the epicardial surface. After waiting thirty minutes to ensure sufficient time for gelation, the 
composite hydrogel/tissue samples (about 2 x 2 cm) were collected from the LV to include the 
transmural injection site from the epicardium to endocardium. Prior to initial imaging session 
(which occurred less than 2 hrs following injection), tissue samples were stored in PBS (Life 
Technologies) supplemented with Penicillin-Streptomycin (1%, P/S; Life Technologies).  
Explants containing MeHA hydrogel injections were imaged using a 9.4 T horizontal bore 
small animal MR scanner (Varian, Palo Alto, CA) using a 35-mm diameter commercial quadrature 
1
H coil (m2m Imaging Corp., Cleveland, OH).  Imaging parameters were adjusted to exploit the 
differences in intrinsic MR properties between the material and myocardium. A T2-weighted spin-
echo pulse sequence was used and the echo time (TE) was varied (30, 40, 50, 60 ms) at a 
constant repetition time (TR, 5.8 sec) to generate optimal image contrast by visual inspection. 
Similarly, the voxel size was adjusted (0.23 x 0.23 x 1.00 mm
3
 vs. 0.23 x 0.23 x 0.23 mm
3
) to 
optimize image resolution. As described in Kichula et al.,
5
 the final imaging parameters selected 
following optimization were as follows: echo time = 40 ms, repetition time = 5.8 sec, averages = 
2, field of view = 30 x 30 mm
2
, matrix size =128 x 128, slices = 128, slice thickness = 0.23 mm, 
voxel size = 0.23 x 0.23 x 0.23 mm
3
. 
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Prior to assessing differences in hydrogel distribution between the four MeHA hydrogel 
formulations (introduced in Section 5.2.1), uncrosslinked MeHA was injected into myocardial 
explants (n=3 samples) and imaged at various time points following injection (i.e., at days 0, 1, 2, 
3, 4, and 5) to assess changes in the MR signal of the macromer alone relative to the background 
myocardial signal using the selected imaging parameters. Between scans, the uncrosslinked 
macromer-explant samples were immersed in 50 mL of sterile PBS (Life Technologies) 
supplemented with Penicillin-Streptomycin (1%, P/S; Life Technologies). While at room 
temperature, the solution of sterile PBS with P/S was changed six times each day to remove the 
uncrosslinked macromer by diffusion. Overnight, tissue samples were stored at 4°C in 200 mL of 
sterile PBS. To assess differences in signal intensity, images were first converted into NIFTI files 
using ImageJ software (NIH; Bethesda, MD) and then converted to their correct dimensions with 
the medical imaging processing tool convert3D (c3D
34
). Subsequently, a MRI bias correction was 
performed with an N4 intensity normalization algorithm (Insight Segmentation and Registration 
Toolkit, ITK; NIH; Bethesda, MD), as previously described,
35,36
 and the difference in signal 
intensity between the injected uncrosslinked macromer and surrounding background myocardial 
tissue was quantified over the 6 day time course (i.e., days 0-5). For each sample, the percent 
change in intensity was calculated for five slices in three regions throughout the transmural cross-
section of the LV wall (i.e., near the epicardium, myocardium, and endocardium). 
Based on the uncrosslinked macromer study, differences in hydrogel distribution between 
the four MeHA hydrogel formulations (n = 4/formulation) were assessed three days following 
injection into myocardial explants. As described previously, samples were maintained at room 
temperature in 50 mL of sterile PBS with P/S that was changed 6 times per day and stored 
overnight at 4°C in 200 mL of sterile PBS. Similarly, images were converted to a NIFTI file format, 
the dimensions were corrected with c3D, and the MRI bias correction was performed to normalize 
intensity. The volumes of the injected hydrogels were quantified using a combination of 
automated and manual segmentation schemes. An automated segmentation was first performed 
using Atropos software (an ITK-based multivariate n-class open source segmentation algorithm 
126 
 
distributed with ANTs)
37,38
 where the input domain was chosen to be only the tissue portion of the 
images. The segmentation was initialized by specifying that three different tissue spaces (i.e. 
segmentation regions) were present: 1) myocardial tissue, 2) hydrogel, and 3) tissue/hydrogel 
composite. After applying a smoothing factor of 0.1 (Markov random field value 1.0, 1x1x1), each 
voxel was then assigned to one of the three tissue labels depending on its intensity. Based on a 
comparison to the uncrosslinked MeHA studies at day 3, the crosslinked hydrogel was defined to 
be regions where the percent change in intensity between the hydrogel and myocardium was 
above 7%. A manual segmentation was then performed to further distinguish the crosslinked 
hydrogel from the myocardium, particularly in the edges of the questionable composite label 
regions from the automated segmentation. From the segmentations, hydrogel distribution 
volumes were quantified and 3D reconstructions generated using ITK-SNAP software.
34
 
5.2.5. MRI of Guest-Host Hydrogels in Myocardium 
Similar to the ex vivo MeHA studies, explanted healthy porcine hearts were acquired from 
a local distributor for MRI assessment of guest-host hydrogel distribution in myocardial tissue. 
Guest-host HA hydrogels were pre-formed in ½ cc syringes by manually mixing the two 
components (Ad-HA and Cd-HA) and centrifuging to remove air. Hydrogels were formed at a final 
HA concentration of 5 wt% using 50% modified Ad-HA and 20% modified CD-HA. Guest-host 
hydrogels were injected into LV wall of explanted hearts at a depth of about 1 cm from the 
epicardial surface using a 28G ½” needle to generate high shear forces for injectability. For 
imaging at 9.4 T, the sites of hydrogel injection were then isolated from the myocardial explant 
and included the transmural thickness of the LV wall. For 3 T MR scans, the entire heart 
remained intact. Tissue samples were stored in PBS with P/S (1%, Life Technologies) before 
initial imaging (<2 hrs post-injection) and between subsequent time points, if applicable, with the 
same rinsing protocol as above (Section 5.2.4).  
Explants with guest-host hydrogel injections were first imaged using the 9.4 T horizontal 
bore MR scanner (Varian) and 35-mm 
1
H coil utilized for ex vivo MeHA hydrogel imaging (Section 
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5.2.4). A T2-weighted spin echo pulse sequence was used with the following imaging parameters: 
echo time = 40 ms, repetition time = 4 sec, averages = 4, field of view = 36 x 36 mm
2
, matrix size 
= 256 x 256, slices = 32, slice thickness = 0.25 mm, voxel size = 0.14 x 0.14 x 0.25 mm
3
. The TE 
was selected from the previously optimized 9.4 T imaging parameters (Section 5.2.4) due to its 
impact on the contrast generated in a T2-weighted sequence. The remaining parameters were 
altered from the previous 9.4 T scans based on sample size and scan time considerations. To 
examine differences in hydrogel dispersion with injection volume, guest-host hydrogels were 
injected at three volumes (50 μL, 150 μL, and 300 μL) and imaged at three time points over the 
course of a week (days 0, 3, and 7 following injection).  
To move towards more clinically relevant scan parameters, an array of nine, 300 μL 
guest-host hydrogels were injected into full porcine explants and imaged using a clinical 3 T Tim 
Magnetom Trio Scanner (Siemens Medical Solutions; Malvern, PA) with an 8-channel 
1
H head 
coil (Nova Medical; Wilmington, MA). Unlike at 9.4 T where the tissue samples were maintained 
under ambient conditions, samples imaged at 3T were submerged in PBS for the duration of the 
scan time to minimize dielectric artifacts near the tissue surface. However, similar to imaging at 
9.4 T, a T2-weighted turbo spin echo pulse sequence was used and the scan parameters were 
first optimized by varying the TE (51, 61, 71, 81, 91 ms) at a constant TR (7 sec) as well as 
varying the TR (6, 7, 8 sec) at a constant TE (71 ms). Based on this optimization study and in 
consideration with sample size and scan time limitations, the following scan parameters were 
used to obtain T2-weighted short-axis images: echo time = 71 ms, repetition time = 6 sec, 
averages = 2, field of view = 100 x 100 mm
2
, matrix size = 320 x 320, slices = 50, slice thickness 
= 1 mm, voxel size = 0.31 x 0. 31 x 1.00 mm
3
.  
The MR images from both the 9.4 T and 3 T scans were analyzed by segmenting the 
guest-host hydrogels from the myocardial tissue in the T2-weighted short-axis images acquired 
from apex to base and reconstructing the 3D volumes of the injected hydrogels. To do so, images 
were first converted into NIFTI files using ImageJ for use in ITK-SNAP segmentation software.
34
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Each short-axis image was first pre-processed by altering signal intensity thresholds to define the 
boundary between the hydrogel from the surrounding myocardium. An automated snake (i.e. 
active contour) segmentation algorithm
34
 was initialized from within each hydrogel injection site 
and allowed to deform until the boundary between the hydrogel and myocardium was met. 
Manual edge corrections were then performed, where necessary, to adjust the hydrogel 
segmentation based on visual inspection. Subsequently, ITK-SNAP was used to reconstruct the 
segmented two-dimensional slices containing hydrogel injection sites into 3D hydrogel distribution 
volumes. The volume of each injected guest-host hydrogel was then quantified from its 3D 
reconstruction. Unlike the MeHA hydrogel/myocardial composites which required an initial 
automated segmentation using Atropos to fully detect the injected hydrogel (Section 5.2.4), all 
segmentations, reconstructions, and quantifications were performed in ITK-SNAP.  
5.2.6. Ex Vivo MRI of HeMA-HA Hydrogels from In Vivo Injections  
To investigate the translational potential of this imaging technique for hydrogel 
assessment, HeMA-HA hydrogels were injected in vivo into a healthy ovine heart and imaged ex 
vivo following sacrifice. A single HeMA-HA hydrogel formulation was used: 25% modified HeMA-
HA at 8 wt% gelled using 5 mM APS and 5 mM TEMED. The animal received care in compliance 
with the University of Pennsylvania’s Institutional Animal Care and Use Committee’s protocols in 
accordance with guidelines for human case (National Institutes of Health, Publication 85-23, 
revised 1996). For material injections, one male Dorset sheep (35-40 kg) was sedated 
(intramuscular ketamine, 25-30 mg/kg), intubated, and mechanically ventilated. General 
anesthesia was maintained using a mixture of inhaled isoflurane (1.5-3.0%) and oxygen.
39
 The 
animal underwent a left thoracotomy to expose the LV free wall and received three 500 μL 
injections of the HeMA-HA prepolymer solution that was mixed for 2 minutes (based on rheology) 
prior to injection and gelation in the posterolateral wall. Following material injection, wire markers 
were sutured to the epicardium near the injection sites for aid in material localization and the 
chest wall was closed. A few hours following injection (~4 hrs), the sheep was euthanized by an 
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over dose of potassium chloride and sodium thiopental while under general anesthesia. The 
animal was pronounced dead after ECG silence was seen for 3-5 minutes and cardiac arrest 
confirmed. The heart containing the in vivo injections was removed and prepared for ex vivo MRI.  
The full heart explant was placed in a MR compatible container and immersed in Fomblin 
Y (Sigma) to fill the void spaces and reduce susceptibility artifacts. The container holding the 
explant was then submerged in a second, larger phantom filled with PBS to aid in shimming to 
correct for magnetic field (B0) inhomogeneity. Similar to the guest-host ex vivo hydrogel imaging, 
HeMA-HA hydrogels were imaged in the explanted myocardial heart using the 3 T MR Scanner 
(Siemens) with an 8-channel 
1
H head coil (Section 5.2.5). T2-weighted short-axis images were 
acquired from the apex to base for hydrogel volume reconstructions during post-processing. As 
determined from the previous 3 T scan (Section 5.2.5), the whole explanted heart was imaged 
using the following parameters: echo time = 71 ms, repetition time = 6 sec, averages = 4, field of 
view = 100 x 100 mm
2
, matrix size = 320 x 320, slices = 40, slice thickness = 1 mm, voxel size = 
0.31 x 0. 31 x 1.00 mm
3
. The volumes of the injected HeMA-HA hydrogels were subsequently 
segmented, reconstructed, and quantified using ITK-SNAP software,
34
 as described above in 
Section 5.2.5. Briefly, an automated segmentation was initially performed to isolate the hydrogel 
injection sites from the surrounding myocardium for each short-axis slice, followed by edge 
manual corrections. 3D reconstructions of the segmented hydrogels were generated and the 
corresponding volumes calculated for each injection using ITK-SNAP.  
Relaxation time mapping was performed using a spin-echo-prepared FLASH sequence 
with scan parameters identical to the corresponding T2-weighted image acquisition above to 
generate T1, T1ρ and T2 maps of a single short-axis slice for each hydrogel injection. For the T1 
maps, the inversion time (TI) was varied as follows: 50, 100, 300, 500, 700, 1000, 1300, 1600, 
and 2000 ms. Using a custom MATLAB (Natick, MA) code, the signal intensity in each TI image 
was fit to the longitudinal magnetization (Mz) equation to calculate the T1 for each pixel, where t is 
the inversion time (Equation 5.1
21
):  
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             (5.1) 
Similarly, the T1ρ and T2 maps were generated from scans with the following spin-lock (TSL) and 
echo (TE) times, respectively: 0, 20, 40, 60, 80, and 100 ms. In this case, the signal in each TSL 
or TE image was fit to the transverse magnetization (Mxy) equation to calculate the T1r or T2 for 
each pixel, where t is the spin-lock or echo time, respectively (Equation 5.2
21
):  
                 
  
  
            (5.2) 
5.2.7. Statistical Analysis 
Data is presented as mean ± standard deviation (SD) or mean ± standard error of the 
mean (SEM), as indicated in each figure caption. Differences were assessed using a one-way 
ANOVA with Tukey’s post hoc evaluation. A p<0.05 was considered to be statistically significant. 
5.3. Results  
5.3.1. MRI Visualization and Quantification of Ex Vivo MeHA Hydrogel Distribution  
Four MeHA hydrogel formulations were selected based on varying a combination of the 
macromer modification and redox initiator concentrations (Figure 5.2A). As anticipated from 
previous studies by our group,
40
 the material properties (i.e., gelation) were tuned such that 
higher methacrylation and higher initiator concentrations led to accelerated hydrogel formation 
(Figure 5.2B). Hydrogels formed from a highly modified MeHA using a high concentration of 
initiators gelled most rapidly (1.75 ± 0.03 min) whereas hydrogels formed using a less modified 
MeHA with a low initiator concentration gelled the slowest (5.2 ± 0.2 min). Moreover, initiator 
concentration had a greater impact on gelation than macromer modification. These formulations 
(which have been used previously
5,32,40
) were applied for subsequent ex vivo imaging studies due 
to statistically significant (p<0.05) differences in their gelation onset times for all comparisons.  
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Figure 5.2. Selection and gelation of MeHA hydrogel formulations applied for ex vivo MRI 
assessment. MeHA hydrogels with varying properties formed by altering a combination of the 
macromer modification and initiator concentration (A). Gelation onset as a function hydrogel 
formulation, n=3-4/group (B). Data presented as mean ± SD. p<0.05 for all comparisons.  
Prior to examining differences in hydrogel distribution in myocardial explants between the 
four formulations, the imaging parameters were optimized at 9.4 T. Using a T2-weighted spin 
echo pulse sequence, the TE was varied at a constant TR (5.8 sec). Higher TE values (i.e., 60 
ms) led to images with overall lower signal intensity whereas lower TE values (i.e., 30 ms) 
resulted in images with higher overall signal intensity (Figure 5.3A). Based on visual inspection of 
the differences in image contrast between the injected hydrogel and surrounding myocardium, an 
intermediate TE of 40 ms was selected for subsequent hydrogel distribution assessment. In 
addition, the image resolution was optimized by altering the voxel size, where the slice thickness 
was decreased to obtain images with smaller voxels.  Reconstruction and quantification of 
hydrogel distribution volume demonstrated that the hydrogel volume calculated from MRI 
decreased as the voxel size decreased, suggesting that use of larger voxels for imaging 
overestimated the hydrogel volume (Figure 5.3B). Thus, the smaller, isotropic voxel size (i.e., 
0.23 x 0.23 x 0.23 mm
3
) was selected for further imaging.  
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Figure 5.3. Optimization of MR imaging parameters for MeHA hydrogels in explants at 9.4 T. 
Representative cross-sections of T2-weighted MRI of a single MeHA hydrogel formulation (high 
MeHA, low A/T) injected into myocardial explants and imaged using different echo time (TE) 
values, as indicated (A). Representative 3D reconstructions (left) and quantified volumes (right) 
as a function of slice thickness for a 300 μL MeHA hydrogel (high MeHA, low A/T) injection 
imaged using different voxel sixes (low resolution: 0.23 x 0.23 x 1.00 mm
3
, high resolution: 0.23 x 
0.23 x 0.23 mm
3
), n=1 (B). Scale bars = 1 cm. 
To determine the optimal day for imaging myocardial explants after MeHA hydrogel 
injections, a study was performed where uncrosslinked MeHA was injected into explants and 
imaged over five days following injection. At each time point, the image contrast between the 
hydrogel and surrounding myocardium was assessed both qualitatively (Figure 5.4A) and 
quantitatively (Figure 5.4B) by calculating the percent change in signal intensity between the 
injection area (dictated from day 0) and the background myocardial tissue. Assessment at day 0 
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(i.e., <2 hours after injection) demonstrated the uncrosslinked MeHA macromer could be clearly 
discerned initially, with a greater than 30% higher signal intensity than the myocardium. As the 
study progressed, the difference in signal intensity between the uncrosslinked macromer and the 
surrounding myocardium decreased with time. A plateau was reached by day 3 following 
injection, where the difference in intensity remained less than 5% for all additional time points 
(Figure 5.4B). Thus, this time point was chosen to evaluate differences in hydrogel distribution. 
 
Figure 5.4. Determination of optimal day for imaging MeHA hydrogels in myocardial explants. 
Representative cross-sections of T2-weighted MRI of uncrosslinked MeHA macromer injected into 
a myocardial explant and imaged over 5 days following injection (day 0) (A). Scale bars= 1 cm. 
Quantification of the percent change in signal intensity between the uncrosslinked injection site 
(outlined at day 0, dashed shape) and the surrounding myocardial tissue as background, n=3 (B). 
Data presented as mean ± SD.  
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Figure 5.5. Visualization and quantification of MeHA hydrogel distribution volumes in myocardial 
explants at 9.4 T. Representative cross-sections of each MeHA hydrogel formulation at day 3 
following injection into myocardial LV tissue (A). Representative 3D reconstructions of hydrogel 
distribution volume for 300 μL injections of each formulation (B). Scale bars = 1 cm in panels A 
and B. Volume quantification of the injection region as a function hydrogel formulation, n=4/group 
(C). Data presented as mean ± SEM. *p<0.05 vs. low MeHA, low A/T hydrogel formulation.  
Differences in hydrogel distribution in myocardial tissue between the four crosslinked 
MeHA formulations were then investigated using MRI. Visual (Figure 5.5A,B) and quantitative 
(Figure 5.5C) assessment of the dispersion volumes of the crosslinked portion of the hydrogels 
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demonstrated that increased macromer modification or initiator concentration led to higher 
volumes. Macromer modification had a pronounced impact on the distribution volumes, 
particularly at the lower initiator concentration where a lower modification led to smaller 
crosslinked volumes.  Moreover, comparing between initiator concentrations within each 
modification, lower amounts of initiators led to smaller crosslinked volumes as compared to 
higher initiator concentration. This trend was most pronounced in the lower modification case 
where the difference was statistically significant (p<0.05). Furthermore, the quantified volumes of 
the crosslinked portions of the hydrogels were higher than the injected volume (300 μL) for all 
formulations aside from the low MeHA, low A/T hydrogels (Figure 5.5C). In addition, while the 
hydrogel dispersion geometries varied both within and between formulations, generally most 
injections took on an ellipsoidal shape, as demonstrated by the cross-sectional slices (Figure 
5.5A) and corresponding 3D volume reconstructions (Figure 5.5B).  
5.3.2. Guest-Host HA Hydrogel Distribution in Explants from MRI Assessment  
After examining differences in hydrogel dispersion based differences in the rate of 
hydrogel formation, an alternative HA hydrogel system was introduced to examine differences in 
hydrogel distribution based on the gelation mechanism. Through collaboration with another 
student in our group, guest-host hydrogels were formed through the supramolecular self-
assembly of adamantine (Ad, guest) and β-cyclodextrin (CD, host) modified HA (Figure 5.1).
33
 
Previous rheological studies demonstrated that both dissolved macromers were viscous solutions 
individually, but upon mixing of Ad-HA and CD-HA, near-instantaneous hydrogel assembly 
occurred with an increase in moduli (i.e., G’, G”) of several orders of magnitude.
33
   
Similar to the MeHA hydrogel studies, guest-host hydrogels were injected into myocardial 
explants and imaged using a 9.4 T MR scanner to obtain T2-weighted images. Visualization of the 
hydrogels in both 2D cross-sectional slices (Figure 5.6A) and 3D volume reconstructions (Figure 
5.6B) revealed distinct, solid plugs in the myocardium that were relatively spherical in geometry. 
Quantification of hydrogel dispersion volumes from the 3D reconstructions demonstrated that 
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differences in injection volume (e.g., 50 μL, 150 μL, 300 μL) could be accurately detected with 
little variation between the calculated and injected volumes, particularly at day 0 (i.e., <2 hours 
after injection) (Figure 5.6C).  To assess changes in hydrogel distribution over time, the samples 
were imaged at various times over a week (i.e., days 0, 3, and 7) with continual washing and 
buffer exchange throughout to remove uncrosslinked material, if it were present. Regardless of 
the injected volume, 3D reconstructions revealed minimal changes in hydrogel surface features 
over time (Figure 5.6B) and corresponding quantifications demonstrated little changes in guest-
host hydrogel distribution volumes (Figure 5.6C). The slight increase in the calculated hydrogel 
volume over time was most observable in the hydrogel with the smallest injection volume (50 μL), 
where an approximately 20% increase was seen by day 7 relative to day 0. The larger injection 
volumes (150 μL or 300 μL) had about a 13% increase in calculated volume by day 7.  
 
Figure 5.6. Visualization and quantification of guest-host HA hydrogel distribution in myocardial 
explants at 9.4 T. Representative cross-sections of T2-weighted MRI of guest-host hydrogels at 
day 3 after injection into myocardial explants at different volumes, as indicated (A). Scale bars = 2 
cm. Representative 3D reconstructions of the 50 μL guest-host hydrogel distribution volume at 
different time points following injection, as indicated (B). Scale bars = 1 cm. Quantification of 
volumes from reconstructions of each hydrogel imaged at different times after injection, n=1 (C). 
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Figure 5.7. Optimization of MR parameters for imaging HA hydrogels in explants at 3 T. 
Representative short axis, T2-weighted MRI slices of 300 μL guest-host hydrogel injections in an 
explanted porcine heart. To optimize the echo time (TE), images were acquired at various TE 
values but a constant repetition time (TR), as indicated (A). MR images were also acquired at 
various TR values but a constant TE, as indicated, to opmize the TR (B). Scale bars = 2 cm.  
The imaging principles utilized at 9.4 T where then applied to clinical field strength of 3 T 
to assess guest-host hydrogel distribution. Prior to visualizing and quantifying hydrogel dispersion 
volumes in the myocardium, the imaging parameters were first optimized by making systematic 
changes in the TE and TR for a T2-weighted spin echo pulse sequence. Similar to the parameter 
optimization scans at 9.4 T (Figure 5.3A), overall image signal intensity was altered with changes 
in TE at a constant TR (7 sec), where the intensity of the PBS surrounding the explants increased 
with increased TE (Figure 5.7A). Visual assessment of the differences in image contrast between 
the hydrogel and myocardium led to the selection of an intermediate TE of 71 ms for subsequent 
scans. In addition, minimal differences in signal intensity were observed when altering the TR at a 
constant TE (71 ms) (Figure 5.7B). Thus, to minimize scan times, a TR of 6 sec was selected for 
assessment of hydrogel distribution. Based on the voxel size optimization scans at 9.4 T above 
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(Figure 5.3B), the slice thickness was minimized as much as possible within the scanner 
limitations and considering the necessary field of view for the larger tissue size.  
 
Figure 5.8. Examination of guest-host HA hydrogel distribution in whole heart explant at 3 T. 
Whole explanted porcine heart indicating array of 9 sites for 300 μL guest-host hydrogel 
injections (A). 3D reconstruction of distribution volume of 9 hydrogel injections in explant (B). 
Representative short axis cross-section of 3D reconstructed hydrogel volumes in the axial plane 
(C). Representative long axis slices in the coronal and sagittal planes of the reconstructed 
hydrogel injections (D, E). Average reconstructed volume = 316.4 (± 58.9) μL. Scale bars = 2 cm.  
Using the optimized scan parameters, an array of nine guest-host hydrogel injections in a 
full heart explant (Figure 5.8A) was visualized using a 3T MR scanner. The pattern of nine 
injections was clearly observed in the 3D volume reconstruction (Figure 5.8B) and corresponding 
short- and long-axis cross-sections of the reconstruction (Figure 5.8C,D,E). Similar to the 9.4 T 
assessment of guest-host hydrogels in myocardial explants (Figure 5.6), each of the nine 
hydrogel injections formed a solid, spherical plug in the myocardial tissue that was distinct from 
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the other injections.  The average reconstructed hydrogel distribution volume over the nine 
injection sites was calculated to be 316.4 (± 58.9) μL, which differed from the injected volume of 
300 μL by approximately 5.5%. Thus, at both 9.4 T and 3T, the reconstructed distribution 
volumes of guest-host hydrogels in the myocardium were similar to those of the injected volume.  
 
Figure 5.9. Assessment of HeMA-HA hydrogel distribution in myocardial explant from in vivo 
injections at 3 T. Explanted ovine heart indicating three sites used for in vivo HeMA-HA hydrogel 
injections (A). 3D reconstruction of distribution volume of three, 500 μL HeMA-HA injections 
performed in vivo but imaged ex vivo (B). Average reconstructed volume = 463.5 (± 66.2) μL. 
Representative short axis, cross-sectional T2 weighted MRI slices of each HeMA-HA hydrogel 
injection (dashed lines) corresponding to 3D reconstruction (C). Representative slices of T1, T1ρ, 
and T2 maps of the first HeMA-HA hydrogel injection (dashed lines) (D). Scale bars = 2 cm.  
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5.3.3. MRI Evaluation of HeMA-HA Hydrogel Distribution Ex Vivo from In Vivo Delivery  
To further the translatability of using T2-weighted MRI to visualize and quantify HA 
hydrogel distribution in the myocardium, HeMA-HA hydrogels were injected in vivo and evaluated 
ex vivo using a clinical 3 T MR scanner. Prior to in vivo delivery, the gelation properties of HeMA-
HA hydrogel formulation selected for T2-weighed MRI were characterized. Rheological 
assessment demonstrated that gelation onset occurred at 2.1 ± 0.5 min and gel completion 
occurred at 15.9 ± 2.9 min after mixing the dissolved macromer and chemical initiators. The gel 
onset time dictated the timing for in vivo injection. The three HeMA-HA injections performed in 
vivo were clearly visible in both the 3D volume reconstruction (Figure 5.9B) and corresponding 
T2-weighted short-axis slices for each injection site (Figure 5.9C). The sites of the markers 
sutured to the epicardial surface immediately following injection (Figure 5.9A) correlated with the 
3D locations of the hydrogels in the volume reconstruction (Figure 5.9B). Similar to the MeHA 
hydrogels, HeMA-HA hydrogel injections took on an ellipsoidal geometry, as seen in both the 
cross-sectional slices (Figure 5.9C) and 3D reconstruction (Figure 5.9B). The average 
reconstructed hydrogel distribution volume of the three injections was determined to be 463.5 (± 
66.2) μL, which suggested greater than 90% retention from the injected volume of 500 μL. 
Relaxation time (i.e., T1, T1ρ, T2) maps were then generated to visualize differences in relaxation 
between the hydrogel and myocardium, where each voxel is assigned to a relaxation time value 
(Figure 5.9D). The greatest differences in voxel intensity between the hydrogel and myocardium 
were seen in the T1ρ and T2 maps.  
5.4. Discussion  
In this chapter, non-contrast based MRI was used to visualize and quantify HA hydrogel 
distribution in the myocardium based on intrinsic differences in the MR properties (i.e., T2 
relaxation) between the injected hydrogel and surrounding tissue. As discussed in Section 5.1, 
these differences can be manipulated to increase image contrast by altering both the RF pulse 
sequence as well as the imaging parameters (i.e., TE, TR, etc.). In this work, a spin-echo pulse 
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sequence was used for all scans to introduce a T2 dependence to the acquired images and the 
scan parameters were optimized to generate T2-weighted images through use of a long TR and 
relatively long TE. A long TR (i.e., on the order of several seconds) reduces T1 contamination by 
allowing the excited protons to return to equilibrium (or near equilibrium) before subsequent RF 
pulse application.
21
 A long TE (i.e., on the order of the tissue’s TE) provides more time for the 
magnetization to decay before measuring the signal (i.e., FID echo)
21
  so materials or tissues that 
have a longer T2 will have less magnetization decay and thus, a higher signal. Based on these 
principles, T2-maps of HA hydrogels injected in vivo but imaged ex vivo confirmed the differences 
in T2 values between the hydrogel and myocardium, in that the hydrogel has a longer T2 than the 
myocardium and thus, higher signal in T2-weighted images (Figure 5.9D). Thus, T2-weighted MRI 
was used to investigate differences in HA hydrogel dispersion in myocardial tissue based on 
changes in material properties (i.e., gelation).  
To introduce differences in injectable HA hydrogel distribution volume in myocardial 
tissue, the materials properties were altered by either varying the time to gelation or the 
mechanism of gel formation. As such, MeHA hydrogel formulations were selected with different 
rates of gelation. To make the system injectable, macromers at different methacrylations were 
crosslinked into hydrogels using a redox initiation system of APS and TEMED. As anticipated 
from the previous characterization studies in Chapter 4, as the macromer modification or initiator 
concentration increased, crosslinks were formed at a quicker rate and gelation onset decreased 
(Figure 5.2B). These differences in gelation onset were used to introduce differences in the 
volume of hydrogel distribution in myocardial explants as assessed by MRI, as supported by 
previous work involving the visual inspection of HA hydrogels in myocardial tissue.
40
  
Prior to assessing differences in hydrogel distribution between the four MeHA hydrogel 
formulations, a preliminary study was performed to better understand the portion of the injected 
precursor solution (i.e., crosslinked vs. uncrosslinked) would be visualized using the optimized 
imaging parameters (Figure 5.4). This study demonstrated that uncrosslinked macromer would 
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no longer be detectable after rinsing the tissue samples for three days following injection. Thus, 
since the imaging of the crosslinked formulations was performed at day 3 following injection, any 
uncrosslinked macromer diffused out of the tissue and only the crosslinked portion of each 
hydrogel was present for detection by 9.4 T MRI. As with the time to gelation, both the macromer 
modification and initiator concentration played a role in the hydrogel volume distribution in 
myocardial explants (Figure 5.5). Higher initiator concentration led to more rapid crosslinking, 
which resulted in larger volumes of crosslinked hydrogel, as assessed by MRI. In addition, higher 
macromer modification led to a larger distribution volume of crosslinked hydrogel. In both cases, 
the increased volumes could be attributed to an increased density of macromer reactive groups 
and radical initiators leading to more complete gelation and thus, measurability by MRI. Similarly, 
the smaller volumes observed with low macromer modification and initiator concentration 
formulations could be contributed to an increased susceptibility of the precursor solutions to be 
diluted by the fluids within the tissue, thus leading to inefficient gel formation and lower 
crosslinked hydrogel volumes. The injection of all formulations at 3 minutes after mixing the 
dissolved macromers and initiators may have resulted in too much time lapse until gelation for the 
low initiator formulations, leading to extensive dispersion of the precursor solution and limited 
proximity of the reactive groups to one another to form crosslinks. Tailoring the injection timing to 
the rheological properties may prevent this extensive dispersion, as seen in recent work.
32
     
Differences in hydrogel formulation also led to differences in the distribution of the 
hydrogels within the myocardial fibers. More specifically, hydrogels crosslinked using the high 
initiator concentration exhibited more frequent “plugs” (i.e., areas of mostly hydrogel) than 
hydrogels formed with the low initiator concentration. Hydrogels with the low initiator 
concentration also dispersed more evenly within the fibers since the slower gelation times and 
lower precursor solution viscosity enabled uniform penetration of the tissue prior to crosslinking. 
Nevertheless, regardless of formulation, all MeHA hydrogels took on a similar ellipsoidal 
geometry that was oriented such that the major axis of the ellipsoid was in the same direction as 
the myocardial fibers. The ellipsoidal distribution of the MeHA injections combined with higher 
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volume quantifications than the injection volume (300 μL) demonstrated that these materials 
dispersed amongst the myocardial fibers during gelation and formed a composite with the 
surrounding myocardial tissue rather than only forming a plug that displaced the tissue.  
To examine differences in injected hydrogel dispersion based on the mechanism of gel 
formation, an alternative hydrogel system was introduced based on guest-host chemistry. Unlike 
MeHA hydrogels which formed by covalent crosslinking over the span of a few minutes (i.e., 2-5 
min, based on rheology; Figure 5.2B), guest-host HA hydrogels self-assembled near-
instantaneously by reversible, physical interactions (Figure 5.1), as demonstrated by rheology in 
previous work.
33
 This difference in hydrogel formation, in turn, led to differences in distribution in 
myocardial tissue. In contrast to the previous in situ gelling MeHA hydrogels which dispersed 
along the myocardial fibers forming a composite (Figure 5.5), guest-host hydrogels formed 
distinct, solid plugs within the myocardial tissue due to their instantaneous formation and stable 
interaction between the guest and host components (Figure 5.6). The volumes calculated from 
the 3D reconstructions of the guest-host hydrogel injections were similar to the injected volume, 
demonstrating retention of the hydrogels at the injection site independent of injection volume (50-
300 μL examined; Figure 5.6C). Furthermore, guest-host hydrogels also remained stable over 
time with 3D reconstructions and corresponding volume quantifications demonstrating little 
change in volumes over one week (Figure 5.6B,C). The slight increases in the calculated 
volumes over time can be attributed to moderate hydrogel swelling since minimal changes in 
surfaces features were observed. Some spreading between the muscle fibers was observed in 
discrete small channels but not to the extent seen with MeHA hydrogels. To move towards 
clinically relevant imaging settings, guest-host hydrogels were then injected into a whole heart 
explant and imaged at 3 T. Despite the decrease in field strength from 9.4 T, guest-host HA 
hydrogels formed discrete plugs within the myocardium with calculated volumes comparable to 
the injected volume (Figure 5.8).  
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To demonstrate the translational applications of T2-weighted MRI of injectable hydrogels, 
HA hydrogels were injected in vivo and imaged ex vivo at 3 T following animal sacrifice. A single 
HeMA-HA hydrogel formulation was selected from previous characterization studies (Section 
4.3.2) for in vivo delivery. The macromer concentration was selected to be relatively high (8 wt%) 
to improve the T2-based MRI contrast between the hydrogel and myocardium but without the 
precursor solution being too viscous to be injectable. The initiator concentrations (5 mM APS, 5 
mM TEMED) were selected to balance the need for relatively rapid hydrogel formation (i.e., over 
the time span of a few minutes) with providing sufficient time for in vivo delivery. Despite delivery 
in an in vivo setting, each of the three injections was retained within the myocardium at the 
injection site (Figure 5.9). In both the short-axis cross-sections and corresponding 3D 
reconstruction, HeMA-HA hydrogels were elliptical in shape and oriented themselves to the 
curvature of the contractile LV tissue  that is known to move in both a radial (i.e., inward or 
contractile) and circumferential (i.e., twisting) direction (Figure 5.9B,C).
41,42
 The quantified 
dispersion volumes were similar but slightly less than the injection volume (500 μL), suggesting a 
lack of complete material retention following delivery into the contracting myocardium. However, 
based on surgeon’s visual observation of ~75-80% material retention upon injection, the 
calculated volumes were higher than the retained volumes, indicating that the HeMA-HA 
hydrogels distributed along the myocardial fibers and formed a composite, similar to the MeHA 
hydrogels previously examined. Finally, relaxation maps (combined with the T2-weighted pulse 
sequence utilized) confirmed that the differences in image contrast between the injected HA 
hydrogels and surrounding myocardium were due to differences in T2 relaxation (Figure 5.9D).  
5.5. Conclusions  
 In this chapter, T2-weighted MRI was used to qualitatively and quantitatively assess 
differences in injectable HA hydrogel distribution in the myocardium. Differences in hydrogel 
dispersion in myocardial explants were introduced by changing the time to gelation and the 
gelation mechanism. Gelation onset was altered in stable MeHA hydrogels by varying both the 
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macromer modification and initiator concentration, which led to differences in the crosslinked 
portion of the hydrogel volume that was reconstructed from MRI. The ability of covalently 
crosslinked MeHA hydrogels to disperse through the myocardial fibers was then compared to the 
tissue distribution of physically crosslinked guest-host hydrogels, which formed discrete plugs in 
myocardial explants. Therefore, tuning of HA hydrogel material properties (i.e., gelation) can be 
used to tailor hydrogel distribution in tissue for an intended application. In the case of LV 
remodeling post-MI, previous modeling studies have shown that hydrogel dispersion correlates 
with resulting cardiac outcomes
3
 and thus, the ability to noninvasively assess injectable material 
properties following delivery into tissue could ultimately provide insight into their in vivo function. 
The next chapter will address an alternative non-contrast MRI technique to visualizing injectable 
HA hydrogels based on differences in exchangeable protons rather than relaxation times.  
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CHAPTER 6 
 
Visualization of Injectable Hyaluronic Acid Hydrogels using Chemical Exchange 
Saturation Transfer MRI 
 
(Adapted from: Dorsey SM, Haris M, Singh A, Witschey WRT, Rodell CB, Kogan F, Reddy R, 
Burdick JA. ACS Biomaterials, in review.) 
6.1. Introduction  
Injectable hydrogels are useful for many biomedical and pharmaceutical applications,
1-4
 
offering the potential for minimally invasive, site-specific delivery of materials, cells, and 
therapeutics directly into voids or tissues. Although numerous hydrogel systems have been 
developed, tools are still needed to assess and monitor the performance of hydrogels after 
injection. Conventional histological and immunohistochemical evaluation of injected hydrogels is 
time-consuming, destructive, and limited to cross-sectional slices that prevent accurate 
assessment of hydrogel features (e.g., distribution volume). Furthermore, to determine the 
optimal material design components (e.g., degradation, molecule release), noninvasive 
techniques to characterize hydrogels once implanted within tissues are needed.  
To address this challenge, various imaging techniques can be used to noninvasively 
characterize hydrogels. Optical and x-ray imaging have been used for in vivo material 
visualization but optical imaging is restricted to superficial tissue locations
5-8
 due to light intensity 
decay with increasing tissue depth
9,10
 and x-ray imaging is limited by the need for high 
concentrations of contrast agents
11-13
 which may produce toxicity or alter material properties.
12,14
 
As an alternative, magnetic resonance imaging (MRI) is well suited for in vivo material 
assessment at any depth due to its ability to provide accurate and reproducible images with high 
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spatial resolution in three dimensions.
15
 MR image contrast is generated by differences in the 
response of bulk water protons in materials or tissues to oscillating magnetic fields; these MR 
properties (i.e., T1/T2 relaxation times, proton density) are intrinsic to the material or tissue of 
interest. In the case of biomaterials where the goal is to mimic native structures, their intrinsic MR 
properties are often similar to those of the surrounding tissue, limiting accurate imaging at 
clinically relevant magnetic field strengths. One approach is to incorporate exogenous contrast 
agents
16,17
 into the biomaterial to generate or enhance the differences in relaxation properties and 
increase image contrast-to-noise ratio (CNR). However, due to inherent sensitivity limitations with 
MRI, high concentrations of contrast agent are needed, which may alter the injected biomaterials’ 
properties, perturb the physiologic environment surrounding the injection site, or lead to toxicity.
18
  
Chemical exchange saturation transfer (CEST) is a new MRI technique that generates 
contrast from protons in specific molecules or metabolites based on their exchange with bulk 
water protons (Figure 6.1).
18,19
 Since MR signal is generated from magnetic field manipulations 
of bulk water protons, CEST is an indirect approach to image smaller pools of non-water protons 
based on their impact on the water proton signal. More specifically, CEST imaging involves 
saturating exchangeable protons, such as those in the material, using a frequency selective 
radiofrequency (RF) pulse. This pulse equalizes the number of protons aligned with and against 
the magnetic field, leading to zero net magnetization, which is termed “saturation” and the result 
of which is zero MR signal. The saturated protons then exchange with the bulk water protons and 
their zero (saturated) magnetization is thereby transferred to the bulk water protons, resulting in a 
proportionate decrease in the bulk water signal.
20
 It is this decrease in the bulk water signal 
intensity that is detected in CEST imaging (Figure 6.1).  
Manipulation of the CEST effect to enhance biomaterial image contrast is particularly 
appealing because it relies completely on the presence of exchangeable protons within the 
hydrogel. Unlike MRI with the use of exogenous contrast agents, CEST imaging does not perturb 
the intrinsic MR properties of native tissues and the image contrast generated by CEST can be 
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selectively turned on or off through gating the RF pulse.
21-23
 In contrast to conventional T1- and 
T2-weighted MRI, since the frequency of the saturation pulse is selected to be the resonance 
frequency of the specific exchangeable proton group within the hydrogel, it enables the imaging 
technique to be highly specific for the biomaterial and thus easily distinguished from native 
tissues. Moreover, CEST imaging provides the opportunity for detection of different injectable 
biomaterials based on their specific functional groups by selectively saturating at the resonance 
frequency of the protons in the dominate functional group (Figure 6.1).  
 
Figure 6.1. Principles of CEST for imaging hydrogels. CEST imaging can distinguish hydrogels 
based on their dominant exchangeable proton groups (e.g., -OH for Hydrogel A or –NH2 for 
Hydrogel B).  The exchangeable protons are saturated at their specific resonance frequency. The 
saturated magnetization is then transferred to the larger pool of bulk water protons, which causes 
a decrease in the bulk water signal that is detected as a decrease in the MRI signal.  
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One biomaterial of particular interest to CEST imaging is hyaluronic acid (HA). HA is a 
linear polysaccharide used for a variety of injectable hydrogel systems due to its native role as an 
extracellular matrix molecule and its ability to be modified with numerous functional groups.
24,25
 
The addition and amount of these groups enables hydrogel formation and tuning of both hydrogel 
(e.g., mechanics, degradation) and CEST properties. In addition, CEST MRI has been used in 
vivo to image endogenous glycosaminoglycans (GAGs), such as HA, through manipulation of 
both the amide (-NH-R) and hydroxyl (-OH) protons (Figure 6.2).
26
 However, CEST has yet to be 
applied to imaging GAG-based biomaterials. In contrast to conventional GAG MRI, such as 
sodium (
23
Na), T1ρ-weighted, and delayed gadolinium-enhanced MRI, CEST MRI enables direct 
GAG mapping specifically and without contrast agent administration.
27
 Therefore, towards the 
goal of developing a non-contrast MRI approach for visualizing injectable HA hydrogels in vivo, 
CEST MRI experiments were performed to characterize the CEST effect of hydroxyethyl 
methacrylate-modified HA (HeMA) hydrogels in vitro and ex vivo and demonstrate the clinical 
potential of this imaging technique for biomaterial assessment.  
 
Figure 6.2. Chemical structure of HeMA-HA, indicating the exchangeable hydroxyl (dashes, red 
circles) and amide (solid, blue circles) protons targeted for CEST imaging.  
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6.2. Materials and Methods  
6.2.1. HeMA-HA Macromer Synthesis  
As previously described in Section 4.2.1, hydroxyethyl methacrylate-modified HA (HeMA-
HA) was synthesized by coupling HA-tetrabutylammonium salt (HA-TBA) to HeMA succinate 
(HeMA-COOH) in dimethyl sulfoxide (DMSO) using 4-dimethylaminopyridine (DMAP, Sigma) and 
the coupling agent di-tert-butyl dicarbonate (BOC2O, Sigma) (45°C, 20hrs).
28
 The macromer was 
purified by dialyzing against deionized (DI) water at 4°C, precipitating in acetone, and dialyzing 
again. The macromer was then frozen and lyophilized. The extent of HA methacrylation was 
assessed with 
1
H-NMR (Bruker, 360 MHz) and determined to be ~25% of the HA repeat units 
(Figure 6.2), as discussed in Section 4.2.1.  
6.2.2. Peptide Coupling to HeMA-HA and Characterization  
HeMA-HA was converted back to a TBA salt using an acidic ion exchange (25°C, 1hr) 
with Dowex resin (50W×8-200, Sigma), followed by neutralization with TBA hydroxide (TBA-OH, 
Sigma) to pH 7.02-7.05
29
 to solubilize in DMSO. HeMA-HA-TBA was then dissolved in DMSO, 
reacted with N-(2-aminoethyl)maleimide trifluoroacetate salt (AEMa, Sigma) in the presence of 
benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP, Sigma) (25°C, 
2hrs), dialyzed against DI water (4°C), filtered to remove insoluble byproducts, frozen, and 
lyophilized. Malemide functionalization of HeMA-HA was ~10% by 
1
H-NMR (Bruker, 360 MHz). 
An arginine dominated (for enhanced CEST contrast
30,31
) peptide GCRRR (MW 646.35 Da) with 
>95% purity (per manufacturer HPLC analysis) was purchased from GenScript (Piscataway, NJ, 
USA) and coupled to Ma-HeMA-HA through a thiol–maleimide click reaction (1.2:1 molar ratio of 
cysteine:maleimide) in DI water (4°C, 4hrs).
32
 The macromer was purified by dialysis against DI 
water (4°C), frozen, and lyophilized. 
1
H-NMR (Bruker, 360 MHz) confirmed the complete 
consumption of malemide with peptide, resulting in a ~10% peptide modification of HeMA-HA.  
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High-resolution spectroscopy was performed on solutions of HeMA-HA (8 wt%), HeMA-
HA-Peptide (8 wt%; 17.5-18.5 mM Peptide), and Peptide alone (18 mM). Solutions were prepared 
in double distilled water (Millipore) or 99.8% D2O (Acros) and the pH was adjusted to 7.00.1 
using 1 N HCl/NaOH. Solutions were transferred to 5-mm NMR tubes. A capillary containing a 
mixture of D2O and tetramethylsilane (TMS) was inserted for signal locking of H2O samples 
during scans and standardization of chemical shifts during post-processing, respectively. Non–
water-suppressed high-resolution 
1
H-NMR spectroscopy (Bruker, 400 MHz) was performed using 
a single pulse-acquire sequence (TR, 8.84 sec; number of averages, 32) with a 5-mm 
radiofrequency probe at room temperature (2950.1 K). Water suppression was not used 
because it would mask the bulk water signal and prevent observation of exchange with the 
exchangeable protons via changes in spectra peaks. The temperature was varied (2800.1 K and 
2950.1 K) for the HeMA-HA-Peptide sample to examine temperature-induced changes in the 
exchangeable proton peak. 
1
H-NMR spectra were obtained from the raw free induction decay 
data by Fourier transformation, phase correction, and baseline removal.  
6.2.3. Hydrogel Formation and Characterization  
As previous described (Section 4.2.3), HA hydrogels were formed using a radical initiator 
system of ammonium persulfate (APS, 5mM, Sigma) and N,N,N,N’,N’-tetramethylenediamine 
(TEMED, 5 mM, Sigma). Hydrogel formation was assessed by monitoring the storage (G’) and 
loss (G”) moduli at 37°C using an AR2000ex Rheometer (TA Instruments) at 1% strain and 1 Hz 
frequency in a cone-plate geometry (1°, 20 mm diameter). 
6.2.4. CEST Imaging  Principles   
CEST images were acquired with a specially optimized saturation pulse sequence, as 
previously described.
33-35
 CEST effects were assessed using a z-spectrum, which is generated by 
sweeping the frequency of saturation pulse across the proton spectrum
18,20,36
 and plotting the 
resulting water signal amplitude as a function of the saturation pulse frequency. Z-spectral data 
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was collected by acquiring images from –5.0 ppm to +5.0 ppm around the bulk water resonance 
(0 ppm) with a 0.1 ppm or 0.2 ppm shift in offset frequency per step. The degree of asymmetry in 
the z-spectra was assessed using asymmetry (CESTasym) plots, which represent the normalized 
difference in magnetization between the exchangeable proton resonance frequency S(+) and 
the corresponding reference frequency on the opposite and symmetrical side of the water 
resonance S(-). One approach is to normalize to the bulk water signal (S0) after saturation at a 
large frequency offset (i.e., +20 ppm or +100 ppm), where  is the frequency difference relative 
to water (Equation 6.1
26,37
):  
              
         
  
           (6.1) 
However, saturation pulses are not perfectly frequency selective and may lead to saturation of 
protons at nearby frequencies.
19
 The smaller the , the greater chance for direct saturation of 
water protons, causing a decrease in the water signal due to pulse application and not exchange. 
To account for the effect of partial direct water saturation, the CEST effect can be normalized to 
S(-) (Equation 6.2
26,37
):  
              
         
    
           (6.2) 
As with all CEST methods, B0 and B1 field inhomogeneities may be of concern.
19,26
 
Localized B0 shimming was manually performed using the Siemens MR scanners’ product 
interactive shim program to ensure that B0 inhomogeneity was less than ±0.3 ppm. To further 
correct for field inhomogeneities, water saturation shift reference (WASSR) images and B1 maps 
were collected, as previously described,
35,38,39
 for use in image post-processing. WASSR images 
were acquired from –0.6 ppm to +0.6 ppm with a step size of 0.05 ppm using a B1 saturation 
pulse amplitude of 20 or 30 Hz and duration of 200 ms and with the same sequence and readout 
parameters as the corresponding CEST scans.  
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Table 6.1. MRI scan parameters optimized for each study.  
 
Figure Imaging Parameters 
B1 Amplitude 
and Duration 
6.4 
Slice thickness = 10 mm, GRE flip angle = 10°, readout TR = 6.2 
ms, TE = 3.0 ms, 1 average, field of view = 100 × 100 mm
2
, 
matrix size = 128 × 128, 1 saturation pulse train every 10 sec 
200 Hz, 4 sec 
6.5 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 7.3 
ms, TE = 3.6 ms, 1 average, field of view = 100 × 100 mm
2
, 
matrix size = 128 × 128, 1 saturation pulse train every 10 sec 
400 Hz, 300 ms 
6.6 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 7.3 
ms, TE = 3.6 ms, 1 average, field of view = 100 × 100 mm
2
, 
matrix size = 128 × 128, 1 saturation pulse train every 10 sec 
Varied 
6.7 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.9 
ms, TE = 3.4 ms, 1 average, field of view = 110 × 110 mm
2
, 
matrix size = 192 × 192, 1 saturation pulse train every 10 sec 
400 Hz, 300 ms 
6.8A 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.9 
ms, TE = 3.4 ms, 1 average, field of view = 110 × 110 mm
2
, 
matrix size = 192 × 192, 1 saturation pulse train every 10 sec 
300 Hz, 300 ms 
6.8B 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.2 
ms, TE = 3.0 ms, 1 average, field of view = 100 × 100 mm
2
, 
matrix size = 128 × 128, 1 saturation pulse train every 10 sec 
300 Hz, 300 ms 
6.9, 
6.10 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.2 
ms, TE = 3.0 ms, 1 average, field of view = 100 × 100 mm
2
, 
matrix size = 128 × 128, 1 saturation pulse train every 10 sec 
Varied 
6.11 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.2 
ms, TE = 3.0 ms, 1 average, field of view = 100 × 100 mm
2
, 
matrix size = 128 × 128, 1 saturation pulse train every 10 sec 
300 Hz, 300 ms 
6.12A 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.6 
ms, TE = 3.2 ms, 1 average, field of view = 122 × 122 mm
2
, 
matrix size = 192 × 192, 1 saturation pulse train every 10 sec 
300 Hz, 300 ms 
6.12B 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 5.6 
ms, TE = 2.7 ms, 1 average, field of view = 140 × 140 mm
2
, 
matrix size = 128 × 128, 1 saturation pulse train every 10 sec 
300 Hz, 300 ms 
6.13 
Slice thickness = 3 mm, GRE flip angle = 10°, readout TR = 6.2 
ms, TE = 3.0 ms, 8 averages, field of view = 96 × 96 mm
2
, matrix 
size = 128 × 128, 1 saturation pulse train every 4 sec 
200 Hz, 250 ms 
6.14 
Slice thickness = 3 mm, GRE flip angle = 10°, readout TR = 6.2 
ms, TE = 3.0 ms, 8 averages, field of view = 96 × 96 mm
2
, matrix 
size = 128 × 128, 1 saturation pulse train every 4 sec 
200 Hz, 250 ms 
6.17 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.9 
ms, TE = 3.4 ms, 1 average, field of view = 110 × 110 mm
2
, 
matrix size = 192 × 192, 1 saturation pulse train every 10 sec 
400 Hz, 300 ms 
6.18 
Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.9 
ms, TE = 3.4 ms, 1 average, field of view = 110 × 110 mm
2
, 
matrix size = 192 × 192, 1 saturation pulse train every 10 sec 
400 Hz, 300 ms 
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6.2.5. MR Imaging of Phantoms at 3 T and 7 T  
Macromer was dissolved at different concentrations in sterile PBS (Life Technologies) 
and the pH of the prepolymer solution was adjusted using 1 N HCl/NaOH (Fisher) to ensure a 
final pH of 7.0 upon hydrogel formation. The dissolved macromer was mixed with chemical 
initiators (5 mM APS, 5 mM TEMED) to induce hydrogel formation. Samples of prepolymer 
solution were added to 10-mm NMR tubes and immersed in a PBS phantom surrounded by a 
custom designed Styrofoam chamber to maintain the temperature at 371C. To measure the pH 
dependence of CEST, hydrogels were formed at a single concentration of 8 wt% while varying 
final pH values within a physiologic range (6.0, 7.0, 7.5). To assess the effect of temperature on 
the CEST contrast, hydrogels of varying concentration (2, 4, 6, 8 wt%) were also scanned at 25C 
as a comparison to 37C. Phantoms of PBS at pH 7.0 were used for background normalization.  
Phantom CEST imaging was performed on 7 T and 3 T whole body scanners (Siemens 
Medical Solutions, Erlangen Germany) with 32-channel and 8-channel 
1
H head coils (Nova 
Medical, Wilmington, MA), respectively. The imaging parameters were optimized based on the 
magnetic field strength, coil, sample size, and required field of view (Table 6.1). The readout 
repetition time (TR) and echo time (TE) were minimized for each scan, but varied with changes in 
the field of view or image matrix size. For all phantom studies, the total repetition time was set to 
10 sec, meaning one saturation pulse train was initiated every 10 seconds. CEST images were 
acquired at varying saturation pulse (B1) amplitudes and durations to empirically optimize the 
CEST saturation parameters: i) 200 Hz, 250 Hz, 300 Hz, 350 Hz, 400 Hz at 300 ms saturation 
duration for 7 T, ii) 100 Hz, 200 Hz, 300 Hz, 400 Hz, 500 Hz at 300 ms saturation duration for 3 T, 
and iii) 300 Hz for 75 ms, 150 ms, 225 ms, 300 ms, 375 ms saturation duration at 3 T.    
6.2.6. MR Imaging of Ex Vivo Tissue at 3 T  
Normal lamb and swine left ventricular (LV) myocardial samples were obtained from a 
local distributor (<24 hrs post mortem) and maintained in PBS until imaging. Ex vivo samples 
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were prepared by mixing the macromer and initiators (5 mM APS, 5 mM TEMED) and injecting 
0.3 mL of the prepolymer solution after 2 minutes (based on rheology, as discussed in Section 
4.2.3) into the LV of the explants. After waiting 30 minutes to provide sufficient time for gelation, 
transmural sections of the injection site were isolated. Samples were placed into test tubes (30 
mm diameter) and immersed in Fomblin Y (Sigma) to fill the void spaces and reduce susceptibility 
artifacts. The test tube was submerged in a larger phantom filled with PBS to aid in shimming for 
B0 homogeneity. CEST images were acquired using a 3 T Tim Magnetom Trio Scanner (Siemens 
Medical Solutions; Malvern, PA) with an 8-channel knee coil or 8-channel 
1
H head coil (Nova 
Medical; Wilmington, MA). Ex vivo scans were performed at 25°C to avoid potential tissue 
degradation at 37°C and due to minimal temperature differences observed in phantoms. Scan 
parameters were optimized based on the coil, sample size, and required field of view (Table 6.1). 
For all explant studies, the total repetition time was set to 4 seconds to minimize overall scan time 
towards the goal of using the same imaging parameters for ex vivo and future in vivo scans.  
Localization of CEST contrast to the site of hydrogel injection in cardiac explants was 
confirmed by traditional T1-, T1ρ- and T2-weighted MR imaging. A spin-echo-prepared FLASH 
sequence with scan parameters identical to the corresponding CEST images was utilized to 
generate T1, T1ρ and T2 maps. For T1 maps, the inversion time (TI) was varied as follows: 50, 100, 
300, 500, 700, 1000, 1300, 1600, and 2000 ms. T1ρ and T2 maps were generated from scans with 
the following spin-lock (TSL) and echo (TE) times, respectively: 0, 20, 40, 60, 80, and 100 ms. A 
spin-lock pulse amplitude of 500 Hz was used for T1ρ image acquisition.  
6.2.7. Processing CEST MRI Data  
All image processing and data analysis was performed using a custom MATLAB (Natick, 
MA) code. B0 and B1 maps were generated to correct for magnetic field inhomogeneity by 
estimating the local field variations to center and scale all CEST data on a voxel-by-voxel basis, 
as previously described.
27,35,38,39
 Z-spectra were generated by plotting the signal intensity from 
bulk water as a function of the saturation frequency with respect to water resonance. Asymmetry 
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curves were generated from the z-spectral data according to Equation 6.2 above by plotting the 
relative water signal difference normalized to S(-) at frequency offsets of 0 to 4.8 ppm.   
 
Figure 6.3. Processing of CEST data. A region of interest (ROI) was first isolated to adjust for 
noise (A). B0 and B1 maps were then used to correct for magnetic field inhomogeneity (B). CEST 
contrast was then calculated using the equation shown (C). Finally, the corrected CEST contrast 
was overlaid on the initial anatomical image (D). Scale bar = 2 cm.  
To generate CEST maps, background noise was first removed by applying a signal 
intensity threshold, generating a mask to isolate the initial region of interest (i.e., phantom or 
tissue), and applying an averaging kernel to minimize spatial noise artifacts in the masked region 
(Figure 6.3A). B0 inhomogeneity was accounted for using a combination of B0 map and multiple 
CEST data acquired in the neighborhood of ±0.4 ppm off the target chemical shift.
33-35
 For this B0 
correction, CEST images were analyzed from +0.6 to +1.4 ppm and +1.4 to +2.2 ppm for hydroxyl 
and amine proton exchange, respectively, with a step size of 0.1 ppm for phantoms and 0.2 ppm 
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for explants. Each voxel in the ±1.0 ppm image or ±1.8 ppm image was then replaced by the 
neighborhood of CEST data fit to a linear curve (Figure 6.3B).
35
 CEST contrast was then 
calculated by further segmenting the region of interest (i.e., hydrogel), measuring the mean signal 
intensity, and inputting the intensities into Equation 6.1 or 6.2 above, where S(-) and S(+) 
are the B0 corrected signals from saturating at  –1.0 ppm and +1.0 ppm or –1.8 ppm and +1.8 
ppm for hydroxyl and amine proton exchange, respectively. CEST maps were then normalized to 
S(-) for phantoms or S0 for explants (Figure 6.3C). Finally, maps were further corrected for B1 
inhomogeneity, as discussed above, and the effect overlaid on the initial image (Figure 6.3D).  
6.2.8. Statistical Analysis  
 All data is presented as mean ± standard deviation (SD). Standard deviations were 
generated from variations in pixel intensity within the region of interest (i.e., hydrogel).   
6.3. Results 
 
Figure 6.4. HeMA-HA as a CEST imaging agent. Z-spectrum (A) and asymmetry plot (B) of 
HeMA-HA hydrogel (1 wt%) at 7 T. Vertical dashed line on (B) indicates the chemical shift of the 
dominate exchangeable proton group (-OH). CEST map of phantom from saturation at 1.0 ppm 
(C). B1 pulse parameters were an amplitude of 200 Hz and duration of 4 sec. Scale bar = 2 cm.  
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Figure 6.5. Characterization of the CEST effect of HeMA-HA hydrogels. Z-spectrum (A) and 
asymmetry plot (B) of HeMA-HA hydrogels at varying macromer concentrations at 7 T and 37°C. 
CEST map (C) and CEST effect quantification (D) of phantom from saturation at 1.0 ppm. A B1 
pulse of 400 Hz for 300 ms was used. Data presented as mean ± SD. Scale bar = 2 cm.  
6.3.1. Characterization of CEST Effect of Hydrogel Phantoms  
Initial CEST studies were performed using a 7 T MR scanner with a single HeMA-HA 
hydrogel formulation: 25% methacrylation at 1 wt% in PBS, gelled using 5 mM APS and 5 mM 
TEMED. The hydrogel phantom was scanned at 37°C using a long B1 pulse duration of 4 sec (to 
generate the maximum CEST contrast) and a pulse amplitude of 200 Hz. The z-spectrum was 
symmetric around the bulk water resonance at 0 ppm (Figure 6.4A) while asymmetry analysis 
revealed a peak around 1 ppm (Figure 6.4B). The peak in the asymmetry plot indicated that the 
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chemical shift of the dominant exchangeable proton group was 1 ppm downfield from the bulk 
water signal. Unless specified, all frequency offsets in this work are reported with respect to the 
water proton resonance frequency at 0 ppm. Saturation of the protons at 1.0 ppm generated a 
CEST effect of 11.57±2.71%, as demonstrated in the CEST map (Figure 6.4C).  
 
Figure 6.6. Saturation pulse dependence of CEST effect at 7T. CEST maps (A) and 
corresponding quantification (B) of HeMA-HA hydrogel phantoms at varying macromer 
concentrations from saturation at 1.0 ppm with varied B1 pulse amplitudes but a constant 
duration of 300 ms. Scans performed at 37°C. Data presented as mean ± SD. Scale bars = 2 cm.  
Characterization studies were performed to assess the effect of altering hydrogel 
macromer concentration on the CEST contrast. As the macromer concentration increased, the z-
spectra became increasingly broader (Figure 6.5A), which may have resulted from increased 
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steric locking of protons with increased hydrogel stiffness. This trend was also reflected in the 
asymmetry plots where increased z-spectral broadening led to higher peak heights (Figure 6.5B). 
Regardless of the macromer concentration, the asymmetry plots had a peak at ~1 ppm to 
indicate the chemical shift for saturation. CEST maps (Figure 6.5C) and contrast quantification 
(Figure 6.5D) from saturation at 1.0 ppm demonstrated an increase CEST contrast with 
increasing macromer concentration. A B1 of 400 Hz for 300 ms was selected for this study and all 
subsequent phantom studies at 7 T based on optimization studies where the pulse amplitude was 
varied at a constant duration (Figure 6.6). The saturation duration was decreased from 4 sec to 
300 ms to decrease  specific absorption rate (SAR) concerns at 7 T and to enable comparison to 
scans performed using lower field strengths (i.e., 3 T), where hardware limitations arise for longer 
pulse durations. Of the amplitudes examined, 400 Hz generated the highest CEST effect.  
 
Figure 6.7. Effect of hydrogel pH and temperature on the CEST effect at 7T. In vitro study 
assessing the effect of gelation on final hydrogel pH (A). CEST map at 1.0 ppm of HeMA-HA 
hydrogels at a single macromer concentration (8 wt%) and uniform temperature (37°C) but 
166 
 
varying pH (B).  Quantification of the effect of hydrogel pH on the CEST effect at 7T (C). CEST 
maps at 1.0 ppm of HeMA-HA hydrogels at varying concentration but uniform pH (7.0) at 25°C 
(D) and 37°C (E). Quantification of the effect of temperature on the CEST contrast (F). Protons 
saturated using a B1 of 400 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.  
 
Figure 6.8. CEST effect of HeMA-HA hydrogel phantoms at varying field strengths. CEST maps 
at 1.0 ppm of hydrogels at varying concentration at 37°C using a magnetic field strength of 7T (A) 
or 3T (B). Quantification of the CEST effect at different field strengths (C). Protons saturated 
using a B1 pulse of 300 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.  
The impact of pH and temperature on CEST contrast was then assessed at 7 T. Prior to 
the CEST imaging study, the impact of hydrogel formation on pH was investigated due to the 
acidic and basic pH of the APS and TEMED used for crosslinking, respectively. To do so, the pH 
of the macromer dissolved in PBS was varied and the final pH of the resulting hydrogel was 
measured (Figure 6.7A). The line of best fit was used to determine the starting pH of the 
precursor solution needed to generate a hydrogel at a desired final pH. Hydrogels could be 
formed within the final pH range of ~5.75 to 7.25. CEST maps at 1.0 ppm of HeMA-HA hydrogels 
formed at varying final pH within that range (Figure 6.7B) and the corresponding quantification 
(Figure 6.7C) demonstrated that as hydrogel pH increased, the CEST effect decreased linearly. 
Similarly, CEST maps at 1.0 ppm of hydrogels at different temperatures (Figure 6.7D,E) and the 
quantification (Figure 6.7F) showed that as temperature increased, the CEST effect decreased.  
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Figure 6.9. Saturation pulse amplitude dependence of CEST effect at 3T. CEST maps (A) and 
corresponding quantification (B) of HeMA-HA hydrogels at varying macromer concentrations from 
saturation at 1.0 ppm with varied B1 pulse amplitudes but a constant duration of 300 ms. Scans 
performed at 37°C. Data presented as mean ± SD. Scale bars = 2 cm.  
To move towards clinically relevant scan parameters, the CEST effect of HeMA-HA 
hydrogels was assessed using at 3 T. CEST maps at 1.0 ppm (Figure 6.8A,B) and contrast 
quantification (Figure 6.8C) showed that as the field strength decreased, the CEST effect at each 
macromer concentration decreased. However, the trend of increased CEST contrast with 
increased macromer concentration was maintained regardless of field strength. To directly 
compare the results between the two fields, a B1 pulse of 300 Hz and 300 ms was used for both 
the 7 T and 3 T scans. The pulse parameters were selected based on optimization studies at 3 T 
(Figures 6.9 and 6.10). A B1 of 300 Hz for 300 ms was used for all subsequent 3 T phantom 
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studies. In addition, pH and temperature characterization studies were performed to confirm that 
as pH or temperature increased, the CEST effect also decreased at 3 T (Figure 6.11). 
 
Figure 6.10.  Saturation pulse duration dependence of CEST effect at 3T. CEST maps (A) and 
corresponding quantification (B) of HeMA-HA hydrogels at varying macromer concentrations from 
saturation at 1.0 ppm with varied B1 pulse durations but a constant amplitude of 300 Hz. Scans 
performed at 37°C. Data presented as mean ± SD. Scale bars = 2 cm.  
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Figure 6.11. Effect of hydrogel pH and temperature on the CEST effect at 3T. CEST map at 1.0 
ppm of HeMA-HA hydrogels at a single macromer concentration (8 wt%) and uniform 
temperature (37°C) but varying pH (A). CEST maps at 1.0 ppm of HeMA-HA hydrogels at varying 
concentration and uniform pH (7.0) but varying temperatures of 25°C (B) and 37°C (C). 
Quantification of the effect of pH (D) and temperature (E) on the CEST contrast at 3T. Protons 
saturated using a B1 of 300 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm. 
6.3.2. Ex Vivo Imaging of Injectable Hydrogels  
To further facilitate translation of this biomaterial imaging technique, the CEST effect of 
HeMA-HA hydrogels was assessed after injection into cardiac explants. CEST maps at 1.0 ppm 
demonstrated the ability to detect the injected hydrogel over the myocardial signal at both field 
strengths. At 7T (Figure 6.12A), a higher CEST contrast was generated from the injected 
hydrogel compared to that obtained at 3T (Figure 6.12B) due to a lower direct water saturation 
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effect at 7T. When the CEST effect of the hydrogel was background corrected using the 
surrounding myocardial signal at the corresponding field strength, the CEST contrast was similar 
between the two field strengths (Figure 6.12C). Similar to the phantom studies, a B1 saturation 
pulse of 300 Hz and 300 ms was used at both field strengths. In contrast to the phantom studies 
performed at 37°C, explant studies were performed at 25°C due to minimal differences in the 
CEST effect with temperature at both 7 T (Figure 6.7F) and 3 T (Figure 6.11E). 
 
Figure 6.12. Ex vivo CEST effect of HeMA-HA hydrogels at varying field strengths. CEST maps 
at 1.0 ppm of 8 wt% HeMA-HA hydrogels injected into cardiac explants at 7 T (A) and 3 T (B). 
Dashed circles indicate hydrogel injection. Quantification of the CEST effect with the surrounding 
myocardium used for background correction (C). Ex vivo scans performed at 25°C. Protons 
saturated using a B1 of 300 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.  
The chemical shift dependence of the CEST effect was then compared in myocardial 
samples with and without HeMA-HA hydrogel injections at 3 T. CEST maps were generated for 
explants at 1.0 ppm, 1.5 ppm, and 2.0 ppm using a saturation pulse of 200 Hz for 250 ms. At 1.0 
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ppm, the hydrogel CEST contrast was greater than that of the surrounding myocardium (Figure 
6.13A), as expected due to saturation of the HA hydroxyl protons. As the chemical shift difference 
from water () increased, the background myocardial CEST effect increased, decreasing the 
difference in contrast between the hydrogel and myocardium (Figure 6.13). The increased 
background myocardial signal with increasing chemical shift was comparable between the 
explant sample with (Figure 6.13C,E) and without (Figure 6.13D,F) hydrogel injections. 
Conventional MRI (i.e., T1, T1ρ, T2) was used to confirm the location of increased CEST contrast 
at 1.0 ppm corresponded to the site of hydrogel injection (Figure 6.14). 
 
Figure 6.13. Chemical shift dependence of the CEST effect. CEST maps of a HeMA-HA hydrogel 
(8 wt%) injected into cardiac explants (left) as compared to myocardial samples alone (right) at 
1.0 ppm (A, B), 1.5 ppm (C, D), and 2.0 ppm (E, F). Dashed circles indicate hydrogel injection (A, 
C, E). Scans performed at 25°C. A B1 pulse of 200 Hz for 250 ms was used. Scale bars = 2 cm.  
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Figure 6.14. Comparison of CEST effect with traditional MRI based on relaxation properties.  
CEST maps at 1.0 ppm of a HeMA-HA hydrogel (8 wt%) injected into an explant (A) relative to a 
myocardial sample without injection (B). Protons were saturated using a B1 of 200 Hz for 250 ms. 
T1 (C), T1ρ (D), and T2 (E) maps of the hydrogel-injected explant to demonstrate co-localization of 
the CEST effect with MRI contrast generated based on relaxation times. Scale bars = 2 cm.  
6.3.3. Alteration of CEST Effect with Peptide Coupling  
A peptide (GCRRR) was coupled to HeMA-HA using the reaction of maleimide-modified 
HA to the thiol on the cysteine of the peptide (Figure 6.15). This peptide sequence was selected 
to alter the CEST contrast based on the presence of additional exchangeable proton groups with 
altered chemical shift (Figure 6.15C).
30,31
 Non–water-suppressed 
1
H-NMR spectra at room 
temperature demonstrated that the additional peaks in the HeMA-HA-Peptide macromer 
originated from the peptide (Figure 6.16A). 
1
H-NMR spectra of the HeMA-HA-Peptide dissolved 
in H2O as compared to D2O indicated the presence of the exchangeable proton peaks in the 
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~6.5-8.6 ppm range (with respect to TMS) when the macromer was dissolved in H2O (Figure 
6.16B). Exchangeable protons peaks disappeared when the macromer was dissolved in D2O 
because the exchangeable protons interchanged with deuterium, which is not observable in 
1
H-
NMR spectra. Comparison of the non–water-suppressed spectra of the HeMA-HA-Peptide 
solution at different temperatures highlighted that the exchangeable proton peak of interest for 
CEST manipulation occurred at ~6.5 ppm with respect to TMS, which is ~1.8 ppm downfield from 
water at 4.7 ppm (Figure 6.16B).
40
 Thus, subsequent CEST imaging experiments of HeMA-HA-
Peptide hydrogels focused on saturating at 1.8 ppm downfield from water.   
 
Figure 6.15. Synthesis of HeMA-HA-Peptide.  HeMA-HA was converted to a TBA salt, then 
reacted with N-(2-aminoethyl)maleimide trifluoroacetate salt and the coupling agent BOP to 
introduce a malemide for subsequent coupling to the cysteine of a RRRCG peptide (A). 
1
H-NMR 
was used to confirm the addition of TBA, the coupling of the malemide, and the consumption of 
the malemide peak (solid, red circles) with the peptide (B). The arginines in the peptide introduce 
additional amine functional groups (dashed, blue circles) to alter the CEST effect (C).  
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Phantom studies were then performed at 7 T to confirm that altering HeMA-HA-Peptide 
hydrogel macromer concentration alters the CEST contrast. Similar to the previous HeMA-HA 
phantom studies, the z-spectra became more broad (Figure 6.17A) and the asymmetry plot peak 
heights increased (Figure 6.17B) with increasing macromer concentration. Relative to the 
asymmetry plots of HeMA-HA hydrogels (Figure 6.5B), the addition of the peptide led to a shift in 
the asymmetry plots, resulting in a broad peak around ~1.8-2 ppm. CEST maps at 1.8 ppm 
(Figure 6.17C) and contrast quantification (Figure 6.17D) confirmed an increase in the CEST 
effect with increasing macromer concentration in HeMA-HA-Peptide hydrogels.  
 
Figure 6.16. Spectroscopy characterization of HeMA-HA-Peptide. Non-water suppressed 
1
H-
NMR spectra of HeMA-HA, peptide, and HeMA-HA-Peptide solutions in H2O at room 
temperature, 295 K (A). Spectra of HeMA-HA-Peptide solution in H2O at different temperatures 
as compared to the macromer in D2O to identify the exchangeable protons peaks (B). 
Temperature-induced changes in the exchange rate of the amine protons (dashed circles) 
highlight their ability to generate a CEST effect. The amine protons resonate at 1.8 ppm downfield 
from the bulk water protons at 4.7 ppm (relative to TMS).  
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Figure 6.17. Characterization of the CEST effect of HeMA-HA-Peptide hydrogels. Z-spectrum (A) 
and asymmetry plot (B) of HeMA-HA-Peptide hydrogels at varying macromer concentrations at 
7T using a B1 of 400 Hz at 300 ms. CEST map from saturation at 1.8 ppm (C) and corresponding 
quantification of the CEST effect (D). Data presented as mean ± SD. Scale bar = 2 cm. 
To further compare the CEST effect of HeMA-HA and HeMA-HA-Peptide hydrogels, 
phantom imaging studies were performed at 7 T, where the chemical shift of the saturation pulse 
was varied to highlight the differences in exchangeable proton chemistry between the two 
materials. CEST maps and quantification from saturation at 1.0 ppm showed a similar CEST 
effect for both hydrogel formulations (Figure 6.18A-C). In contrast, CEST maps and 
quantification from saturation at 1.8 ppm demonstrated that the CEST effect of HeMA-HA-Peptide 
hydrogels was maintained (relative to their CEST effect at 1.0 ppm), whereas the CEST contrast 
of HeMA-HA hydrogels decreased by a factor of two (Figure 6.18D-F).  
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Figure 6.18. Altering the CEST effect by changing the chemistry and saturation frequency. CEST 
maps at 1.0 ppm (left) and 1.8 ppm (right) of HeMA-HA (A, D) and HeMA-HA-Peptide (B, E) 
hydrogel phantoms at 7 T and 37°C. CEST effect quantification at 1.0 ppm (C) and 1.8 ppm (F). 
Protons saturated using 400 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.  
6.4. Discussion  
Initial CEST imaging studies of a HeMA-HA hydrogel at 7 T demonstrated that the 
exchangeable protons present on the HA backbone could be manipulated using CEST MRI. More 
specifically, the hydroxyl protons were targeted over the amide protons on HA due to their higher 
concentration. Since CEST asymmetry analysis is based on the subtraction of images at 
corresponding but opposite chemical shifts around the water resonance, a peak in the plot 
indicates a decrease in the + signal due to saturation of the exchangeable protons resonating 
at that frequency (Figure 6.4B). Since the peak in the asymmetry plot occurred around 1 ppm, it 
confirmed that these exchangeable protons reside in the hydroxyl groups on HA (Figure 6.2), 
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which is consistent with previous studies.
19,30
 Even though both the hydroxyl protons and amide 
protons on GAGs have been identified as suitable CEST agents, the high concentration and the 
fast exchange rate of hydroxyl protons make them a favorable option.
26
  To further confirm the 
ability to visualize HA hydrogels using CEST imaging, saturation at the hydroxyl proton 
resonance frequency resulted in a CEST effect >10% (Figure 6.4C).  
 
Figure 6.19. CEST effect of HeMA-HA hydrogels tracks with degradation at both field strengths. 
In vitro degradation of HeMA-HA hydrogels at varying macromer concentrations (A). CEST effect 
quantification of hydrogels at decreasing macromer concentrations (B). CEST maps at 1.0 ppm of 
hydrogels at varying concentration at 37°C using a field strength of 7T (C) or 3T (D). Protons 
saturated using a B1 of 300 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.  
Towards the goal of understanding injectable hydrogels in vivo, the ability to detect 
differences in material properties (i.e., macromer concentration) based on altering the CEST 
contrast is of great importance. As the concentration of the exchangeable proton pool increased 
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(due to the increase in macromer concentration), a larger extent of saturated magnetization could 
be transferred to the bulk water protons, leading to a greater decrease in the water signal. This 
trend was observed in the characterization study at 7T through the asymmetry analysis (Figure 
6.5B) and visualization of the CEST effect in overlaid maps (Figure 6.5C). Furthermore, at both 7 
T and 3 T, the CEST effect increased linearly with increasing macromer concentration (Figure 
6.8) and therefore, a diminishing macromer concentration would be reflected by a smaller CEST 
effect. This decrease in macromer concentration could be used for future applications to mimic 
diminished hydrogel crosslinking or hydrogel degradation in vitro (Figure 6.19). Previous studies 
using injectable HA hydrogels demonstrated that their impact in vivo was dependent on both their 
degree of crosslinking (i.e., mechanics) and degradation profile.
28
 Thus, the ability to visualize 
hydrogel crosslinking and/or degradation using CEST MRI could be used to predict hydrogel 
outcomes in vivo and provide insight into identifying optimal material properties.  
To enable future in vivo applications of this technique, CEST was used to image HA 
hydrogels using clinically relevant scan parameters and in tissue explants. When initially 
determining if CEST could be a viable tool for hydrogel imaging, a long B1 pulse duration was 
used to maximize the CEST signal by ensuring the protons have sufficient time to relax back to 
their steady state after manipulation.
19
 After validating the use of CEST imaging, the pulse 
duration was decreased for all subsequent scans due to increased SAR concerns for in vivo 
injectable hydrogel applications
18
 and hardware limitations at clinical field strength scanners. The 
relationship between long pulse durations leading to increased signal outputs accounts for the 
difference in CEST contrast generated between the initial characterization of a low macromer 
concentration hydrogel using a long duration (Figure 6.4) and the subsequent characterization of 
hydrogels at higher macromer concentrations using a shorter pulse duration (Figure 6.5). It is 
also advantageous to have the ability to restrict the pulse duration but maintain generation of a 
CEST contrast because the specific biological application may dictate time restraints, such as the 
case for cardiac CEST imaging.
35
 Finally, shorter pulse durations are suitable for CEST imaging 
specific to hydroxyl protons due to their relatively rapid exchange rate.
19,41
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To further the translational value of CEST for biomaterial imaging, ex vivo scans were 
performed to distinguish injectable HA hydrogels from surrounding tissue (Figures 6.6, 6.7). 
Despite the decreased signal when transitioning from 7 T to 3 T (Figures 6.5, 6.6), the impact on 
the ex vivo hydrogel CEST effect was minimal when background corrected with the myocardial 
CEST signal (Figure 6.12C). Moreover, the large increase in power deposition at 7 T limits 
clinical use.
18
 In the subsequent 3 T ex vivo scans, comparison of CEST maps at 1.0 ppm of 
myocardial samples with and without the hydrogel injections showed increased CEST contrast at 
the hydrogel location (Figure 6.13A,B). Conventional MRI using of T1, T1ρ, and T2 mapping 
further confirmed the site of the injected hydrogel coincided with the location of increased CEST 
contrast (Figure 6.14).  
In contrast to conventional MRI contrast, such as T1- and T2-weighting, CEST probes 
specific functional groups in biomaterials based on their exchangeable protons in a frequency-
specific manner.
42
 This was evident in this study because the greatest difference in the hydrogel 
to myocardial CEST contrast occurred at the HA hydrogel hydroxyl proton resonance frequency 
(Figure 6.13A). As  increased such that saturation occurred further from the resonance 
frequency of the hydroxyl protons, the background myocardial CEST effect increased (Figure 
6.13). This endogenous myocardial CEST contrast was likely due to saturation of native 
exchangeable protons, such as those present in extracellular matrix (ECM) molecules or in 
cardiac metabolites. One such metabolite is creatine, which is involved in the production of 
energy to power myocardial contraction.
35
 The labile amine protons in creatine are known to 
resonate at ~1.8 ppm downfield of bulk water,
34,35
 which was confirmed in this work by the 
increased CEST contrast when saturation occurred at 2.0 ppm (Figure 6.13E,F) relative to 1.5 
ppm (Figure 6.13C,D) or 1.0 ppm (Figure 6.13A,B). Due to this chemical shift dependence, 
injectable materials with different functional groups possessing exchangeable protons with 
distinct chemical shifts could be designed such that CEST imaging could simultaneously visualize 
and discriminate between these materials.
30,31,43
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To demonstrate the ability of CEST imaging to differentiate injectable hydrogels based on 
the resonance frequency of their exchangeable protons, a peptide was coupled to HeMA-HA. The 
peptide was chosen to contain three arginines because the amine protons in arginine are known 
to resonate at 1.8 ppm downfield from the bulk water protons, which differs from the hydroxyl 
proton resonance at 1.0 ppm.
30,31,34,35
 Amine protons not only offer the advantage of being at a 
chemical shift farther from water, which decreases direct water saturation and hence increases 
CEST sensitivity, but they also exchange at a relatively slower rate than hydroxyl protons, 
allowing more time for selective saturation before exchange, thus resulting in a larger CEST 
effect.
19,41
 In addition, amine-based CEST has recently been used to image endogenous 
metabolites in vivo for cardiac and calf muscle applications.
35
   
 Non-water suppressed spectroscopy was used to confirm the presence of additional 
exchangeable protons in the HeMA-HA-Peptide macromer relative to HeMA-HA alone (Figure 
6.16A) and highlight the potential for the arginine-based amine protons to generate a CEST effect 
(Figure 6.16B). To do so, the HeMA-HA-Peptide solution was exposed to varying temperatures 
since changes in temperature and pH are known to alter the exchange rate, and hence CEST 
effect.
22,44
 As the temperature or pH increase, the proton exchange rate increases, leading to less 
time available for saturation and an overall decrease in the generated CEST contrast (Figures 
6.7, 6.11). Similarly, as the temperature the HeMA-HA-Peptide solution was increased from 280 
K to 295 K in the spectrometer, the exchange rate of the amine protons increased, resulting in 
formation of a single broad peak at 295 K from two separate, resolved peaks at 280 K at ~6.5 
ppm with respect to TMS. The two peaks evident at the lower temperature represent the two 
equivalent amines in the guanidine group at the distal end of each arginine in the peptide where 
the delocalization of the positive charge between the double bond and the nitrogen lone pair 
facilitates exchange (Figure 6.15C).  
The exchangeable proton and saturation frequency specificity of the CEST effect was 
further confirmed by phantom studies comparing HeMA-HA and HeMA-HA-Peptide hydrogels 
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(Figure 6.18). Since both macromers contain the same concentration of hydroxyl protons, they 
generated a similar CEST effect when saturated at the hydroxyl resonance frequency of 1.0 ppm 
(Figure 6.18A-C). In contrast, only the HeMA-HA-Peptide macromer contains the exchangeable 
arginine-based amine protons shown to resonate ~1.8 ppm downfield of water protons (Figure 
6.16B). Therefore, application of the saturation pulse at 1.8 ppm led to generation of a CEST 
effect specific to the amine protons in the peptide. The two hydrogels were distinguished from 
one another at the resonance frequency of the amine protons because HeMA-HA-Peptide 
hydrogel generated a strong CEST effect whereas the HeMA-HA hydrogel did not (Figure 6.18D-
F). The ability to visualize differences in hydrogels based on modulation of the exchangeable 
proton pool and chemical shift of saturation highlights the novelty of CEST as an imaging tool that 
can be tuned to the properties of the injectable material of interest.  
6.5. Conclusions  
In summary, this chapter demonstrated that a new MRI technique based on saturation 
transfer of specific exchangeable protons was successfully used to visualize injectable HA 
hydrogels in vitro and ex vivo. Alteration of hydrogel properties (i.e., macromer concentration) led 
to differences in the CEST contrast, indicating that this imaging approach could be used to 
identify different compositions or to track dynamic changes in biomaterial properties. In addition, 
the CEST effect was altered by changing the exchangeable proton group and saturation 
frequency, demonstrating the ability of CEST imaging to specifically image and discriminate 
between different injectable materials based on their chemistry. Moreover, the use of CEST MRI 
to accurately detect injectable hydrogels in tissue explants using clinically relevant scan 
parameters and magnetic field strengths highlights the potential for CEST imaging to be used as 
tool to simultaneously visualize and assess material properties of injectable materials in vivo for 
future biomaterial optimization. The next chapter will focus on applying injectable, degradable HA 
hydrogels to an in vivo infarct model and assessing outcomes using MRI.  
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CHAPTER 7 
 
Investigation of Injectable Hyaluronic Acid Hydrogel Therapy to Alter Myocardial 
Tissue Properties for Infarct Repair using MRI and FE Modeling 
 
(Adapted from: Dorsey SM, McGarvey JR, Wang H,  Nikou A, Arama L, Koomalsingh KJ, Kondo 
N, Pilla JJ, Gorman JH III, Gorman RC, Wenk JF, Burdick JA. Biomaterials, in preparation.)  
7.1. Introduction 
Heart failure is a leading cause of morbidity and mortality, affecting almost 23 million 
individuals worldwide and 6 million in the US alone.
1,2
 Of these cases, nearly 70% are due to left 
ventricular (LV) remodeling initiated by myocardial infarction (MI).
3
 LV remodeling is manifest by 
progressive LV dilation which results in thinning of the LV wall and a change in heart shape that 
can alter function.
4
 The mechanical phenomenon that both initiates and sustains the adverse LV 
remodeling process is the initial infarct expansion. Infarct expansion is a progressive pathologic 
process that results from abnormal loading of the noncontractile infarcted myocardium, leading to 
increased mechanical stress in the perfused borderzone regions surrounding the infarct, altered 
systolic contractile properties, and eventual progression to heart failure.
5-8
 Limiting infarct 
expansion has thus been identified as a potential therapy to reduce the morbidity associated with 
LV remodeling. Previous strategies to limit infarct expansion include surgical reconstruction of the 
dilated LV and physical LV restraint with polymeric meshes to prevent dilation.
9-13
  
In contrast to passive restraint devices, injectable biomaterials offer the potential for 
minimally invasive delivery, which may limit tissue damage and enable rapid clinical translation. 
As discussed in Section 3.2.2, injectable acellular hydrogels have been used to mechanically 
stabilize the infarcted myocardial wall to prevent initial infarct thinning and attenuate remodeling 
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post-MI.
14,15
 Several natural and synthetic injectable materials have been successful in 
maintaining cardiac structure and function in animal models,
16
 but further information is needed to 
understand the impact of injectable materials on myocardial tissue properties.
17
 Recent studies 
using injectable hyaluronic acid (HA) hydrogels were the first to investigate the importance of 
material mechanics
18
 and degradation
19
 in attenuating remodeling. However, the specific 
hydrogel properties for optimal in vivo outcomes are not clear.  
To further elucidate how injectable hydrogels alter LV remodeling, tools are needed to 
assess the effects of these therapies on the infarcted myocardium. However, traditional 
histological analysis is invasive, thereby limiting temporal assessment, as it can ultimately only be 
performed in an excised heart. Imaging modalities, such as magnetic resonance imaging (MRI), 
can noninvasively provide information about the infarcted heart following treatment with injectable 
hydrogels. Unlike other well-established cardiac imaging modalities, advances in cardiac MRI 
offer the ability to not only assess standard geometrics but also depict myocardial wall motion 
with high image contrast and spatial resolution without using ionizing radiation.
20-25
 Cine MRI 
continues to be the most accurate modality for evaluating LV structure and function with high 
spatial and temporal resolution.
26,27
 MRI with the use of gadolinium contrast agents enables 
visualization of infarcted regions due to differences in tissue perfusion using late-gadolinium 
enhancement (LGE) MRI.
28
 Myocardial (SPAMM) tagging with MRI can be used to visualize 
regional heart motion at high spatial resolution and quantify regional myocardial displacement 
(strain) as a measure of LV contractility.
29,30
 Thus, within a single scan period, MRI can monitor 
changes in global LV structure and function, infarct properties, and regional wall motion to provide 
insight into the impact of injectable hydrogels on myocardial tissue parameters post-MI.  
Theoretical finite element (FE) models can also be used to provide information on how 
injectable hydrogels attenuate LV remodeling. Previous FE models have shown that injectable 
materials decrease myocardial stresses after remodeling with levels that depend on hydrogel 
properties, such as mechanics and volume.
31-33
 A FE model of injections into the borderzone 
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region with mechanical properties 20% greater than the stiffness of the native myocardium led to 
a concomitant 20% decrease in myocardial fiber stress relative to controls.
31
 In a subsequent 
study, it was shown that this decreased stress depended on both the injection pattern and the 
volume of material dispersion, with larger numbers of injections and larger injection volumes 
having the greatest effects on myocardial fiber stress.
32
 Despite these findings, the models used 
simulated injections
31,32
 or three-dimensional echocardiographic data from large animal studies.
33
 
In contrast, MRI myocardial tagging enables a highly detailed assessment of myocardial motion 
as a measure of myocardial strain.
34
 FE models using MRI tagging strains as input parameters 
have been examined in large animals
33,35-37
 and humans
34,38
 post-MI, but none have done so in 
the context of assessing the ability of injectable biomaterials to decrease myocardial stress.  
The goal of this chapter was to better understand the role that injectable hydrogels have 
on positive structural and functional outcomes post-MI using cardiac MRI and FE modeling. As 
discussed in Section 4.1, hydrogels were formed by crosslinking HA, a linear polysaccharide 
found in native cardiac extracellular matrix (ECM) that plays a role in cardiac embryogenesis, 
scar reduction, cell migration and angiogenesis.
39-42
 In vivo function was assessed in a well-
established porcine infarct model at 1, 4, 8, and 12 weeks post-MI to determine the temporal 
effect of HA hydrogels on global LV remodeling, infarct expansion, myocardial wall motion, and 
myocardial stiffness. This study was the first to examine the efficacy of hydrogel therapies for MI 
repair using MRI-derived measures of regional myocardial systolic strain and FE-model derived 
measures of passive myocardial stiffness based on in vivo inputs. Ultimately, these results can 
broaden our understanding of hydrogel therapies to prevent progression to heart failure. 
7.2. Materials and methods 
7.2.1. Synthesis of HeMA-HA Macromer  
As discussed previously in Section 4.2.1, HA was modified to include a hydrolytically 
degradable group, hydroxyethyl  methacrylate (HeMA). Briefly, HeMA-HA was made by coupling 
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HA-tetrabutyl-ammonium salt (HA-TBA) to 2-hydroxyethyl-methacryl-succinate (HeMA-COOH) 
using 4-dimethylaminopyridine (DMAP, Sigma) and the coupling agent di-tert-butyl dicarbonate 
(BOC2O, Sigma) for 20 hours at 45°C.
19
 The macromer was purified by dialyzing against 
deionized (DI) water at 4°C, acetone precipitating, and dialyzing again. The macromer was then 
frozen and lyophilized. The extent of HA modification with HeMA was assessed with 
1
H-NMR 
(Bruker, 360 MHz) and found to be ~25% of the HA repeat units, as in Section 4.2.1.  
7.2.2. Hydrogel Formation and Characterization 
Hydrogels were formed by crosslinking the methacrylate groups of HeMA-HA using a 
redox initiator system of ammonium persulfate (APS, 5 mM, Sigma) and N,N,N,N’,N’-
tetramethylenediamine (TEMED, 5 mM, Sigma),
43
 as discussed in Section 4.2.3. Gel onset was 
quantified using an AR2000ex Rheometer (TA Instruments) by monitoring the storage (G’) and 
loss (G”) moduli over time at 37°C under 1% strain and 1 Hz frequency in a cone-plate geometry 
(1°, 20 mm diameter). For in vitro characterization of mechanics and degradation, hydrogels were 
formed between two glass slides in a Teflon mold sealed with vacuum grease. Compression 
testing was performed on gels using a Dynamic Mechanical Analyzer (DMA) (Q800 TA 
Instruments) at a strain rate of 10%/min and compressive moduli were calculated from 10 to 20% 
strain.
44 
Degradation was monitored in PBS at 37°C and mass loss quantified using an uronic 
acid assay.
45,46
 Mechanics and degradation were assessed immediately after gelation (day 0) and 
at desired time points throughout degradation (i.e., days 1, 7, 14, 28, 56 and 84 after gelation). 
7.2.3. In Vivo Evaluation in Porcine Infarct Model  
Fourteen male Yorkshire swine weighing 40-50 kg were enrolled in this study (n=8 
hydrogel treatment, n=6 saline control).  All animals received care in compliance with protocols 
approved by the University of Pennsylvania’s Institutional Animal Care and Use Committee in 
accordance with the National Institutes of Health’s “Guide for the Care and Use of Laboratory 
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Animals” (NIH Publication 85-23, revised 1996). All animals received a baseline MRI scan to 
evaluate LV volumes and regional strains 5-7 days prior to MI. 
 
Figure 7.1. MRI analysis of in vivo porcine infarct model. In vivo function (n=3-6/group) was 
assessed in a porcine MI model (A). Inserts in panel A show a 3D MRI reconstruction of a 
hydrogel in a myocardial explant (top) and visibility of a MRI marker (white, dashed circle) placed 
post-MI for tracking infarct expansion (bottom). Thirty minutes post-MI, animals underwent an 
array of twenty 0.3 mL injections of either prepolymer solution or saline in the infarct (B). MRI 
compatible markers (white, dashed circles) are visible. MRI scans were performed at baseline 
(i.e., prior to infarction) and at 1, 4, 8 and 12 weeks post-MI. MRI data was analyzed to assess 
global LV structure and function from segmentation of the blood volume (red shape) in cine MRI 
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(C), infarct (red arrow) expansion from LGE MRI (D), and myocardial wall function from tracking 
grid displacement (red circles highlight select tags) in SPAMM tagged MRI (E). Scale bar = 2 cm.  
For infarct induction, pigs were anesthetized and the LV free wall exposed through a left 
thoracotomy. Throughout the procedure, pigs were monitored with electrocardiography and 
aseptic technique was maintained. Animals were first sedated with intramuscular ketamine 
injection (25-30 mg/kg), intubated, and mechanically ventilated. General anesthesia was 
maintained on mixed isoflurane (1.5-3.0%) and oxygen, which was delivered by volume-
controlled ventilation (tidal volume 10-15 mg/kg).
47
 A posterolateral infarction was induced by 
ligation with nonabsorbable polypropylene suture of the left circumflex artery (LCX) and select 
obtuse marginal (OM) branches. In nearly all cases, this pattern of coronary ligations produced an 
infarct comprising 20-25% of the left ventricle.
48
 Akinesis of the infarcted myocardium was 
confirmed using intraoperative echocardiography. Following infarct induction, thin MRI 
compatible, platinum wire markers were sutured to the epicardium to outline the infarct. These 
markers were tracked for quantitative assessment of infarct expansion over time (Figure 7.1A).
47
  
Thirty minutes after infarction, animals received twenty evenly distributed 0.3 mL 
injections of either 0.9% normal saline (control) or HeMA-HA pre-hydrogel solution (treatment) in 
the infarct (Figure 7.1B). Real time 3D echocardiographs and hemodynamic data were obtained 
at baseline, immediately prior to MI, 30 minutes after MI, and 30 minutes post injection. After 
ensuring hemodynamic and electrophysiologic stability, all animals were recovered. MRI scans 
were performed at 1, 4, 8, and 12 weeks after injection. Animals were sacrificed at 12 weeks and 
histological evaluation of Masson’s Trichrome and H&E staining was performed. Morphometric 
analysis was performed to assess infarct wall thickness using planimetry.
47
 
7.2.4. MRI Acquisition  
Serial cardiac MRI was used to noninvasively assess global and regional cardiac 
structure and function in each animal through a series of three scans: 1) cine imaging to assess 
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global LV morphology and function (Figure 7.1C), 2) late-gadolinium enhancement (LGE) 
imaging to assess infarct area thinning and expansion (Figure 7.1D), and 3) SPAMM (SPAtial 
Modulation of Magnetization) tagging to assess regional wall motion and function (Figure 7.1E). 
MR images were acquired using a 3T Tim Magnetom Trio Scanner (Seimens, Inc.; Malvern, PA). 
General anesthesia was maintained throughout all imaging procedures, as described above. For 
each MRI scan, a high-fidelity pressure transducer (Millar Instruments; Houston, TX) was guided 
into the LV for cardiac gating; the measured pressure was later used as an input for a finite 
element (FE) model to assess in vivo myocardial stress-strain relationships. 
LV volume imaging was performed using prospectively-gated 3D steady-state free 
precession (SSFP) cine MRI with the following imaging parameters: field of view = 300 x 244 
mm
2
, matrix size = 192 x 156, repetition time = 3.11 ms, echo time = 1.53 ms, bandwidth = 1184 
Hz/pixel, slice thickness = 4 mm, averages = 2.
47
 Assessment of infarct location and wall 
thickness occurred fifteen minutes following intravenous injection of 0.1 mmol/kg 
gadobenatedimeglumine (MultiHance; Bracco Diagnostics, Princeton, NJ) using a 3D LGE 
spoiled gradient echo sequence with the following parameters:  field of view = 350 x 350 mm
2
, 
matrix size = 256 x 256, repetition time = 591.28 ms, echo time = 2.96 ms, inversion time = 200-
300 ms, flip angle = 25˚, averages = 2.
47
 Finally, regional LV strain was assessed using a 3D 
SPAMM tagged sequence with the following parameters: field of view = 260 x 260 mm
2
, matrix 
size = 256 x 128, repetition time = 34.4 ms, tag spacing = 6 mm, bandwidth = 330 Hz/pixel, slice 
thickness = 2 mm, averages = 4.
47
 Separate scans were performed for systolic and diastolic 
strain assessment. Images were archived and stored off-line for post-processing. 
7.2.5. MR Image Post-Processing  
7.2.5.1. LV Volume Measurement  
Global LV structure and function was assessed from prospective SSFP cine MRI (Figure 
7.1C). Raw short-axis images were automatically sorted, cropped, and contrast-normalized in a 
195 
 
custom MATLAB (Natick, MA) program to ensure homogenous LV coverage and image quality, 
respectively. Segmentation was subsequently performed throughout all cardiac phases using a 
semi-automated 3D active contour segmentation program (ITK-SNAP, open access/source)
49
 
using edge-based snakes to identify the LV blood volume. LV end-diastolic volume (EDV), end-
systolic volume (ESV), and ejection fraction (EF) were calculated throughout the entire cardiac 
cycle from segmented images using inputs of in-plane and through-plane spatial resolution. 
7.2.5.2. Infarct Assessment  
Myocardial wall thickness was measured over the course of the study from cine MRI 
images at end diastole. For infarct thickness assessment, thirty radially-oriented spokes were 
randomly positioned throughout each 3D infarct area in fifteen mid-ventricular slices using ImageJ 
software (NIH; Bethesda, MD). Platinum markers placed immediately post-MI and LGE images 
were used to confirm infarct boundaries. Infarct thickness was computed at each time point from 
the average spoke length. Similarly, remote wall thickness was also measured as a comparison.  
Infarct surface area and volume were assessed at end diastole from the LGE images at 
each imaging time point using MIPAV software (NIH; Bethesda, MD; Figure 7.1D). Both infarct 
surface area and volume were normalized to total LV surface area and volume for each data set, 
respectively. The epicardium, endocardium, and infarct regions were manually contoured in 
fifteen slices from base to apex. The infarct was identified from the enhanced region in the LGE 
images and confirmed by comparing to platinum marker locations in the cine and SPAMM 
images. Surface area was calculated by multiplying contour perimeters by the slice thickness (4 
mm) and number of analyzed slices. Volume was calculated by converting LGE image contours 
to binary masks to sum the voxels and computing a volume based on the spatial resolution 
(1.37x1.37x4.00 mm
3
). It should be noted that the epicardial, endocardial, and infarct contours 
were the same for both the surface area and volume calculations.  
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7.2.5.3. Myocardial Strain Analysis  
Regional wall function was assessed in terms of contractility and passive properties using 
systolic and diastolic strains, respectively. Regional strain measurements were calculated from 
3D SPAMM acquisitions using an optical flow technique (Figure 7.1E).
50
 Raw short-axis SPAMM 
images were first manually cropped to include only the left ventricle from the apex to the mitral 
annulus using ImageJ. Epicardial and endocardial contours were manually segmented at the 
early systolic or early diastolic reference state for the systolic and diastolic SPAMM data sets, 
respectively. Image masks were created from the segmented contours at the reference state to 
isolate the LV myocardium. A custom optical flow mapping algorithm integrated into ImageJ was 
used to derive high resolution, 3D displacement flow fields and strain tensors from the SPAMM 
images tracking from the reference state through end systole or end diastole for the systolic and 
diastolic SPAMM data, respectively.
50
 In both data sets, the endocardial and epicardial infarct 
boundaries were identified using the previously placed platinum markers and confirmed by 
comparison with the enhanced region in the LGE images.  
A custom MATLAB program was used for subsequent regional systolic strain analysis. 
First, a centroid was placed within the LV for each short-axis slice. The borderzone myocardium 
was then automatically defined to be the region extending 20 degrees beyond the infarct 
boundaries on each side.
7
  Remote regions were automatically defined as extending 60 degrees 
beyond the borderzone boundaries on each side. The endocardial and epicardial edges were 
excluded to reduce noise from blood and lung movement, respectively. Maximum (εmax) principal 
strains were then calculated from the strain tensors for each myocardial region (i.e., borderzone, 
remote), where εmax represents the maximum systolic thickening as an estimate of myocardial 
contractility. Three-dimensional strain maps were generated to pictorially represent transmural 
differences in regional systolic strain.   
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7.2.6. In Vivo Diastolic Material Property Estimation  
The details of the diastolic material property estimation scheme, which employs a 
combination of MRI data, finite element (FE) simulations, and numerical optimization, have been 
described previously.
37
 Briefly, early diastole was taken to be the reference state for the animal-
specific ventricular FE models since it represents a relatively stress-free state due to minimal LV 
pressure. LV volume was calculated at early and end diastole using endocardial contours 
performed at those respective time points multiplied by the spatial resolution (area x in-plane 
resolution x through-plane resolution). Synchronous LV pressure was recorded throughout 
diastole and used as a pressure boundary condition in the model. 
 
Figure 7.2. Development of finite element models from MRI-based animal specific data. FE 
models were generated by fitting MRI-derived endocardial and epicardial contours with 3D 
surfaces to represent the animal-specific geometry (A, B) and filling the myocardial space with 
hexahedral brick elements (C). The boundary between the infarct (blue) and remote (red) region 
was defined using 3D spline curves created from MRI-derived infarct contours projected onto the 
endocardial and epicardial surfaces (C). Myofiber angles were fixed for the remote region and 
assigned via optimization for the infarct region with respect to the circumferential direction (D).  
As previously described,
37
 FE models were generated by fitting the MRI-derived 
endocardial and epicardial contours at early diastole with 3D surfaces (Rapidform; INUS 
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Technology, Inc., Sunnyvale, CA; Figure 7.2A,B) and filling the myocardial space with 
hexahedral trilinear elements (TrueGrid; XYZ Scientific, Inc., Livermore, CA, USA; Figure 7.2C). 
The boundary between the infarct and remote region was defined using 3D spline curves created 
from MRI-derived infarct contours projected onto the endocardial and epicardial surfaces (Figure 
7.2C). Myofiber angles were assigned for each hexahedral element using a custom MATLAB 
code. Remote angles were fixed to be 83° at the endocardial surface and -37° at the epicardial 
surface, with respect to the circumferential direction
51-53
 whereas the infarct angles were assigned 
via an optimization algorithm (Figure 7.2D), which will be discussed later. For both the remote 
and infarct regions, the fiber angles were assumed to vary linearly in the transmural direction.  
The diastolic material properties of both the control myocardial data and hydrogel-
injected myocardial data were described by a nearly incompressible, transversely isotropic 
hyperelastic constitutive model given by:  
    
 
 
                  (7.1) 
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            (7.2) 
The parameters C,   ,   ,    , are constants that describe diastolic myocardial material properties 
and Eii are the components of the Green–Lagrange strain tensor relative to the myofiber 
coordinate system (E11 = fiber direction, E22 = cross-fiber in-plane direction, E33 = transverse-fiber 
direction) and the remaining Eij parameters are shear strains.
37
 After splitting the strain energy 
function into dilatational and deviatoric components, near incompressibility was enforced using a 
penalty method on the dilatational part. Similar to Kichula et al.,
53
 the same constitutive law was 
used to describe both the saline- and hydrogel-treated infarcts so that differences in myocardial 
stiffness could be attributed to altered material parameters with hydrogel delivery. The strain 
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energy function (Equation 7.1) was implemented using LS-DYNA software (Livermore Software 
Technology Corporation; Livermore, CA, USA).  
Subsequently, LS-OPT software (Livermore Software Technology Corporation; 
Livermore, CA, USA) was used to determine the optimal set of material parameters by minimizing 
the error between the FE model predicted strain and the in vivo MRI measured strain. The 
parameters optimized included the diastolic material parameters (Equation 7.1) for the remote 
and infarct regions as well as the endocardial and epicardial fiber angles in the infarct. The mean 
standard error (MSE)
37
 was the objective function minimized during the optimization to enable a 
direct comparison of the fit between the FE model- and MRI-derived strains. This was possible 
because the LV contours used to generate the model and the MRI-derived diastolic strains were 
from the same SPAMM data. In addition to the diastolic strain, constraints on LV cavity volume 
were incorporated into the MSE calculation to ensure better agreement, as described earlier. The 
parameters obtained from the optimization were then input into an equi-biaxial extension 
simulation to obtain representative stress-strain curves of the saline control and hydrogel treated 
regions.
37
 To do so, it was assumed that the fiber and cross-fiber directions aligned with the two 
loading directions and that the simulated sample was a thin, incompressible tissue with uniform 
fiber orientation transmurally.  Using a custom MATLAB code, stress was calculated for a range 
of strain values to facilitate a clearer interpretation of differences in myocardial properties.  
7.2.7. Statistical Analysis 
Data is presented as mean ± standard deviation (SD) or mean ± standard error of the 
mean (SEM), as indicated in each figure legend. Comparisons in LV volumes and function, wall 
thickness, infarct surface area, infarct volume, regional systolic strain, and diastolic material 
property estimations were performed using a one-way ANOVA with Tukey’s post hoc evaluation.  
A p<0.05 was considered statistically significant.  
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7.3. Results  
7.3.1. In Vitro Characterization of Selected Hydrogel Formulation  
 
Figure 7.3. In vitro characterization of hydrogel selected for use in vivo. Chemical structure of 
HeMA-HA, where 25% of the HA repeat units were modified with HeMA (A). Representative 
rheological time sweep after mixing HeMA-HA with APS and TEMED, where the intersection of 
the storage (G’) and loss (G”) moduli is defined as gel onset (B). Representative temporal 
degradation, n=1, (C) and compressive mechanical, n=4, (D) profiles. Degradation and initial 
mechanics of selected HeMA-HA formulation, n=4 (E). Data presented as mean ± SD.  
Based on previous HeMA-HA hydrogel characterization studies (Section 4.3.2), a single 
HeMA-HA formulation was selected for in vivo assessment: 25% modified HeMA-HA (Figure 
7.3A) at 8 wt% and gelled using 5 mM APS and 5 mM TEMED. Prior to its application in vivo, the 
properties of this selected formulation were characterized in vitro. Gelation onset occurred at 2.1 
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± 0.5 min and the crosslinking reaction reached a plateau within 20 minutes (gel completion: 15.9 
± 2.9 min) after introducing the dissolved macromer to the initiators (Figure 7.3B). As discussed 
in Section 5.2.6, the timing of gelation onset dictated the timing for injection in vivo. The temporal 
degradation (Figure 7.3C) and compressive mechanical (Figure 7.3D) profiles demonstrated 
hydrogels of this formulation gradually degraded and lost their mechanics over 12 weeks, which 
was the intended duration of the in vivo study. In addition, hydrogels were formed with an initial 
compressive modulus of 147.7 ± 34.2 kPa and degraded at 11.9 ± 3.6 weeks (Figure 7.3E). 
 
Figure 7.4. Histological assessment of infarcts. Histological evaluation using Masson’s Trichrome 
(A, C) and H&E (B, D) stains of saline treated (A, B) and hydrogel treated (C, D) animals at 12 
weeks post-MI. Inset indicated by black square. Scale bar = 2 mm; scale bar for inset = 200 μm. 
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7.3.2. Histological Evaluation and Ex Vivo Infarct Thickness 
Histological assessment of the infarct region at the terminal time point revealed similar 
stages of remodeling (i.e., extensive collagen staining, lack of functional myocytes, etc.) in both 
the hydrogel treated and saline control animals (Figure 7.4). Hydrogel was not observed at 12 
weeks following injection in the treatment animals, which is consistent with the previous in vitro 
degradation (Figure 7.3C,E). Regional myocardial wall thickness measured ex vivo at 12 weeks 
using planimetry showed greater thicknesses in the infarct, borderzone, and remote regions in the 
hydrogel treated animals relative to saline control animals (Figure 7.6A,B). In both the hydrogel 
and saline treated animals, the myocardial wall was most thin in the infarct region and became 
increasingly thicker moving outward to the borderzone and then the remote regions.  
 
Figure 7.5. Global cardiac structural and functional outcomes. LV volume and function assessed 
by segmenting cine MRI images throughout all cardiac phases, n=3-6/group. Hydrogel treatment 
led to decreased LV volumes (A, B) and improved cardiac function in terms of ejection fraction 
(D). Data presented as mean ± SEM. *p<0.05 vs. saline controls.  
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 7.3.3. Global LV Structure and Function  
Analysis of the cine MRI data revealed that delivery of the injectable HeMA-HA hydrogel 
system to an in vivo porcine infarct model led to smaller LV end systolic volumes (ESV) and end 
diastolic volumes (EDV) at all time points relative to control animals that received saline injections 
(Figure 7.5A,B). Moreover, the LV volumes in the hydrogel treated animals were significantly 
smaller than the volumes of the saline control animals at 1 week post-MI (EDV, p=0.005; ESV, 
p=0.03). Overall, a trend towards progressively increasing LV volumes over time was observed in 
both the saline control and hydrogel treatment animals. Comparison of the saline treated volumes 
relative to the baseline (pre-MI) volumes (EDV, 69.4 ± 7.9 mL; ESV, 35.5 ± 5.7 mL) indicated that 
the majority of the ventricular expansion occurred within the first week post-MI. For the saline 
control group, all volumes were statistically greater (p<0.05) than the baseline volumes. For the 
hydrogel treatment group, all ESV were statistically greater than baseline whereas the EDV were 
not statistically different (p>0.05) from baseline values aside from at 8 weeks (p=0.04).  
Ventricular function measured in terms of ejection fraction (EF) was greater with hydrogel 
therapy than saline at all time points (Figure 7.5C). At 8 weeks, the average EF of the hydrogel 
animals was significantly different (p<0.05) than controls. Relative to baseline (51.2 ± 3.5%), EF’s 
were statistically different in the saline group at all time points and in the hydrogel group at 1 and 
4 weeks post-MI. At 8 and 12 weeks post-MI, the EF of the hydrogel animals was not significantly 
different (p>0.05) than the baseline. 
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Figure 7.6. Myocardial wall thicknesses measured ex vivo and in vivo. Wall thickness was 
measured ex vivo at different locations (INF: infarct; BZ: borderzone; REM: remote) at 12 weeks 
using planimetry (A, B) and in vivo in the infarct (white arrows) throughout the study by analyzing 
cine MRI at end diastole (C, D). Representative MRI at 12 weeks indicating infarct region (arrows) 
are given for saline and hydrogel animals (A, C). Quantification both ex vivo, n=5-6/group (B) and 
in vivo, n=3-6/group (D) showed increased myocardial wall thickness with hydrogel therapy. Data 
presented as mean ± SEM. *p<0.05 vs. saline controls. Scale bars = 1 cm.  
7.3.4. In Vivo Infarct Thickness and Expansion over Time 
Infarct wall thickness measured in vivo throughout the duration of the study from cine 
MRI demonstrated increased thickness with hydrogel therapy as compared to controls that was 
statistically significant past one week (Figure 7.6C,D). Progressive infarct wall thinning occurred 
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in both groups over time. This trend was confirmed qualitatively in the LGE MRI, where regions of 
enhanced signal were localized to the infarct (Figure 7.7). All infarct thicknesses in both groups 
were statistically significant from the baseline posterolateral wall thickness (9.6 ± 0.4 mm) aside 
from the hydrogel group at 1 week post-MI (8.4 ± 0.5 mm, p=0.07). As a comparison, the remote 
wall thickness remained unchanged over the 12 week study for both groups (average over time 
points: hydrogel, 9.5 ± 0.1 mm; saline, 9.6 ± 0.1 mm) and there was no statistically significant 
difference as compared to the baseline value at each time point (baseline, 9.6 ± 0.2 mm).   
 
Figure 7.7. Infarct area assessment from late-gadolinium enhancement (LGE) MRI. 
Representative images from saline (A) and hydrogel (B) treated animals demonstrate thinning of 
the infarct (enhanced region) without therapy and hydrogel presence (dark regions) out to 8 
weeks with treatment (arrows).  
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Figure 7.8. Contributions of infarct thinning and expansion from in vivo assessment. Infarct 
surface area and volume were quantified by contouring the infarct and LV in LGE images in 
MIPAV. Infarct surface area was similar between saline and hydrogel animals (A). Infarct volume 
was consistent in hydrogel animals due to bulking but decreased with saline due to thinning (B), 
n=3-6/group. Data presented as mean ± SEM. *p<0.05 vs. saline. 
Changes in infarct expansion were assessed by analyzing the LGE MR images to 
measure infarct surface area and infarct volume. Infarct surface areas normalized to the total LV 
surface area were maintained throughout the duration of the study in both the hydrogel and saline 
groups without significant differences between the two groups (Figure 7.8A). Thus, the infarct 
surface area expanded at the same rate as the LV surface area over the course of the study. In 
contrast, infarct volumes normalized to the total LV volumes were maintained in the animals with 
hydrogel injections but decreased in saline treated animals over the four time points (Figure 
7.8B). Beyond 1 week post-MI, the infarct volume in the hydrogel animals was significantly 
different (p<0.05) than the control animals.   
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Figure 7.9. Regional wall function assessed in terms of contractility using systolic strain. Three-
dimensional models of regional maximum principal strain (εmax) from a representative baseline 
animal (A) and saline (B) and hydrogel (C) treated animals generated from SPAMM images using 
an optical flow method to track tag displacement. Strain was calculated for different myocardial 
locations (INF: infarct; BZ: borderzone; REM: remote) at 1, 4, 8, and 12 weeks post-MI.  
7.3.5. Myocardial Systolic Strain as an Estimate of Contractility 
Regional principal strain analysis of the systolic SPAMM data demonstrated increased 
maximum principal strain (εmax) magnitude moving from the borderzone to the remote regions at 
each time point in both the hydrogel treatment and saline control groups. This trend was reflected 
both qualitatively through 3D strain models (Figure 7.9) and quantitatively (Figure 7.10). Beyond 
one week, the systolic borderzone strain magnitudes were higher with hydrogel therapy than 
saline delivery (Figure 7.10B), whereas remote systolic strain magnitude remained similar 
between the two conditions (Figure 7.10C). However, no statistical differences were observed in 
systolic strain magnitudes between the hydrogel and saline groups at each time point or between 
the different time points within each group for the borderzone and remote regions. In all regions at 
all time points and for both conditions, the systolic strain magnitude was significantly reduced 
(p<0.05) relative to the baseline systolic strain magnitude (15.5 ± 1.5%).  
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Figure 7.10. Quantification of regional systolic strain as an estimate of myocardial contractility. 
Regional radial maximum principal strain (εmax) was calculated from systolic SPAMM images for 
the borderzone (A) and remote (B) regions. Beyond one week, systolic borderzone strain was 
higher with hydrogel therapy than saline, implying preserved contractility (A), whereas remote 
systolic strain remained similar between conditions (B), n=3-6/group. In all regions, systolic strain 
was significantly decreased (p<0.05) relative to the baseline (pre-MI) systolic strain of 15.5 ± 
1.5%. Data presented as mean ± SEM.  
7.3.6. Estimation of In Vivo Diastolic Myocardial Properties using FE Modeling  
Animal-specific FE models were used to predict diastolic principal strains, for a given 
applied pressure, as a measure of passive myocardial properties (Figure 7.11). The constitutive 
model parameters (C,   ,   ,    ) and infarct fiber angles were determined via optimization to 
represent the diastolic myocardial properties for each treatment and control animal (Tables 7.1, 
7.2). The MSE values, which describe the degree of error between the MRI-derived and FE-
model predicted strains, range from 6.1 ± 1.5 to 11.3 ± 9.5. The average MSE values are 
consistent with previous studies
36,54
 and imply good agreement between the data and models. 
Also, the values were comparable over the different time points and similar but slightly less for the 
hydrogel data sets as compared to the saline data.  
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Table 7.1. FE model optimization results for infarct region. 
 
  
Time Point 
  
Pre-MI 1 Week 4 Week 8 Week 12 Week 
S
a
li
n
e
 
C (kPa) 0.39 ± 0.10 1.48 ± 1.40 6.08 ± 4.03 9.38 ± 5.10 4.01 ± 2.34 
bf 72.03 ± 29.63 171.53 ± 39.78 13.77 ± 12.54 15.28 ± 19.71 19.01 ± 31.15 
bt 5.08 ± 4.53 24.22 ± 19.62 6.58 ± 5.96 8.32 ± 4.59 8.07 ± 5.64 
bfs 36.69 ± 18.23 22.25 ± 17.55 8.64 ± 2.51 25.27 ± 27.41 17.19 ± 18.13 
epi-angle 
(deg)  
-14.89 ± 21.30 -23.00 ± 25.01 -18.15 ±21.81 -33.54 ± 25.73 
endo-angle 
(deg)  
43.56 ± 2.50 35.66 ± 21.41 26.69 ± 14.61 9.18 ± 15.42 
MSE 8.64 ± 1.53 7.43 ± 4.02 7.62 ± 2.08 11.31 ± 9.46 8.14 ± 3.63 
H
y
d
ro
g
e
l 
C (kPa) 
 
4.05 ± 2.86 4.38 ± 5.00 1.47 ± 1.54 5.36 ± 6.28 
bf 
 
137.67 ± 102.75 122.59 ± 94.49 139.26 ± 99.94 41.27 ± 67.66 
bt 
 
11.38 ± 6.95 9.21 ± 6.31 18.55 ± 23.25 14.46 ± 14.47 
bfs 
 
25.63 ± 21.05 30.02 ± 25.12 25.74 ± 20.63 23.54 ± 29.29 
epi-angle 
(deg)  
-8.88 ± 15.60 -10.07 ± 17.17 -2.16 ± 3.07 -24.28 ± 20.95 
endo-angle 
(deg)  
56.84 ± 16.75 32.07 ± 18.96 25.63 ± 17.16 28.83 ± 24.93 
MSE 
 
6.14 ± 1.53 7.08 ± 2.16 9.81 ± 4.25 8.87 ± 3.55 
 
Table 7.2. FE model optimization results for remote region. 
 
  
Time Point 
  
Pre-MI 1 Week 4 Week 8 Week 12 Week 
S
a
li
n
e
 
C (kPa) 0.39 ± 0.10 2.59 ± 2.13 1.85 ± 2.66 0.52 ± 0.18 0.41 ± 0.24 
bf 72.03 ± 29.63 29.44 ± 39.21 30.15 ± 39.21 37.67 ± 28.94 29.52 ± 11.15 
bt 5.08 ± 4.53 11.04 ± 15.64 9.28 ± 4.21 17.39 ± 15.75 11.14 ± 7.92 
bfs 36.69 ± 18.23 19.35 ± 16.46 28.45 ± 18.67 23.12 ± 15.77 30.86 ± 15.45 
H
y
d
ro
g
e
l 
C (kPa) 
 
0.75 ± 0.62 0.52 ± 0.43 0.69 ± 0.36 1.19 ± 1.37 
bf 
 
31.77 ± 26.07 56.01 ± 33.62 40.55 ± 28.70 42.29 ± 34.98 
bt 
 
22.11 ± 16.87 25.14 ± 14.68 19.62 ± 15.13 17.39 ± 18.33 
bfs 
 
33.84 ± 13.89 45.49 ± 6.55 43.07 ± 11.50 46.02 ± 4.31 
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Figure 7.11. Finite element model to assess passive myocardial properties. Representative finite 
element models of a baseline animal (A) and saline (B) and hydrogel (C) treated animals at 1, 4 
and 8, and 12 weeks. The infarct (red) and remote (blue) regions were assigned different 
myocardial tissue properties. Short axis views taken from roughly the same position at mid-
ventricle demonstrate thinning of the infarct region over time (arrows). 
The optimized infarct fiber angles ranged from -33.5 ± 25.7° to -2.2 ± 3.1° at the 
epicardial surface and 9.2 ± 15.4° to 56.8 ± 16.8° at the endocardial surface. In both animal 
conditions, the fiber angles were closer to 0° at the epicardial than endocardial surface, where 
proximity to 0° dictates the degree of circumferential fiber orientation. Comparison of the fiber 
angles between the hydrogel and saline data sets revealed that the epicardial fiber angles were 
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closer to 0° in the hydrogel data but the endocardial angles were closer to 0° in the saline data. 
Over time, the epicardial angles increased to be further away from 0° whereas the endocardial 
angles decreased closer to 0° in both conditions. Using the optimized parameters, FE models 
showed small strains in the infarct that increased outward to the surrounding remote regions in 
both groups (Figure 7.12). Also, both the remote and infarct strains increased over the study. 
 
Figure 7.12. Short-axis view of the diastolic principal strain generated from FE model simulations.  
Representative short-axis strain maps of a baseline animal (A) and saline (B) and hydrogel (C) 
treated animals at 1 and 12 weeks. The end-diastolic pressure was set to be a constant 10 
mmHg to ensure all data sets experienced the same load.  
To better understand differences in passive myocardial properties, simulated equi-biaxial 
tests were used to estimate stress over a given range of strain values and generate stress-strain 
curves in the fiber and cross-fiber direction. The Green–Lagrange strain ranges were selected 
from the FE model predicted diastolic strains (Figure 7.12). Examination of the stress-strain 
curves revealed stiffening of the infarct in both the hydrogel and saline animals at 1 week 
following infarct induction as compared to baseline (Figure 7.13). With each subsequent time 
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point, the infarct became progressively less stiff in both animal groups, yet remained stiffer than 
at baseline even out to 12 week post-MI. These trends were consistent between the fiber and 
cross-fiber direction but the stiffness in the fiber direction was greater than the cross-fiber 
direction at each time point when comparing within each animal condition. Most importantly, at 
each time point, the stiffness of the infarct in the hydrogel treated animals was greater than that of 
saline injected animals in both the fiber and cross-fiber direction.  
 
Figure 7.13. Simulated equi-biaxial extension tests using FE model optimization parameters. 
Stress-strain equations were implemented to calculate stress at the same set of strain points for 
each case. Average stress-strain plots for the infarct region of saline (top) and hydrogel (bottom) 
animals in the fiber (A, C) and cross-fiber (B, D) direction in saline treated animals over time.  
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Figure 7.14. Quantification of moduli in the infarct region from simulated equi-biaxial tests. Moduli 
were calculated at different strain ranges for extension in both the fiber (A, C) and cross-fiber (B, 
D) direction in saline and hydrogel treated animals over time. Data presented as mean ± SEM.  
Quantification of the moduli from the stress-strain plots over different strain ranges (0-
0.05 and 0.05-0.10) further confirmed greater infarct stiffness in the hydrogel animals as 
compared to the saline control animals at each time point out to 12 weeks, particularly in the fiber 
direction (Figure 7.14). In addition, infarct stiffness was greater with extension simulated in the 
fiber direction relative to the cross-fiber direction and this stiffening response progressively 
declined as time from infarct induction increased. Despite the trends, there were no statistical 
differences between the hydrogel and control moduli. For the 0-0.05 strain range, all moduli were 
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statistically greater than baseline aside from the hydrogel group at 12 weeks in the fiber direction 
(p=0.01) and the saline group at 8 weeks in the fiber direction (p=0.03) and at 4 and 8 weeks in 
the cross-fiber direction (4 weeks, p=0.03; 8 weeks, p=0.04). For the 0.05-0.10 strain range, all 
moduli were significantly different than baseline aside from the moduli in the cross-fiber direction 
for the hydrogel group at 12 weeks (p=0.03) and the saline group at 8 weeks (p=0.03). 
7.4. Discussion  
Over the past decade, it has become evident that the regional mechanical changes in the 
myocardium must be considered when designing biomaterial approaches for MI repair.
4,17,55
 
Previous biomaterial studies designed to alter myocardial mechanics post-MI have demonstrated 
that delivery of injectable materials leads to thicker, stiffer infarcts with limited infarct expansion 
and preserved LV geometry.
18,19,56,57
 Although promising, increased myocardial wall thickness
58-62
 
and/or decreased infarct size
58
 alone do not directly correlate with improved cardiac function. 
Thus, a better understanding of the correlations between myocardial tissue properties and 
improved outcomes is needed to identify optimal biomaterial properties and improve therapy 
design. Towards this goal, this work used MRI and FE modeling as tools to examine the impact of 
an injectable hydrogel system on myocardial tissue properties in terms of regional thickness and 
expansion, contractility, and stiffening.  
In this chapter, a HA hydrogel with high initial mechanics was used to investigate the 
ability of injectable hydrogels to alter myocardial tissue properties as a means to attenuate LV 
remodeling. Previous in vivo studies using HA hydrogels demonstrated that gels that were 
present for over eight weeks with initial mechanics greater than that of the normal myocardium 
(compressive modulus ~7-10 kPa) were more effective at maintaining LV structure post-MI than 
hydrogels with lower mechanics in an ovine infarct model.
18,19
 Moreover, FE modeling using 
experimentally derived biaxial inputs from HA hydrogel-myocardial composites indicated that a 
stiffer hydrogel formulation will further reduce wall stress to attenuate remodeling.
53
 Therefore, a 
single hydrogel formulation was selected for in vivo application with the following anticipated 
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optimal properties: an in vitro degradation profile greater than eight weeks and an initial 
compressive modulus greater than ten times that of the normal myocardium. LGE MR images 
throughout the 12 week study correlated with the in vitro degradation profile (Figure 7.3C,E) of 
this formulation in that the material appeared to be present in the infarct region at the 8 week time 
point but was no longer present at 12 weeks (Figure 7.7). This was further confirmed by histology 
where gel was not observed at the terminal time point (Figure 7.4). Even though one hydrogel 
formulation was applied, the use of in vivo-derived MRI data and FE modeling as tools to better 
understand impact of hydrogels on LV remodeling can be applied to any injectable system.  
Remodeling post-MI was evaluated using MRI at 1, 4, 8, and 12 weeks following injection 
of either hydrogel for the treatment animals or saline for the control animals. Outcomes were 
assessed into the chronic remodeling period to contrast with the majority of previous cardiac 
biomaterial studies which focus on acute remodeling out to 4 or 8 weeks post-MI.
63
 The impact of 
hydrogel delivery on LV remodeling was first examined in terms of global ventricular structure and 
function. As expected, intramyocardial hydrogel injection resulted in preserved LV geometry and 
improved cardiac function as compared to saline delivery at all time points (Figure 7.5). Although 
both groups demonstrated signs of adverse remodeling relative to baseline conditions, the ability 
of hydrogel therapy to minimize LV dilation was maintained throughout the 12 week study, in 
contrast to previous work where structural LV benefits observed at 4 weeks were lost by the 2 
month terminal time point.
61
 These findings correlated with our previous echocardiographic 
studies which demonstrated better maintenance of LV structure with HA hydrogel injection 
compared to infarct controls in an ovine anteroapical infarct model.
18,19
 To expand upon our 
previous work, this chapter used MRI to serially examine the impact of hydrogel delivery on in 
vivo infarct thinning and expansion, myocardial contractility, and passive myocardial stiffening to 
better understand how hydrogel therapy led to these positive structural and functional outcomes.  
Thinning of the myocardium post-MI has been identified to be an important contributor to 
increased wall stress, both in the infarct and surrounding borderzone regions. Thus, myocardial 
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thickness was measured to assess the ability of hydrogel therapy to bulk and stabilize the heart 
wall to attenuate remodeling. As anticipated, ex vivo assessment at the terminal time point 
revealed increased thickness in the infarct, borderzone, and remote myocardium with hydrogel 
therapy, and in vivo assessment over the course of the 12 week study demonstrated increased 
infarct thickness in the infarct at each time point due to hydrogel bulking (Figure 7.6A,B). Many 
studies have demonstrated similar increases in ex vivo infarct thickness with material 
delivery
18,19,63
, but few have quantified parameters of infarct thinning noninvasively over time 
similar to this study.
47
 Moreover, the progressive decrease in infarct wall thickness observed over 
time in both groups is consistent with the global LV outcomes and provides insight into the 
biological consequence of remodeling. A contributing factor to remodeling is the increase is the 
activation of matrix metalloproteinases (MMPs) in the myocardium which leads to extracellular 
matrix (ECM) breakdown;
60,64,65
 this offers a biological explanation for the global LV dilation and 
associated infarct thinning and expansion.  
The infarct expansion into the surrounding borderzone regions that occurs as the heart 
dilates and myocardial walls thin has been shown to both precipitate and sustain the entire 
remodeling process.
6,66-68
 Thus, the impact of hydrogel injection on infarct expansion (i.e., 
stretching) was assessed by measuring the infarct surface area and volume and normalizing to 
total LV surface area and volume, respectively. Infarct surface area is primarily a measure of 
infarct expansion whereas infarct volume accounts for both infarct thinning and expansion. From 
the global ventricular assessment of EDV and ESV (Figure 7.5A,B), it was known that the LV 
was dilating outward in both groups over the 12 weeks. The minimal change in infarct surface 
area over time and between the two groups suggests that the rate of infarct expansion was 
similar to the rate of LV dilation in both hydrogel and saline treated animals (Figure 7.8A). 
However, since there was less overall LV dilation with hydrogel delivery at each time point 
(Figure 7.5A,B), the infarct in the hydrogel treated animals expanded less than in the saline 
animals. Furthermore, since the infarct at the time of induction comprised 20-25% of the LV 
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surface area by the surgeon’s visual assessment,
48
 infarct surface areas on the order of ~30% at 
1 week indicate that the majority of the infarct expansion occurred within the first week after MI.  
In contrast to infarct surface area, assessment of infarct volume resulted in differences 
between the hydrogel and saline groups. Since infarct volume accounts for both infarct thinning 
and expansion, the maintained infarct volume relative to the total LV volume over the four time 
points with hydrogel therapy (Figure 7.8B) is consistent with the minimal changes in infarct 
thickness (Figure 7.6C,D) and infarct surface area as a measure of expansion (Figure 7.8A). 
Similarly, the decrease in infarct volume over time with saline delivery correlates with the extreme 
thinning observed over time due to matrix degradation in the infarct (Figure 7.6), since minimal 
changes were observed in rate of infarct expansion (Figure 7.8B). Thus, assessment of infarct 
surface area demonstrated less infarct expansion with hydrogel therapy due to less LV dilation as 
compared to controls whereas assessment of infarct volume over time further confirmed the 
trends in infarct thickness in that injectable hydrogels function by bulking the myocardial wall.  
Abnormal stress distributions in the borderzone myocardium which result from infarct 
thinning and expansion may lead to global contractile dysfunction and heart failure.
5,6,8,66,69
 Thus, 
regional myocardial systolic strain was measured as an estimate of myocardial contractility and 
regional wall function. The low principal strain magnitudes at 1 week seen in all regions and in 
both groups can be explained by myocardial stunning in the acute post-MI period.
71
 Past 1 week, 
hydrogel delivery was shown to improve borderzone myocardial contractility throughout the 
duration of the study relative to saline injections (Figure 7.10B). By bulking the myocardial wall in 
the region of infarction (Figure 7.6), the injectable HA hydrogels facilitated an environment where 
normally perfused myocardium could continue to contract. Combined with a limitation in outward 
infarct extension (Figure 7.8B), this suggests that hydrogel therapy prevented the expansion of 
contractile dysfunction to progressively larger regions of perfused borderzone myocardium, which 
in turn led to improved global cardiac outcomes (Figure 7.5). The increased systolic borderzone 
strain in the hydrogel treated animals as compared to controls supports the theory that LV 
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remodeling is driven by thinning of the myocardial wall in the region of infarction leading to 
increased wall compliance. However, systolic myocardial wall strain and global LV function are 
indirect measures of in vivo myocardial compliance and wall stress, parameters that are 
traditionally assessed using ex vivo biaxial testing. To circumvent the need for ex vivo 
assessment, in vivo strain data was subsequently input into a FE model to simulate LV diastolic 
filling and measure forces in the myocardial wall.  
 Due to the role of increased infarct compliance in sustaining adverse remodeling,
70,72
 
MRI-derived diastolic strains were input into a FE model to directly quantify in vivo passive 
mechanical properties in the myocardium and provide an understanding of the impact of hydrogel 
delivery on in vivo wall compliance (Figure 7.11). Assessment of regional stress-strain 
relationships using simulated equi-biaxial extension tests demonstrated that hydrogel injection led 
to increased myocardial stiffness in the infarct region relative to controls, with a larger impact on 
mechanics in the fiber direction as compared to the cross-fiber direction (Figures 7.13, 7.14). In 
both animal groups, extensive stiffening of the infarct was seen at 1 week post-MI compared to 
baseline and the stiffening response progressively decreased over time. This initial stiffening 
response can be attributed to the collagen deposition occurs in the infarct region during 
remodeling as the infarct attempts unsuccessfully to repair itself
73,74
 whereas the gradual 
decrease in infarct stiffness could result from a combination of matrix degradation due to MMP 
activation
60,64,65
 and extensive loss of type I collagen post-MI,
75
 leaving the myocardium at a 
mechanical disadvantage. Furthermore, the increased stiffening with hydrogel injection indicates 
that hydrogel delivery successfully altered the material properties of the infarct at a time point 
prior to when the body had compensated for remodeling and highlights the importance of 
appropriately timing hydrogel delivery in the remodeling process to maximize benefit. In 
combination with the systolic strain assessment of contractility, this suggests that the stiffening of 
the infarct with hydrogel injections led to stabilization of the borderzone myocardium, which in 
turn preserved the contractile function in this region (Figure 7.10B). 
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7.5. Conclusions 
An injectable, degradable hydrogel system was successfully applied to an in vivo porcine 
infarct model to examine its effect on global LV remodeling, infarct thinning and expansion, and 
regional myocardial wall function using MRI and FE modeling. MRI analysis demonstrated that 
injectable HA hydrogels can improve LV structure and function, preserve infarct thickness, limit 
infarct dilatation, and preserve borderzone contractility. Input of MRI-derived diastolic strain 
parameters into a FE model showed hydrogel delivery led to increased myocardial stiffness in the 
infarct that was better maintained throughout the 12 week study as compared to saline-treated 
controls. Overall, evaluation of myocardial properties using MRI and FE modeling provides 
additional insight into the mechanism by which injectable materials improve long-term structural 
and functional outcomes post-MI and ultimately, can serve as a tool to determine optimal 
biomaterial properties for MI repair. 
 
 
  
220 
 
7.6. References 
1.  Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev 
Cardiol 2011;8(1):30-41. 
2.  Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease 
and stroke statistics-2014 update: A report from the American Heart Association. Circulation 
2014;129(3):e28-e292. 
3.  Gheorghiade M, Bonow RO. Chronic heart failure in the United States: A manifestation of 
coronary artery disease. Circulation 1998;97(3):282-289. 
4.  Buckberg GD. Architecture must document functional evidence to explain the living rhythm. 
Eur J Cardiothorac Surg 2005;27(2):202-209. 
5.  Jackson BM, Gorman JH,3rd, Salgo IS, Moainie SL, Plappert T, St John-Sutton M, et al. 
Border zone geometry increases wall stress after myocardial infarction: Contrast 
echocardiographic assessment. Am J Physiol Heart Circ Physiol 2003;284(2):H475-H479. 
6.  Kramer CM, Lima JA, Reichek N, Ferrari VA, Llaneras MR, Palmon LC, et al. Regional 
differences in function within noninfarcted myocardium during left ventricular remodeling. 
Circulation 1993;88(3):1279-1288. 
7.  Pilla JJ, Blom AS, Gorman JH,3rd, Brockman DJ, Affuso J, Parish LM, et al. Early 
postinfarction ventricular restraint improves borderzone wall thickening dynamics during 
remodeling. Ann Thorac Surg 2005;80(6):2257-2262. 
8.  Epstein FH, Yang Z, Gilson WD, Berr SS, Kramer CM, French BA. MR tagging early after 
myocardial infarction in mice demonstrates contractile dysfunction in adjacent and remote 
regions. Magn Reson Med 2002;48(2):399-403. 
221 
 
9.  Kelley ST, Malekan R, Gorman JH,3rd, Jackson BM, Gorman RC, Suzuki Y, et al. 
Restraining infarct expansion preserves left ventricular geometry and function after acute 
anteroapical infarction. Circulation 1999;99(1):135-142. 
10.  Klodell CT,Jr, Aranda JM,Jr, McGiffin DC, Rayburn BK, Sun B, Abraham WT, et al. 
Worldwide surgical experience with the Paracor HeartNet cardiac restraint device. J Thorac 
Cardiovasc Surg 2008;135(1):188-195. 
11.  Sartipy U, Albage A, Lindblom D. The Dor procedure for left ventricular reconstruction. Ten-
year clinical experience. Eur J Cardiothorac Surg 2005;27(6):1005-1010. 
12.  Starling RC, Jessup M, Oh JK, Sabbah HN, Acker MA, Mann DL, et al. Sustained benefits of 
the CorCap Cardiac Support Device on left ventricular remodeling: Three year follow-up 
results from the Acorn clinical trial. Ann Thorac Surg 2007;84(4):1236-1242. 
13.  Batista R. Partial left ventriculectomy--the Batista procedure. Eur J Cardiothorac Surg 
1999;15 Suppl 1:S12-9; discussion S39-43. 
14.  Shapira K, Dikovsky D, Habib M, Gepstein L, Seliktar D. Hydrogels for cardiac tissue 
regeneration. Biomed Mater Eng 2008;18(4-5):309-314. 
15.  Nelson DM, Ma Z, Fujimoto KL, Hashizume R, Wagner WR. Intra-myocardial biomaterial 
injection therapy in the treatment of heart failure: Materials, outcomes and challenges. Acta 
Biomater 2011;7(1):1-15. 
16.  Tous E, Purcell B, Ifkovits JL, Burdick JA. Injectable acellular hydrogels for cardiac repair. J 
Cardiovasc Transl Res 2011;4(5):528-542. 
17.  Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial infarcts. 
Annu Rev Biomed Eng 2005;7:223-253. 
222 
 
18.  Ifkovits JL, Tous E, Minakawa M, Morita M, Robb JD, Koomalsingh KJ, et al. Injectable 
hydrogel properties influence infarct expansion and extent of postinfarction left ventricular 
remodeling in an ovine model. Proc Natl Acad Sci U S A 2010;107(25):11507-11512. 
19.  Tous E, Ifkovits JL, Koomalsingh KJ, Shuto T, Soeda T, Kondo N, et al. Influence of 
injectable hyaluronic acid hydrogel degradation behavior on infarction-induced ventricular 
remodeling. Biomacromolecules 2011;12(11):4127-4135. 
20.  Reeder SB, Du YP, Lima JA, Bluemke DA. Advanced cardiac MR imaging of ischemic heart 
disease. Radiographics 2001;21(4):1047-1074. 
21.  Steffans JC, Sakuma H, Bourne MW, Higgins CB. Magnetic resonance imaging in ischemic 
heart disease. Am Heart J 1996;132(1 Pt 1):156-173. 
22.  Unlu M, Anik Y, Demirci A, Ural D, Kahraman G, Komsuoglu B. Cardiac MRI in ischemic 
heart disease with severe coronary artery stenosis. Acad Radiol 2006;13(11):1387-1393. 
23.  Viswamitra S, Higgins CB, Meacham DF, Mehta JL. Magnetic resonance imaging in 
myocardial ischemia. Curr Opin Cardiol 2004;19(5):510-516. 
24. Rerkpattanapipat P, Link KM, Hamilton CA, Hundley WG. Detecting left ventricular 
myocardial ischemia during intravenous dobutamine with cardiovascular magnetic 
resonance imaging (MRI). J Cardiovasc Magn Reson 2001;3(1):21-25. 
25.  Sakuma H. Magnetic resonance imaging for ischemic heart disease. J Magn Reson Imaging 
2007;26(1):3-13. 
26.  Ishida M, Kato S, Sakuma H. Cardiac MRI in ischemic heart disease. Circ J 
2009;73(9):1577-1588. 
223 
 
27.  Watzinger N, Maier R, Reiter U, Reiter G, Fuernau G, Wonisch M, et al. Clinical applications 
of cardiovascular magnetic resonance. Curr Pharm Des 2005;11(4):457-475. 
28.  Ligabue G, Fiocchi F, Ferraresi S, Barbieri A, Romagnoli R, Torricelli P. How to quantify 
infarct size on delayed-enhancement MR images: A comparison between visual and 
quantitative approach. Radiol Med 2007;112(7):959-968. 
29.  Axel L, Dougherty L. Heart wall motion: Improved method of spatial modulation of 
magnetization for MR imaging. Radiology 1989;172(2):349-350. 
30.  Zerhouni EA, Parish DM, Rogers WJ, Yang A, Shapiro EP. Human heart: tagging with MR 
imaging - A method for noninvasive assessment of myocardial motion. Radiology 
1988;169(1):59-63. 
31.  Wall ST, Walker JC, Healy KE, Ratcliffe MB, Guccione JM. Theoretical impact of the 
injection of material into the myocardium: A finite element model simulation. Circulation 
2006;114(24):2627-2635. 
32.  Wenk JF, Wall ST, Peterson RC, Helgerson SL, Sabbah HN, Burger M, et al. A method for 
automatically optimizing medical devices for treating heart failure: Designing polymeric 
injection patterns. J Biomech Eng 2009;131(12):121011. 
33.  Wenk JF, Eslami P, Zhang Z, Xu C, Kuhl E, Gorman,Joseph H.,,III, et al. A novel method for 
quantifying the in-vivo mechanical effect of material injected into a myocardial infarction. Ann 
Thorac Surg 2011;92(3):935-941. 
34.  Wenk JF, Klepach D, Lee LC, Zhang Z, Ge L, Tseng EE, et al. First evidence of depressed 
contractility in the border zone of a human myocardial infarction. Ann Thorac Surg 
2012;93(4):1188-1194. 
224 
 
35.  Walker JC, Ratcliffe MB, Zhang P, Wallace AW, Fata B, Hsu EW, et al. MRI-based finite-
element analysis of left ventricular aneurysm. Am J Physiol Heart Circ Physiol 
2005;289(2):H692-700. 
36.  Sun K, Stander N, Jhun C, Zhang Z, Suzuki T, Wang G, et al. A computationally efficient 
formal optimization of regional myocardial contractility in a sheep with left ventricular 
aneurysm. J Biomech Eng -Trans ASME 2009;131(11):111001. 
37.  Mojsejenko D, McGarvey JR, Dorsey SM, Gorman JH,3rd, Burdick JA, Pilla JJ, et al. 
Estimating passive mechanical properties in a myocardial infarction using MRI and finite 
element simulations. Biomech Model Mechanobiol 2014. 
38.  Xi J, Lamata P, Niederer S, Land S, Shi W, Zhuang X, et al. The estimation of patient-
specific cardiac diastolic functions from clinical measurements. Med Image Anal 
2013;17(2):133-146. 
39.  Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater 
2011;23(12):H41-H56. 
40. Li Y, Toole BP, Dealy CN, Kosher RA. Hyaluronan in limb morphogenesis. Dev Biol 
2007;305(2):411-420. 
41.  Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer 
2004;4(7):528-539. 
42.  Toole BP. Hyaluronan in morphogenesis. J Intern Med 1997;242(1):35-40. 
43.  Temenoff JS, Kasper FK, Mikos AG. Fumarate-based macromers as scaffolds for tissue 
engineering applications. In: Ashammakhi N, Reis R, Chiellini E, editors. Topics in Tissue 
Engineering. 3rd ed. Oulu, Finland: University of Oulu; 2007. p. 6.1-6.16. 
225 
 
44.  Anseth KS, Bowman CN, Brannon-Peppas L. Mechanical properties of hydrogels and their 
experimental determination. Biomaterials 1996;17(17):1647-1657. 
45.  Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem 1962;4:330-334. 
46.  Platzer M, Ozegowski JH, Neubert RH. Quantification of hyaluronan in pharmaceutical 
formulations using high performance capillary electrophoresis and the modified uronic acid 
carbazole reaction. J Pharm Biomed Anal 1999;21(3):491-496. 
47.  McGarvey JM, Kondo N, Witschey WRT, Takebe M, Aoki C, Burdick JA, et al. Injectable 
microsphere gel progressively improves global ventricular function, regional contractile 
strain, and mitral regurgitation after myocardial infarction. in review . 
48.  Witschey WRT, Pilla JJ, Ferrari G, Koomalsingh K, Haris M, Hinmon R, et al. Rotating frame 
spin lattice relaxation in a swine model of chronic, left ventricular myocardial infarction. 
Magn Reson Med 2010;64(5):1454-1461. 
49.  Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active 
contour segmentation of anatomical structures: Significantly improved efficiency and 
reliability. Neuroimage 2006;31(3):1116-1128. 
50.  Xu C, Pilla JJ, Isaac G, Gorman JH,3rd, Blom AS, Gorman RC, et al. Deformation analysis 
of 3D tagged cardiac images using an optical flow method. J Cardiovasc Magn Reson 
2010;12:19. 
51.  Lee W, Pernot M, Couade M, Messas E, Bruneval P, Bel A, et al. Mapping myocardial fiber 
orientation using echocardiography-based shear wave imaging. IEEE Trans Med Imaging 
2012;31(3):554-562. 
226 
 
52.  Hooks DA, Trew ML, Caldwell BJ, Sands GB, LeGrice IJ, Smaill BH. Laminar arrangement 
of ventricular myocytes influences electrical behavior of the heart. Circ Res 
2007;101(10):E103-E112. 
53.  Kichula ET, Wang H, Dorsey SM, Szczesny SE, Elliott DM, Burdick JA, et al. Experimental 
and computational investigation of altered mechanical properties in myocardium after 
hydrogel injection. Ann Biomed Eng 2014;42(7):1546-1556. 
54.  Wenk JF, Sun K, Zhang Z, Soleimani M, Ge L, Saloner D, et al. Regional left ventricular 
myocardial contractility and stress in a finite element model of posterobasal myocardial 
infarction. J Biomech Eng -Trans ASME 2011;133(4):044501. 
55.  Gupta KB, Ratcliffe MB, Fallert MA, Edmunds LH,Jr, Bogen DK. Changes in passive 
mechanical stiffness of myocardial tissue with aneurysm formation. Circulation 
1994;89(5):2315-2326. 
56.  Morita M, Eckert CE, Matsuzaki K, Noma M, Ryan LP, Burdick JA, et al. Modification of 
Infarct Material Properties Limits Adverse Ventricular Remodeling. Ann Thorac Surg 
2011;92(2):617-625. 
57.  Ryan LP, Matsuzaki K, Noma M, Jackson BM, Eperjesi TJ, Plappert TJ, et al. Dermal filler 
injection: A novel approach for limiting infarct expansion. Ann Thorac Surg 2009;87(1):148-
155. 
58.  Yu J, Christman KL, Chin E, Sievers RE, Saeed M, Lee RJ. Restoration of left ventricular 
geometry and improvement of left ventricular function in a rodent model of chronic ischemic 
cardiomyopathy. J Thorac Cardiovasc Surg 2009;137(1):180-187. 
227 
 
59.  Landa N, Miller L, Feinberg MS, Holbova R, Shachar M, Freeman I, et al. Effect of injectable 
alginate implant on cardiac remodeling and function after recent and old infarcts in rat. 
Circulation 2008;117(11):1388-1396. 
60.  Mukherjee R, Zavadzkas JA, Saunders SM, McLean JE, Jeffords LB, Beck C, et al. 
Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in 
pigs. Ann Thorac Surg 2008;86(4):1268-1276. 
61.  Dobner S, Bezuidenhout D, Govender P, Zilla P, Davies N. A synthetic non-degradable 
polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling. J Card 
Fail 2009;15(7):629-636. 
62.  Rane AA, Christman KL. Biomaterials for the treatment of myocardial infarction: A 5-year 
update. J Am Coll Cardiol 2011;58(25):2615-2629. 
63.  Dorsey SM, Burdick JA. Hydrogels for cardiac repair. In: Khademhosseini A, Demirci U, 
editors. Applications of Hydrogels in Regenerative Medicine; in press. 
64.  Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, et al. Myocardial 
infarct expansion and matrix metalloproteinase inhibition. Circulation 2003;107(4):618-625. 
65.  Mukherjee S, Venugopal JR, Ravichandran R, Ramakrishna S, Raghunath M. Multimodal 
biomaterial strategies for regeneration of infarcted myocardium. Journal of Materials 
Chemistry 2010;20(40):8819-8831. 
66.  Jackson BM, Gorman JH,3rd, Moainie SL, Guy TS, Narula N, Narula J, et al. Extension of 
borderzone myocardium in postinfarction dilated cardiomyopathy. J Am Coll Cardiol 
2002;40(6):1160-7; discussion 1168-71. 
67.  Weisman HF, Healy B. Myocardial infarct expansion, infarct extension, and reinfarction - 
Pathophysiologic concepts. Prog Cardiovasc Dis 1987;30(2):73-110. 
228 
 
68.  Erlebacher JA, Weiss JL, Weisfeldt ML, Bulkley BH. Early Dilation of the Infarcted Segment 
in Acute Transmural Myocardial-Infarction - Role of Infarct Expansion in Acute Left-
Ventricular Enlargement. J Am Coll Cardiol 1984;4(2):201-208. 
69.  Weisman HF, Bush DE, Mannisi JA, Bulkley BH. Global cardiac remodeling after acute 
myocardial-infarction - A study in the rat model. J Am Coll Cardiol 1985;5(6):1355-1362. 
70.  Pilla JJ, Koomalsingh KJ, McGarvey JM, Witschey WRT, Dougherty L, Gorman JH,3rd, et 
al. Regional myocardial three-dimensional principal strains during post-infarction left 
ventricular remodeling. in review . 
71.  Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial 
viability. Circulation 2008;117(1):103-114. 
72.  Pilla JJ, Gorman JH,3rd, Gorman RC. Theoretic impact of infarct compliance on left 
ventricular function. Ann Thorac Surg 2009;87(3):803-811. 
73.  Holmes JW, Nunez JA, Covell JW. Functional implications of myocardial scar structure. 
American Journal of Physiology-Heart and Circulatory Physiology 1997;272(5):H2123-
H2130. 
74.  Fomovsky GM, Rouillard AD, Holmes JW. Regional mechanics determine collagen fiber 
structure in healing myocardial infarcts. J Mol Cell Cardiol 2012;52(5):1083-1090. 
75.  Herpel E, Pritsch M, Koch A, Dengler T, Schirmacher P, Schnabel P. Interstitial fibrosis in 
the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-
stage dilated, ischaemic and valvular cardiomyopathy. Histopathology 2006;48(6):736-747. 
  
229 
 
CHAPTER 8 
 
Conclusions, Limitations, and Future Directions 
 
8.1. Conclusions  
Left ventricular (LV) remodeling initiated by a myocardial infarction (MI) continues to be a 
large clinical burden due to the high rate of progression to heart failure. Current treatment 
approaches focus on pharmacological and/or surgical therapies which are either insufficient to 
limit remodeling or highly invasive to deploy, respectively. Therefore, as described in Chapter 1, 
both noninvasive therapies and noninvasive techniques to assess the effects of therapies are 
needed to address the clinical burden of MI induced heart failure.  
 As discussed in Chapter 3, injectable hydrogels offer a noninvasive approach to target LV 
remodeling by simultaneously mechanically stabilizing the myocardial wall and modulating 
maladaptive biological processes as a delivery vehicle for therapies, such as cells and growth 
factors. Even though injectable materials have shown success in locally delivering cells and 
molecules to the heart, concerns with retention, engraftment, and dosage motivate the use of 
acellular materials as bulking agents to counteract the geometric changes post-MI in this 
dissertation. In addition, various natural and synthetic injectable materials have been investigated 
to attenuate remodeling, but the mechanism by which these injectable systems lead to positive 
structural and functional outcomes post-MI remains unclear. One step towards understanding this 
mechanism is the application of noninvasive imaging techniques to evaluate the reciprocal 
interaction between the injected material and the surrounding myocardial tissue. Of the imaging 
modalities, magnetic resonance imaging (MRI) is particularly well suited for material assessment 
and temporal evaluation of myocardial properties due to its high spatial and temporal resolution.  
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 To assess differences in material properties once delivered to the myocardium, injectable 
systems with tunable properties are needed. Thus, Chapter 4 focused on the in vitro 
characterization of tunable, injectable hyaluronic acid (HA) hydrogels. Macromers were 
synthesized with a range of modifications by coupling either hydroxyethyl methacrylate (HeMA) or 
methacrylate (Me) to HA to generate the gel precursors HeMA-HA and MeHA, respectively. 
Hydrogels were formed by covalently crosslinking the methacrylate groups using a two 
component redox initiator system of APS and TEMED. In HeMA-HA homopolymer hydrogels, the 
initiator concentration, macromer modification, and macromer concentration were altered to 
investigate their effect on hydrogel gelation, degradation, and mechanics. Increased initiator 
concentration, macromer modification, or macromer concentration led to accelerated gelation, 
prolonged degradation, and higher initial mechanics that were maintained over longer durations. 
Altering a combination of the macromer modification and concentration was used to tailor HeMA-
HA hydrogel degradation while maintaining similar initial mechanics. For hydrogels with 
approximately the same initial mechanics (30 kPa, 60 kPa, or 90 kPa), formulations with a higher 
modification but lower macromer concentration maintained their mechanics for longer and 
degraded slower (on the order of 6 weeks or more) than formulations with a lower modification 
but higher macromer concentration. Another approach to tuning hydrogel degradation was to 
form copolymer hydrogels of HeMA-HA and MeHA, where increased incorporation of non-
hydrolytically susceptible MeHA led to slower degradation. The tunability of HA hydrogel 
properties was then applied to investigate the ability of MRI to detect these differences ex vivo in 
myocardial explants (Chapters 5 and 6) and to select a single hydrogel formulation with 
anticipated positive outcomes
1,2
 for use in an in vivo infarct model (Chapter 7).  
Two MRI approaches were then explored to visualize and characterize the properties of 
HA hydrogels in myocardial tissue explants. Theoretical models have demonstrated that hydrogel 
dispersion in tissue directly correlates with their ability to attenuate LV remodeling.
3
 Thus, in 
Chapter 5, conventional MRI was used to quantify differences in three-dimensional hydrogel 
distribution in tissue based on varied gelation properties. Gelation onset was altered in MeHA 
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hydrogels such that an increased initiator concentration or macromer modification led to 
accelerated gelation, with initiator concentration having a greater impact on the time to gelation. 
Differences in the time to gelation led to differences in the distribution of the crosslinked (MRI 
detectable) portion of each hydrogel, with higher initiator concentration and higher macromer 
modification (at low initiator concentration) leading to a larger crosslinked volume. To investigate 
differences in the mechanism of gelation, hydrogel volumes were also assessed for self-
assembling guest-host hydrogels. Unlike covalently crosslinked HA hydrogels which distributed 
along the myocardial fibers and formed a composite with the surrounding myocardial tissue, 
physically crosslinked guest-host HA hydrogels formed distinct plugs with calculated volumes 
comparable to the injected volume. Thus, MRI was successfully shown to characterize 
differences in hydrogel distribution based on gelation timing and mechanism of formation.  
In Chapter 6, CEST MRI was used to visualize injectable HeMA-HA hydrogels either 
alone or after injection into tissue based on manipulation of the exchangeable hydroxyl (–OH) 
protons on the HA backbone. The CEST effect was shown to track with changes in material 
properties such that as hydrogel macromer concentration increased, the CEST contrast 
increased linearly. Furthermore, CEST MRI was used to detect HA hydrogels injected once into 
cardiac explants with an increase in signal at the hydrogel site relative to the surrounding 
myocardial signal. Unlike conventional MRI, CEST was shown to simultaneously visualize and 
discriminate between different injectable materials based on their specific chemical composition. 
More specifically, the CEST signal was tuned to detect differences in two hydrogel systems 
based on their dominant functional groups. The covalent addition of an arginine-based peptide to 
HeMA-HA hydrogels led to a two-fold increase in signal when the exchangeable amine (–NH2) 
protons in the peptide were targeted. Therefore, CEST MRI was demonstrated to be a valuable 
tool for studying injectable hydrogel properties and could enable further optimization of 
biomaterial therapies aimed at clinical translation. 
232 
 
 After examining the use of MRI to characterize the properties of injectable hydrogels 
once delivered to myocardial tissue, the focus of this dissertation shifted to using MRI to evaluate 
the effects of HA hydrogels on myocardial tissue properties as a means to understand their role in 
attenuating adverse remodeling following infarction. In Chapter 7, we investigated the long-term 
effects of degradable HeMA-HA hydrogels on global LV remodeling, infarct thinning and 
expansion, myocardial wall motion, and myocardial stiffness in a porcine infarct model out to 12 
weeks post-MI using MRI and finite element (FE) modeling. Hydrogel treatment generally led to 
decreased LV volumes, improved ejection fractions, and increased wall thicknesses as compared 
to saline injected controls. Beyond 1 week post-MI, systolic borderzone strain was higher with 
hydrogel therapy than saline, implying preserved borderzone contractility. Furthermore, FE model 
simulations with diastolic strain inputs demonstrated that hydrogel therapy increased infarct 
stiffness out to 12 weeks post-MI. Hence, evaluation of myocardial tissue properties through MRI 
and FE modeling provided insight into the effect of injectable HA hydrogels therapies on 
myocardial structure and function post-MI and more universally, could serve as tools to 
investigate the impact of any injectable system on myocardial tissue properties.  
8.2. Limitations  
Specific Aim 1: Synthesize and characterize degradable HA hydrogels with a range of properties, 
particularly gelation, degradation, and mechanics.  
8.2.1. Limitations in In Vitro Characterization Studies  
A limitation in the in vitro characterization studies performed for Aim 1 was that 
degradation and mechanics were coupled in the HA hydrogel systems used (i.e., HeMA-HA and 
MeHA). In pure HeMA-HA hydrogels, even though a wide range of degradation profiles (1.7 to 
22.5 weeks) and initial mechanics (2.6 to 457.6 kPa) were achieved by altering the macromer 
modification and concentration, the system was limited in that the degradation could only be 
tuned within a narrow range without altering the mechanics. To achieve similar initial mechanics, 
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the time to hydrogel degradation had to be relatively long (i.e., greater than 7 weeks). Similarly, to 
achieve large differences in degradation (i.e., 6 weeks or more), the initial mechanics had to be 
high relative to normal myocardial mechanics (i.e., 30 kPa or greater). Thus, it was not possible to 
form hydrogels with different rates of degradation but similar initial mechanics that matched those 
of the native myocardium (compressive modulus ~7-10 kPa). As will be discussed in Section 
8.3.2, to achieve HeMA-HA hydrogels with degradation profiles that fit different stages of LV 
remodeling (i.e., ~2-3 weeks for acute remodeling and ~10-12 weeks for chronic remodeling),
4
 
the desire to have similar initial mechanics had to be sacrificed. Moreover, the incorporation of 
MeHA to form HeMA-HA/MeHA copolymer hydrogels further prolonged the degradation, where 
gels were stable over the span of several months, which was not physiologically relevant for a 
degradable system for MI repair. To decouple degradation and mechanics, other HA hydrogel 
systems should be explored with different mechanisms of crosslinking.
5,6
 
Specific Aim 2: Visualize HA hydrogels using MRI as a means to examine hydrogel dispersion 
and detect differences in hydrogel chemical composition ex vivo. 
8.2.2. Limitations in T2-Weighted Imaging  
In Aim 2 of this dissertation, the T2-weighted imaging of HA hydrogels was limited to ex 
vivo studies and did not progress to in vivo studies. An in vivo study at 3 T was attempted where 
HeMA-HA hydrogels were injected into the posterolateral wall of a healthy sheep but magnetic 
field inhomogeneities, particularly in the free wall at the injection locations, severely limited 
material detection. Magnetic field inhomogeneity in the heart is primarily due to differences in 
magnetic field susceptibility
7,8
 between the myocardium, blood, lung parenchyma and, in the case 
of animals that have undergone a recent thoracotomy, air spaces in the chest wall. Delivery of 
injectable materials via catheter may decrease magnetic field susceptibility differences to improve 
homogeneity by eliminating air in the chest cavity. However, since the magnetic susceptibility of 
cardiac tissue is spatially varying and unique to each animal (i.e., dependent on the animal’s size 
and organ distribution), it is not possible to eliminate these effects completely. Shimming, or 
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mapping the magnetic field inhomogeneity to compensate for it, does help improve magnetic field 
homogeneity but is particularly challenging in the posterolateral heart wall due to the proximity to 
the lung parenchyma, which leads to a significant magnetic field gradient.
9
 Moreover, maintaining 
field homogeneity is more difficult at higher field strengths because, from an engineering 
perspective, it is more challenging to induce a strong homogeneous magnetic field than a weak 
one.
7
 This not only impacts the main B0 field but also the homogeneity of the RF (B1) field, which 
scales linearly with the main field. Thus, moving to lower but still clinically relevant magnetic field 
strength, such as 1.5 T, would decrease the inhomogeneity effects. Finally, certain pulse 
sequences are more susceptible to field inhomogeneity. As opposed to cardiac sequences such 
as those used for cine, perfusion, or SPAMM-tagging MRI, T2 sequences are especially sensitive 
to field inhomogeneity because the RF refocusing pulses depend on precise B1 homogeneity and 
the signal readout depends on excellent B0 homogeneity.
9
  
Another limitation of the T2-weighted MRI of HA hydrogels in myocardial explants was 
that hydrogel visualization and quantification was only possible using normal, non-infarcted 
myocardial tissue. Whereas hydrogel distribution was easily quantified in explants following in 
vivo injection then sacrifice in a normal animal (Section 5.3.3), it was barely detectable in 
infarcted myocardial tissue where HA hydrogels were injected into mini-pigs immediately 
following MI and sacrificed at various time points out to two weeks post-MI. The adverse 
physiologic state of the infarcted myocardium, consisting of disordered collagen and myofiber 
architecture, fibrosis, and inflammation leading to iron deposition,
10-13
 prevented quantification of 
hydrogel volumes in infarcted explants, potentially due to similarities in T2 relaxation properties 
between the injected hydrogel and the surrounding damaged myocardial tissue.  
8.2.3. Limitations in CEST Imaging  
There were also several limitations and challenges encountered for the second non-
contrast MRI technique explored in Aim 2. CEST imaging of HeMA-HA hydrogels phantoms at 
both 7 T and 3 T demonstrated that the CEST effect was not uniform within the hydrogels, 
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perhaps due to inhomogeneous crosslinking. Furthermore, ex vivo studies showed that the CEST 
effect from HeMA-HA hydrogels was fairly small (i.e., less than 3%) and also variable within the 
injection site, as may be expected due to crosslinking variations as the material dispersed 
between the myocardial fibers. This made translation to in vivo studies challenging. Moving to 
high field strength (i.e., 7 T) may help due to the improved signal-to-noise ratio (SNR) and spatial 
resolution, as demonstrated in Section 6.3.2. However, as discussed previously, magnetic field 
inhomogeneities scale with increased field strength, so increased inhomogeneity would make in 
vivo material detection more challenging. In addition, the large increase in power deposition at 7 
T limits its clinical use,
14
 as opposed to 3 T MR scanners which are utilized clinically.  
Moreover, despite the higher concentration of hydroxyl (–OH) protons on the HA 
backbone, hydroxyl CEST is generally challenging due to the proximity of the –OH proton 
resonance to that of bulk water protons, leading to a higher potential for direct water saturation. 
Partial direct water saturation leads to a decrease in the water signal due to the RF pulse 
application and not from proton exchange, misconstruing the true CEST effect and thus 
decreasing CEST sensitivity.
15,16
 As seen in the non-water suppressed spectroscopy studies 
(Section 6.3.3), where direct saturation effects should be smaller than at 3 T due to the higher 
magnetic field strength of the spectrometer (9.4 T), the –OH proton peak could not be resolved 
from the bulk water proton peak. Furthermore, it is possible that partial direct saturation could 
explain the positive CEST contrast seen in the phantom and explant studies.  
Finally, similar to the T2-weighted hydrogel imaging, CEST MRI was also limited to 
myocardial explants. Whereas ex vivo 3 T studies targeting the –OH protons on HA were 
promising, an in vivo study of HeMA-HA hydrogel injections attempted at 3 T in a normal sheep 
was unsuccessful. The injection site of the material in the posterolateral free wall made detection 
challenging due to substantial motion, particularly at higher saturation frequencies further from 
the bulk water resonance, despite both respiratory and cardiac gating. This motion led to large 
magnetic field inhomogeneities that were not able to be perfectly corrected for using the standard 
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WASSR techniques,
17,18
  and thus prevented accurate z-spectral fitting of the CEST effect as a 
function of chemical shift to extract a reliable CEST contrast. To address the motion concerns of 
cardiac CEST in vivo, our collaborators in the Reddy lab developed a more accurate z-spectral 
fitting technique based on a probabilistic combination of Lorentzian functions to account for the  
direct saturation, magnetization transfer and CEST effects impacting the myocardial tissue.
19,20
 
When applied to the–OH CEST data from the in vivo injection study, there was substantial 
overlap in the proton resonance peaks between the bulk water protons and nearby –OH protons 
preventing resolution of the separate peaks for accurate fitting.   
The partial direct saturation effect concerns with manipulating the –OH protons on HA 
motivated the switch to targeting amine (–NH) protons in an arginine-dominate peptide coupled to 
HA since they resonate further downfield from the bulk water protons.
20-23
 Even though phantom 
studies demonstrated the ability to generate a CEST effect specific to the exchangeable proton 
group of interest (Section 6.3.3), this was unsuccessful in attempted explant studies. This 
limitation was most likely due to the high background myocardial CEST effect from endogenous 
amines that prevented detection of the arginine-based amines in the HA coupled peptide. More 
specifically, the labile amines in endogenous myocardial creatine, which is involved in energy 
production to power contraction, are known to resonate ~1.8 ppm downfield of bulk water,
20,23
 
which is identical to the resonance of the amines in the peptide as identified from spectroscopy. 
Future work should focus on the coupling of peptides with exchangeable protons whose 
resonance differs from that of endogenous myocardial metabolites. HeMA-HA-peptide hydrogels 
were also delivered in vivo to a healthy sheep and in vivo CEST imaging attempted. However, 
despite the decrease in direct water saturation, the same motion and inhomogeneity concerns as 
previously described with the HeMA-HA injections were encountered.  
Specific Aim 3: Assess the temporal effects of degradable HA hydrogel therapy on long-term 
myocardial tissue remodeling post-MI using cardiac MRI and FE modeling in an in vivo porcine 
infarct model. 
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8.2.4. Limitations in In Vivo Study  
A limitation of the in vivo work performed in Aim 3 was that only a single hydrogel 
formulation was assessed. Even though it was selected based on previous studies from our 
group
1,2
 to have optimal properties (i.e., an in vitro degradation profile greater than eight weeks 
and an initial compressive modulus greater than ten times that of the normal myocardium), 
delivery of only one formulation prevented assessment of the correlation between material 
properties and positive in vivo outcomes. Based on the study design, it could not investigate the 
optimal degree and duration of mechanical stabilization needed to attenuate remodeling, and 
thus, the specific hydrogel properties for optimal in vivo outcomes remains unclear. 
The animal model also involved injecting the hydrogel therapy into the infarct at thirty 
minutes following infarction. Even though this timing for delivery has been used by our group
1,2,24
 
and others
25-27
 to evaluate the efficacy of injectable materials in animal MI studies, it is not 
clinically relevant
28,29
 as MI patients would not receive therapy for at least several hours after the 
onset of MI. In addition, patients may be unstable during the initial period following MI trauma due 
to the upregulation of MMPs, which may cause the ventricle to be vulnerable to rupture.
30-34
 
Delivery at one week post-MI would be more clinically practical as it would give patients a period 
to recover and stabilize before undergoing an injection procedure. 
The mode of material delivery directly into the myocardium through the epicardial surface 
with the need for a thoracotomy was also not clinically translatable. As discussed in Chapter 1, 
the primary advantage of injectable biomaterials over other tissue engineering strategies for 
cardiac repair, such as LV restraints or cardiac patches, is the potential for minimally invasive 
delivery, which decreases damage to the target tissue and other surrounding tissues and enables 
more rapid translation. Catheter-based approaches are ideal for a clinical setting to decrease 
procedure and recovery times for patients. Recent studies have shown the ability for injectable 
biomaterials to be delivered to large animal MI models using catheters.
35
 However, the hydrogel 
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system utilized in this dissertation was unable to be delivered in vivo via catheter due to its rapid 
gelation time over the course of a few minutes.  
Furthermore, the in vivo work in Aim 3 focused on the mechanical benefits of injectable 
HA hydrogels and their impact on myocardial tissue mechanics. However, biological processes, 
such as the activation of MMPs, play an important contributing factor in the progression to global 
LV remodeling and thus should be evaluated. In this work, temporal assessment with MRI 
prevented examination of the biological aspects of remodeling, aside from at the terminal time 
point. In addition, previous studies have demonstrated that HA itself has biological benefits with 
the ability to increase angiogenesis and potentially aid in cardiac regeneration in a MI model.
36,37
 
In the injectable system utilized in Aim 3, the biological benefits of HA delivery could not be 
evaluated separately from the mechanical benefits of the hydrogel because degradation and 
mechanics were coupled. Comparison to a non-bioactive material with similar hydrogel 
degradation and mechanics would demonstrate the biological significance of HA.  
8.2.5. Limitations in FE Model  
Even though the FE model developed in Aim 3 was novel in that it incorporated in vivo-
derived parameters to describe the LV geometry and myocardial tissue properties in terms of 
regional strains, it was also limited. Myocardial fiber architecture was not incorporated, as the 
average myofiber angles were assigned to the myocardium and assumed to vary linearly in the 
transmural direction. To generate a more anatomically representative FE model, the spatially 
varying myofiber architecture should have been assessed using diffusion tensor MRI as another 
input for the model.
38
 In addition, the model only examines the LV, which is directly impacted by 
the infarct, but does not incorporate pressures and deformations caused by the adjacent RV. 
Finally, early diastole was selected to be the reference state on which the FE model was built 
since pressure is at a minimum. However, the LV is still partially loaded at this phase and there 
may be residual active tension in the myocardial fibers that, if not adequately accounted for, 
would alter the mechanical properties of the myocardium. Recent studies have incorporated 
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techniques for determining the unloaded LV geometry
39
 that should be utilized in the future to 
make the model more physiologically relevant.  
8.3. Future Directions  
8.3.1. In Vivo Hydrogel Imaging  
Based on the limitations of the studies performed throughout this dissertation, there are 
several avenues for future exploration related to the assessment of injectable HA hydrogels using 
MRI. First of all, future studies should involve the translation of the T2-weighted and CEST MRI 
techniques investigated in Aim 2 to imaging injectable hydrogels in vivo. As discussed previously 
in Section 8.2.2, a major challenge of the in vivo T2-weighted imaging was the presence of 
magnetic field inhomogeneities at 3 T.
7
 If remaining at 3 T, injection via catheter to prevent air 
spaces in the chest cavity or injection into a location farther from the lung parenchyma (i.e., 
septum) may decrease the magnetic field susceptibility differences to improve homogeneity, but 
an ideal imaging technique would enable material detection regardless of delivery method or 
injection site. Preliminary work from the explanted heart following in vivo HeMA-HA injection 
suggests that the T2 relaxation times of the material and surrounding myocardium are different 
enough to enable in vivo detection of the hydrogel if the magnetic field inhomogeneity is 
decreased by moving to a lower field strength of 1.5 T; thus, this is the most promising approach.  
Due to the specificity of CEST imaging for the specific functional groups in the hydrogel, it 
would be highly beneficial to progress to in vivo work as well. Unlike T2-weighted imaging, CEST 
MRI may provide the opportunity to image hydrogels in vivo after infarction if the exchangeable 
proton group manipulated is selected appropriately. Recent work from our collaborators 
demonstrated that amine protons in creatine can be manipulated by CEST to distinguish between 
healthy and infarcted myocardium in large animals.
20
 A decrease in creatine-based CEST 
contrast was observed in infarcted relative to healthy tissue, suggesting a decrease in creatine 
levels in the akinetic, ischemic tissue as contractile function becomes limited.
20
 Due to the known 
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background myocardial signal from predominately amine protons resonating at about 1.8 ppm 
away from bulk water, selection of a functional group or peptide sequence to couple to HA with an 
exchangeable proton group that resonates away from the endogenous amines, preferably further 
downfield from bulk water protons, would enable detection of HA hydrogels within the infarct. In 
addition, the functional group or peptide sequence should have a single, uniform peak for the 
exchangeable protons, unlike the peptide sequence chosen for this study which had multiple 
exchangeable protons peaks, as demonstrated by high-resolution, non-water suppressed 
spectroscopy. A single resolved peak will not only lead to enhanced CEST contrast but also 
enable application of the new fitting technique based on a probabilistic model to better 
compensate for magnetic field inhomogeneity in vivo, as previously described.
20
  
The ability to specifically visualize injectable hydrogels in vivo using CEST MRI would 
provide the opportunity to track changes in hydrogel properties over time. One material property 
of particular interest is the rate of in vivo degradation since previous MI studies in large animals 
have demonstrated that the therapeutic impact of hydrogels depends on their duration of 
mechanical stabilization and thus, degradation.
1
 To determine the optimal rate of degradation for 
positive in vivo outcomes, different hydrogel formulations could be directly compared and tracked 
over the chronic remodeling process. Furthermore, previous studies from our lab have shown that 
encapsulated small molecule release tracks with HA hydrogel degradation.
5,40
 Thus, the ability to 
track hydrogel degradation in vivo would provide an indirect assessment of therapeutic molecule 
release, as will be discussed further in Section 8.3.2. Ultimately, the use of a single, clinically 
relevant imaging modality (i.e., MRI) to simultaneously track hydrogel properties over time in vivo 
and investigate their impact on myocardial tissue properties (as described in Aim 3) would enable 
direct correlation between specific material properties and their positive effects on tissue 
remodeling post-MI within a single scan period. This would provide insight for the future 
development of biomaterial systems with optimal properties to attenuate infarct remodeling.  
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Figure 8.1. Tuning HeMA-HA hydrogel properties to alter degradation and small molecule 
release. Gel onset and completion, n=3-4/group, for selected formulations (A). Degradation time 
and initial compressive moduli, n=3-4/group (B). Degradation (C) of both formulations correlated 
with release of r-TIMP-3 (D), n=3-4/group. Degradation and release performed in PBS with 1% 
reagent diluent BSA. Data presented as mean ± SEM. All comparisons between polymers were 
statistically significant (p<0.05) in panels A and B. Differences between formulations were 
statistically significant (p<0.05) in panel C aside from at days 1 and 12 and in panel D past day 2.  
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8.3.2. Small Molecule Release from Injectable HA Hydrogels   
  To further apply the temporal control of HA hydrogel degradation discussed in Aim 1 and 
expand the in vivo application investigated in Aim 3 to biological process post-MI, HA hydrogels 
could be used to deliver encapsulated small molecules; as the hydrogel degrades, the molecule 
is released.
5,40,41
 A model small molecule that has recently been explored by our group for MI 
repair is tissue inhibitor of metalloproteinase-3 (TIMP-3).
5
 As previously discussed in Chapter 1, 
following MI, there is an increase in the activation of matrix metalloproteinases (MMPs) in the 
myocardium, which contributes to breakdown of extracellular matrix (ECM) and consequently 
infarct expansion and associated LV dilation.
42-45
 Whereas MMPs are upregulated post-MI, their 
endogenous tissue inhibitors (TIMPs) are not.
46-48
 More specifically, TIMP-3 is a critical regulator 
of MMP activity; all four TIMPs inhibit MMPs but TIMP-3 has the broadest inhibition spectrum.
49
 In 
addition, unlike the other TIMPs, TIMP-3 is tightly bound to the ECM due to interactions with 
GAGs,
49-51
 suggesting there is a native affinity between HA and TIMP-3.
5
 Thus, HA hydrogels can 
serve as a platform for TIMP-3 release as a model small molecule both in vitro and in vivo.  
To demonstrate the feasibility of tuning small molecule release based on differences in 
degradation, release of rTIMP-3 was examined from two HeMA-HA hydrogels formulations with 
anticipated differences in degradation based on previous studies (Section 4.3.2): 10% modified 
HeMA-HA at 5 wt% and 25% modified HeMA-HA at 8 wt%, both gelled using 5 mM APS/TEMED. 
As predicted, gel onset and completion times were slightly slower in the 10% than 25% modified 
gels (Figure 8.1A) and the initial compressive moduli slightly lower (Figure 8.1B). More 
importantly, degradation of the 25% modified gels (11.6 ± 3.8 weeks) was significantly (p<0.05) 
slower than the 10% modified gels (3.1 ± 0.4 weeks, Figure 8.1B). Quantification of mass loss 
over time further highlighted these degradation differences, with significantly less HA loss from 
the 25% modified gels at all time points aside from days 1 and 12 (Figure 8.1C). 
Correspondingly, release of rTIMP-3 as a model small molecule was slower in the 25% than 10% 
modified gels and significantly so past day 2 (Figure 8.1D). Due to the native affinity between HA 
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and TIMP-3,
49-51
 as the HA-based hydrogels degraded, TIMP-3 was released through both 
diffusion and bound with HA fragments.   
For future in vivo applications similar to the study design of Aim 3, the hydrogel 
degradation profiles selected for rTIMP-3 release targeted different phases of the LV remodeling 
process, as discussed in Chapter 3.
4
 This is particularly beneficial for TIMP release since the 
activation of MMPs post-MI is time-dependent.
48,51
 The degradation of the 10% modified hydrogel 
at about 3 weeks correlates well with the acute LV remodeling stage, whereas the degradation of 
the 25% modified hydrogel at slightly before 12 weeks corresponds well to the chronic remodeling 
stage. In addition, previous studies from our group examined the in vivo benefit of rTIMP-3 
release from HA hydrogels post-MI.
5
 However, these studies were performed using a single 
hydrogel formulation and outcome assessment primarily occurred during the acute period out to 2 
weeks post-MI with minor assessment of LV volumes at 4 weeks post-MI.
5
 Therefore, comparing 
in vivo outcomes between hydrogels with different release profiles (Figure 8.1) would elucidate 
the optimal rate of TIMP-3 delivery. Furthermore, future studies assessing the therapeutic benefit 
of TIMP-3 delivery out to 12 weeks post-MI with an emphasis on the myocardial tissue properties 
(as utilized in Aim 3) would provide insight as to if early MMP inhibition delays the progression of 
global LV remodeling or permanently interrupts maladaptive myocardial remodeling. Ultimately, 
delivery of small, physiologically relevant molecules using the degradable HA hydrogels explored 
in Aim 1 would enable HA hydrogel therapy to address the biological implications of post-MI 
remodeling in addition to the mechanical benefits discussed in Aim 3 of this dissertation. 
8.3.3. Improved In Vivo Study Design  
In Aim 3 of this dissertation, a single hydrogel formulation was delivered in vivo as a 
platform to develop tools to assess the impact of hydrogel therapy on myocardial tissue 
properties. Future in vivo work should focus on applying the combination of MRI and FE modeling 
assessment to evaluate a range of hydrogels with varying properties. To make the material 
system more clinically applicable, hydrogel injection should occur farther past the onset of MI 
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(i.e., 1 week post-MI). Delivering hydrogels at even later times into the chronic remodeling stages 
(i.e., weeks to months following MI) would also lead to a better understanding of the therapeutic 
window during which injectable materials need to be delivered to optimize their therapeutic 
benefit. Finally, the percutaneous delivery of the hydrogels through catheters would facilitate 
clinical translation and allow for therapeutic hydrogel application in a wider population of patients 
where a thoracotomy is not part of their standard clinical care.  
8.4. Summary  
Myocardial tissue remodeling following infarction is considered the main contributing 
factor in the progression to heart failure, yet current therapies do little to address these alterations 
in tissue properties over time. Injectable materials offer a minimally invasive strategy to attenuate 
myocardial remodeling, but noninvasive tools are also needed to assess the effects of these 
therapies. The goal of this dissertation was to use MRI to investigate injectable HA hydrogel 
properties and their therapeutic effect on myocardial properties for infarct repair. The data 
presented in this dissertation demonstrates that differences in hydrogel properties can be 
noninvasively assessed after delivery to the myocardium and that injectable hydrogels positively 
impact myocardial mechanical properties (e.g., thickness, strain, stiffness) into the chronic 
remodeling stages. The findings of this dissertation represent advancements in imaging 
technology and provide insight into biomaterial design criteria for better therapies to target 
myocardial infarct remodeling and prevent progression to heart failure.  
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